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ABSTRACT
Over the past several decades, the fatality rates in traffic crashes related to drug-impaired driving
have increased significantly. Specialized law enforcement officers are currently being deployed
to help reduce the number of drug-related traffic crash fatalities and identify drugged impaired
drivers. The National Highway Traffic Safety Administration (NHTSA) and the International
Association of Chiefs of Police (IACP) developed the drug evaluation and classification program
(DECP) to certify law enforcement officers as drug recognition experts (DREs). An evaluation
and validation study was conducted on the DECP in Florida. The purpose of the study was to
evaluate the DECP in Florida to determine the accuracy rates of DREs and determine which core
set of measurements (signs and symptoms) from the drug influence evaluation (DIE) face sheets
correspond to each of the seven drug categories, and to determine if any core set of
measurements from the DIEs are identified with the inaccuracies of DRE opinions. This study is
a quantitative cross-sectional descriptive and predictive examination of Florida's DECP. The
population for this study comprised the enforcement DIEs and toxicological results for 2019 in
the state of Florida with a target sample size being calculated for a logistic regression analysis.
This study analyzed the DECP accuracy rates in Florida during 2019. The study also completed a
binary logistic regression analysis to determine the core set of measurements (signs and
symptoms) to predict the drug categories determined by toxicology results and the core set of
measurements (signs and symptoms) to predict the drug categories inaccurately determined by
the DREs.

Keywords: drug evaluation and classification program, drug recognition experts, drug
influence evaluation.
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CHAPTER ONE: INTRODUCTION
Overview
According to the 2019 National Survey of Drug Use and Health, an estimated 57.2
million people aged twelve or older used illicit drugs, and 16.3 million people misused
prescription psychotherapeutic drugs (Substance Abuse and Mental Health Services
Administration, 2020). In 2019, the Florida Department of Highway Safety and Motor Vehicles
recorded a total of 1,150 crashes in which the drivers had both alcohol and drugs in their system.
Of these 1,150 crashes, there were a combined total of 969 injuries and 723 fatalities (Florida
Department of Highway Safety and Motor Vehicles, 2021). The elevated level of drug users
combined with the number of drug-related driving fatalities requires a specialized law
enforcement officer to detect and remove drug-impaired drivers from the roadways to save lives.
These specialized law enforcement officers are classified as Drug Recognition Experts (DREs)
(International Association of Chiefs of Police [IACP], 2018c). The Drug Evaluation and
Classification Program (DECP) was established in Florida in 1993. In 2019, 405 certified DREs
removed an estimated 2,100 drug-impaired drivers from the roads and completed 986 drug
influence evaluations (Florida Department of Transportation, 2020).
Background
Alcohol-impaired driving has been well documented and researched, while drug-impaired
driving has been far less researched. Increased interest over the past decade is attributed to the
decriminalization and legalization of marijuana in many States (National Highway Traffic Safety
Administration [NHTSA], 2018). NHTSA developed the Drug-Impaired Driving Initiative in
2018 for engaging stakeholders in addressing the problem of drug-impaired driving (NHTSA,
2018). In 2017, a survey found that 91% of individuals considered driving after using illegal
drugs a personal safety issue (American Automobile Association [AAA], 2018). A roadside
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study conducted by NHTSA in 2013 gathered oral fluid samples from 7,881 drivers and blood
samples from an additional 4,686 drivers in the United States (Berning et al., 2015). The survey
results revealed that 15.2% tested positive for illegal drugs, 7.3% for over the counter and
prescription medications that cause impairment. In addition, 12.6% tested positive for delta-9Tetrahydrocannabinol (THC), which is an increase of 48% from a similar study conducted in
2007 (Berning et al., 2015). Additional studies were completed that showed similar results to the
increase of drug-impaired driving over the past ten years (Banta-Green et al., 2016; Compton &
Berning, 2015; Ramirez et al., 2016; Tefft et al., 2016). Each of these studies focused on the
increased numbers of individuals driving with drugs in their systems.
Alcohol-impaired driving has dominated the field of impaired driving research,
enforcement, deterrence, and education. The result of alcohol dominance in the subject of
impaired driving has created a lack of research literature on drug-impaired driving (PorathWaller & Beirness, 2009; Porath-Waller et al., 2010; Porath-Waller et al., 2021). Research in
alcohol impairment set the standard and strategies for law enforcement officers when attempting
to detect drug-impaired drivers. During the 1970s, the National Highway Traffic and Safety
Administration (NHTSA) developed a standardized battery of tests to assist law enforcement
officers in identifying alcohol impaired drivers validly and reliably (Porath-Waller & Beirness,
2013). In addition, all fifty states in the United States require subjects arrested for driving under
the influence to provide a breath sample to determine the level of alcohol concentration in their
blood (Venkatraman et al., 2021).
At the end of the 1970s, the Los Angeles Police Department (LAPD) officers were
noticing that some subjects who provided a zero-alcohol concentration level were impaired by
drugs and not alcohol. This became problematic for officers, and prosecutors because a
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toxicological analysis of bodily fluids, such as blood or urine was the only way to determine if
the subjects had ingested drugs (Porath-Waller et al., 2021). The second issue with drugimpaired driving cases at the time was that even if the toxicological analysis revealed the
ingestion of drugs, an officer and prosecutor still needed to prove in the court system that the
driver was under the influence at the time of the traffic stop. Bodily fluid toxicological analysis
reveals the presence of a drug but does not show impairment from the drug (International
Association of Chiefs of Police [IACP], 2018c).
LAPD collaborated with research psychologist, toxicologists, medical professionals, and
medical doctors to develop a 12-step systematic and standardized process to identify druginfluenced drivers (Beirness & Porath, 2019; Porath-Waller et al., 2008; Porath-Waller &
Beirness, 2010; Talpins et al., 2018). The 12-step process consisted of officers examining
individuals through interviews, behavioral tests, physical assessments, and measuring vital signs
and clinical indicators consistent with the effects of psychoactive substances (Beirness & Porath,
2019; Porath-Waller & Beirness, 2010; Talpins et al., 2018).
The 12-step process became known as the Drug Recognition Expert (DRE) protocol
(Beirness & Porath, 2019; Porath-Waller & Beirness, 2010; Talpins et al., 2018). DREs are
trained in recognizing the signs and symptoms associated with seven drug categories of central
nervous system depressants, central nervous system stimulants, hallucinogens, dissociative
anesthetics, narcotic analgesics, inhalants, and cannabis (International Association of Chiefs of
Police [IACP], 2018c; Porath-Waller et al., 2021). In the 1980s, LAPD and the National
Highway Traffic Safety Association (NHTSA) conducted several research projects to develop a
standardized methodology. The results of the studies created the Drug Evaluation and
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Classification Program (DECP) (International Association of Chiefs of Police [IACP], 2018c;
Porath-Waller et al., 2021).
The DECP process is a systematic and standardized method for DREs to determine and
verify that a subject's impairment is inconsistent with a measured alcohol level. The
inconsistency between observable impairment and alcohol levels suggests the presence of some
other drug(s) or some other complicating factors. DECP process then determines if the visible
impairment is due to illness or injury requiring medical attention or drug-related. Once a DRE
determines the subject's impairment is not consistent with alcohol levels in the blood, and
medical issues are not related, then a Drug Influence Evaluation (DIE) is completed to determine
which categories of drugs are primarily causing the impairment (Heishman et al., 1996;
International Association of Chiefs of Police [IACP], 2018c; Porath-Waller et al., 2021). "The
process is systematic in that it is based on a careful assessment of a variety of observable signs
and symptoms known to be reliable indicators of drug impairment" (International Association of
Chiefs of Police [IACP], 2018c, p. 86).
The DRE protocol consists of a 12-step standardized and systematic process documented in
the drug influence evaluation (International Association of Chiefs of Police [IACP], 2018c;
Porath-Waller et al., 2021; Scherer et al., 2020; Talpins et al., 2018; Vaillancourt et al., 2021).
The twelve steps of the DRE protocol are as follows:
1. Breath alcohol test.
2. Interview of the arresting officer.
3. Preliminary examination.
4. Examinations of the eyes.
5. Divided attention tests.
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6. Examination of vital signs.
7. Darkroom examinations.
8. Examination of muscle tone.
9. Examination for injection sites.
10. Suspect's statements and other observations.
11. Opinion of the evaluator.
12. Toxicological examination.
DREs document the 12-step protocol on a DIE face sheet (Appendix A). After the evaluation
is completed, DREs develop an opinion based on the signs and symptoms exhibited by
participants. DREs will then classify which of the seven-drug category or categories is currently
psychoactive during the evaluation (International Association of Chiefs of Police [IACP], 2018c;
Porath-Waller et al., 2021). The seven drug categories are central nervous system depressants,
central nervous system stimulants, hallucinogens, dissociative anesthetics, narcotic analgesic,
inhalants, and cannabis (International Association of Chiefs of Police [IACP], 2018c; PorathWaller et al., 2021).
Law enforcement officers seeking the certification of becoming a DRE will participate in a
three-phase training program governed by the IACP, which consist of a sixteen-hour DRE preschool, fifty-six-hour DRE school, and a hands-on evaluation phase including a final knowledge
exam. The details of the DECP certification process are addressed in chapter two of this
dissertation in the literature review (International Association of Chiefs of Police [IACP],
2018c).
The DECP was validated by NHTSA when a controlled laboratory and field study was
conducted in the early 1980s designed in the same manner as previous alcohol validation studies
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of psychomotor tasks (Bigelow et al., 1985; Compton, 1986; International Association of Chiefs
of Police [IACP], 2018c). The two-phase validation study was then followed by a third
validation study conducted in Arizona with the Phoenix Police Department resulting in DREs
having an accuracy rate of 85%, agreeing with Compton's previous field validation study in 1986
(Adler & Burns, 1994). The research studies concluded that the DRE process is a validated
method for officers to identify drug-impaired drivers. DREs can identify and classify which drug
categories are causing impairment to the individuals participating in a drug influence evaluation
(Alders & Burns, 1994; International Association of Chiefs of Police [IACP], 2018c; PorathWaller et al., 2021).
Research conducted on the DECP has been limited. The three primary validation studies
were conducted in 1984, 1985, and 1994 (Alder & Burns, 1994; Bigelow et al., 1985; Compton,
1986). Between 2000 and 2015, researchers focused on individual drugs and their respective
signs and symptomology. Researchers examined how drugs affected the human body and
compared these results with the DECP curriculum for validation (Bramness et al., 2003;
Bramness et al., 2009; Declues et al., 2018; Downey et al., 2015; Hartman et al., 2016; Heishman
et al., 1998; Khiabani et al., 2007; Perry et al., 2015; Silber et al., 2005). Research has been
completed on the DECP in Canada examining the accuracy rates of DRE opinions, but data is
lacking for the United States. Porath-Waller et al. (2021) conducted a study in the United States
focusing on "which combinations of drug-related signs and symptoms from the DECP protocol
can most efficiently and effectively predict the drug category or combination used by the
subject" (p. v). No empirical studies have been conducted regarding the DECP in Florida
concerning the effectiveness of DRE's ability to identify persons impaired by drugs other than
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alcohol. As a result, there is currently a gap in the research and additional studies need to be
conducted in this particular area.
Problem Statement
Although research has increased on the potential impairing effects of drugs in drivers in
the United States, the research remains primary focused on driving under the influence of
alcohol. Alcohol-impaired driving is a singular item issue that researchers can focus on with the
results of breath samples and alcohol blood concentration levels. Drugs are more challenging to
address in drug impairment due to several factors, which include: a wide range of drugs from
licit to illicit, drugs are constantly changing, the relationship of drug levels and impairment has
not been established for DUI related crimes, and blood levels of drugs can disappear after sample
collection (Arnold & Scopatz, 2016; Berning & Smither, 2014; Compton, 2017; Logan et al.,
2016; Smith et al., 2018). Delta-9-tetrahydrocannabinol (THC) concentrations decrease rapidly
after smoking cannabis, from high peak concentrations of 100 to 400 ng/ml to levels of 1 to 10
ng/ml in a few hours (Brubacher et al., 2019; Karschner et al., 2009; Peng et al., 2020). As a
result, researchers in the field of drug-impaired driving have begun to focus on singular drugs
and their effects on the human body, causing impairment (Strand et al., 2016). The DECP was
developed to assist law enforcement officers with detecting and gathering evidence of drugimpaired drivers. As more research is conducted on individual drugs effects, the DECP advances
the program to increase the accuracy rates of DREs when predicting drug categories causing
impairment (Porath-Waller et al., 2021).
Under Florida law (F.S. 316.193), an individual arrested for Driving Under the Influence
(DUI) who gives a breath sample of .000 breath alcohol content and then refuses to provide a
urine sample cannot be prosecuted for DUI. The State Attorney Office (SAO) in Florida must
articulate what specific drug is believed to be impairing the driver. DREs are only allowed to
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make an opinion of a broad drug category, which is then confirmed by the toxicology of the
specific drug. So, if a driver refuses to provide a toxicology sample for testing, the SAO will
never be able to identify a specific drug. The exception to this rule is if a driver confesses to a
specific drug or is found to be in possession of a specific drug. In addition, drivers must be under
the influence of a listed controlled substance in Florida. Also, Florida DUI law requires law
enforcement officers and prosecutors to prove an individual was under the influence of alcohol
or a controlled substance at the time of operating a motor vehicle. A roadblock for law
enforcement officers in Florida is that the definition of 'controlled substance' does not include
many prescriptions, over-the-counter drugs, and designer drugs known to impair drivers.
The Florida impaired driving coalition is currently attempting to have the language of the
DUI statute changed so that the opinions of a certified DRE can bear enough weight as to the
intoxication of a driver arrested for DUI. A DRE conducts an evaluation after an individual has
been arrested for a DUI. The evaluation and opinion formed by the DRE is an evidence
collection tool for law enforcement officers that State prosecutors can utilize in the prosecution
of DUI cases if the language in the statute is changed as it pertains to the definition of ‘controlled
substance’. The proposal of the new DUI law changes the language of a specific drug to a drug
category. Florida's 2021 Senate Bill 436 and House Bill 271 request the DUI law be updated to a
more rational definition of drug-impaired driving by upgrading the current law to include "or any
other impairing substance, or combination thereof." The legislation enables prosecutors to
address impaired driving no matter what drug is causing the driver to be impaired. To assist the
coalition, a research study is needed to provide the accuracy rates of DRE opinions compared to
toxicology results of suspected DUI offenders. If the requested legislative changes are made, the
DECP will be critical to proving impairment in DUI cases.
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The existing empirical research on the DECP focuses on the program's curriculum. DECP
was developed to train law enforcement officers in the DRE 12-step protocol (Porath-Waller et
al., 2021). Empirical research has focused on individual components that make up the process,
and little research has examined the accuracy rates of the DREs compared to toxicological
results. Most of the empirical research was conducted prior to 2007, and over the past twenty
years, researchers have ignored the program in the United States (Alder & Burns, 1994; Bigelow
et al., 1985; Bramness et al., 2003; Compton, 1986; Heishman et al., 1998; Preusser et al., 1992;
Shinar & Schechtman, 2004; Smith et al., 2006). The most recent empirical research on the
program has been conducted with the DECP in Canada (Porath-Waller & Beirness, 2010; PorathWaller & Beirness, 2013; Porath-Waller et al., 2009; Porath & Beirness, 2019). The lack of
empirical research in the United States is collecting data for the DECP. Prior to 2020, all DREs
entered their opinions and toxicology results in a national database. The individual DREs kept
the DIE face sheets and narratives completed by DREs in their respective law enforcement
organizations. The United States lacked a centralized repository of drug influence evaluations
prior to 2020.
Since the inception of the DECP in Florida, no research studies have been completed on
the effectiveness of Florida's DREs abilities to accurately predict which drug category or
categories are impairing the driver's ability to operate a motor vehicle. There have been very few
studies across the United States addressing the accuracy rate of DRE opinions, and the studies
that have been conducted were in the 1980s and early 1990s. Although three primary studies
have been conducted on the proper administration and validation of the DECP 12-step protocol
in identifying drug categories impairing individuals, no empirical data has been collected and
analyzed for the drug evaluation and classification program in Florida (Alder & Burns, 1994;
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Bigelow et al., 1985; Compton, 1986; Preusser et al., 1992). As a result, tens of thousands of
drivers have been arrested and convicted in Florida for driving under the influence of a chemical
or controlled substance with the assistance of a DRE's testimony without the results of an
analytical study of the DREs accuracy rates in Florida. Continued research is also needed to
determine the DREs missed or inaccuracy in predicting the drug category or categories impairing
an individual's ability to operate a motor vehicle safely. An analysis of DRE opinions' misses or
inaccuracy could identify common themes or traits to assist the DECP training. The problem is a
lack of research on the accuracy rates of DREs in Florida and a lack of research on the
inaccuracy of DRE opinions related to the drug categories correlations to the signs and
symptoms of subjects.
Purpose Statement
The purpose of this study was to evaluate the DECP in Florida to determine the accuracy
rates of DREs and determine which core set of measurements (signs and symptoms) from the
Drug Influence Evaluation (DIE) face sheets correspond to each of the seven drug categories. In
addition, a statistical analysis was conducted to determine which core set of measurements from
the DIEs are identified with the inaccuracies of DRE opinions. The DIE face sheet contains over
one hundred data points that can be coded and entered into a statistical software program for
analysis. There is a clear gap in the literature focusing on DRE opinions inconsistencies with
toxicological results in the DECP. There is also a gap in the literature related to DECP in Florida.
To date, there has never been a validation study performed to determine the accuracy rates of
DRE opinions compared to toxicological results in Florida. To ascertain which core set of
measurements from the DIEs in missed opinions of DRE’s and corresponding toxicological
results, a statistical analysis of the DIE face sheets were conducted. An analysis of the DIE face
sheets collected in Florida during 2019 were coded using Porath-Waller’s (2021) data coding
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instrument as a foundation coding instrument. The resulting coding instrument for this study
expanded on Porath-Waller’s (2021) coding instrument to include additional variables obtained
from the DIE face sheets.
This study was a quantitative cross-sectional descriptive and predictive examination of
Florida's DECP study using existing data. The dependent (criterion) variable was the DRE
opinion of which drug category was psychoactive during the evaluation causing impairment.
According to the DRE 12-step protocol, an opinion was formulated by the DRE administering
the DIE. The DRE opinion was influenced by the independent (predictor) variables of the signs
and symptoms observed during the evaluation and recorded on the DIE face sheet.
The toxicology results of the subject’s bodily fluid sample of blood or urine was another
dependent (criterion) variable. The toxicology results indicate which impairing substances
belonging to the seven drug categories were ingested by the subject. The impairing substances
ingested by the subject are independent variables due to influencing the toxicology results.
Accuracy rates were computed from the DRE opinions and toxicology results. A binary logistic
regression analysis was performed to use measures from the DIE face sheets to predict the drug
categories determined by the toxicology results. Another binary logistic regression analysis was
performed to use measures from the DIE face sheets to predict the drug categories inaccurately
determined by the DREs. The binary logistic regression analyses are discussed in Chapter 3.
The DIE face sheets were collected from around Florida through the coordination of the
NHTSA DECP State Coordinator. The DIE face sheets utilized for this study consisted of
enforcement evaluations in 2019. Each subject evaluated by a DRE was placed under arrest for
DUI and agreed to submit to a breath test. The breath test results were not consistent with the
impairment level of the subject, and a DRE completed a drug influence evaluation.
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Significance of Study
Previous literature has focused on validating the DECP, DRE accuracy rates, signs and
symptoms associated with individual drugs, and statistical analysis of signs and symptoms
predictability. Bigelow et al. (1985), Compton (1986), Preusser et al. (1992), Alder & Burns
(1994) focused research on the validation of the DECP and DRE accuracy rates to assist law
enforcement and prosecutors in meeting standards for the criminal justice court system. This
study continued the research of determining the accuracy rates of DREs by evaluating Florida's
DECP in 2019.
Multiple research studies focused on the signs and symptoms produced by individual
types of drugs have been conducted (Bramness et al., 2003; Downey et al., 2012; Hartman et al.,
2016; Heishman et al., 1998; Perry et al., 2014; Shinar & Schechtman, 2005; Silber et al., 2005;
Vaillancourt et al., 2021). Additional researchers focused their studies on performing statistical
analysis of the drug influence evaluations to determine which signs and symptoms help with the
predictability of the DREs opinions for drug classification causing impairment (Beirness et al.,
2009; Beirness et al., 2013; Porath-Waller et al., 2009; Porath-Waller et al., 2010: 2013: 2019;
Porath-Waller et al., 2021). This study added to the existing body of knowledge on the DECP by
adding current and updated findings on the program. The study also contributed to the body of
knowledge by analyzing the inaccuracy of DRE opinions related to the drug categories'
correlations to the signs and symptoms of subjects.
Florida is currently in the process of trying to amend the driving under the influence law
to include language identifying "any substance that causes impairment," which will need a DRE
to conduct a DIE to show impairment. This study will assist Florida legislators in the confidence
of the DECP accuracy rates. Researchers for NHTSA will also be able to use the data contained
in this study to produce further research studies on the DECP. Another advantage of conducting

15
this study was identifying common themes or traits related to DRE missed opinions and the signs
and symptoms associated with the evaluations.
Research Questions
RQ1: What is the accuracy rate of DRE opinions compared to the toxicology results for
drug influence evaluations completed by DREs in Florida during 2019?
RQ2: What set of measures (signs and symptoms) from the drug influence evaluations
completed by DREs in Florida during 2019 significantly predict the drug categories
determined by toxicology results?
RQ3: Among the inaccurate drug influence evaluations (missed opinions) completed by
DREs in Florida during 2019, what set of measures (signs and symptoms) significantly
predict the drug categories inaccurately determined by the DREs?

16
Definitions
1. Analgesic – A medication or drug that relieves pain (International Association of Chiefs
of Police [IACP], 2018c).
2. Bivariate Analysis – Analysis used to determine the relationship between two variables
(Maxfield & Babbie, 2017; Meier et al., 2014; Porath-Waller et al., 2021).
3. Blood Alcohol Concentration (BAC) – Percentage of alcohol in a subject’s blood
expressed in number of grams of alcohol per one hundred milliliters of blood
(International Association of Chiefs of Police [IACP], 2018c).
4. Breath Alcohol Concentration (BrAC) – Percentage of alcohol in subject’s blood
measured by a breath testing device expressed in number of grams of alcohol per 210
liters of breath (Fiorentino et al., 2020; International Association of Chiefs of Police
[IACP], 2018c).
5. Central Nervous System (CNS) – System within the human body consisting of spinal
cord, brain, and brain stem (International Association of Chiefs of Police [IACP], 2018c).
6. Corroboration Rate – is the proportion of all persons identified by the DRE procedure as
being under the influence of a given substance that are subsequently confirmed by
toxicology as being correctly identified (Beirness et al., 2007).
7. Divided Attention Tests – Four psychophysical tests used in drug influence evaluations,
accessing the subject’s ability to concentrate on more than one thing at a time dividing
their attention on both simple mental and simple physical tasks at the same time
(International Association of Chiefs of Police [IACP], 2018c).
8. Drug – Any substance that, when taken into the human body, can impair the ability of the
person to operate a vehicle safely (International Association of Chiefs of Police [IACP],
2018c).
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9. Drug Evaluation & Classification Program (DECP) – Trains certified law enforcement
officers in the detection and identification of drug impaired drivers. DECP was developed
and maintained by IACP and NHTSA (Fiorentino et al., 2020; International Association
of Chiefs of Police [IACP], 2018c; Porath-Waller & Beirness, 2019; Porath-Waller et al.,
2021).
10. Drug Influence Evaluation (DIE) – A standard and systematic process of examining a
suspected subject of being under the influence of a drug, for the purpose of determining
what category of drug or categories of drugs causing the impairment (International
Association of Chiefs of Police [IACP], 2018c).
11. Drug Recognition Expert (DRE) – Law enforcement officer who successfully completes
all phases of the DRE training requirements for certification established in the DECP by
IACP and NHTSA (Fiorentino et al., 2020; International Association of Chiefs of Police
[IACP], 2018c; Solensten & Willits, 2021).
12. False Alarm Rate – is the proportion of all drug negative cases in which a DRE indicates
the subject is under the influence of a drug (Beirness et al., 2007).
13. Hallucinogen – Drugs that affect a person’s perceptions, sensations, thinking, selfawareness and emotions (International Association of Chiefs of Police [IACP], 2018c).
14. Homeostasis – Dynamic balance involving levels of salts, water, sugars, and other
material in the human body’s fluids (International Association of Chiefs of Police
[IACP], 2018c).
15. Horizontal Gaze Nystagmus (HGN) – Involuntary jerking of the eyes occurring as the
eyes gaze to the side (Bertolli et al., 2007; International Association of Chiefs of Police
[IACP], 2018c).
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16. Impairment – One of the several items used to describe the degradation of mental and/or
physical abilities necessary for safely operating a vehicle (International Association of
Chiefs of Police [IACP], 2018c).
17. Intoxication – The degradation of mental and/or physical abilities due to the ingestion of
an impairing substance (International Association of Chiefs of Police [IACP], 2018c).
18. Lack of Convergence (LOC) – Inability of a subject’s eyes to converge, or cross, as the
subject attempts to focus on a stimulus moving slowly towards their nose (International
Association of Chiefs of Police [IACP], 2018c).
19. Major Indicators – Physiological signs that are specifically assessed and are involuntary
reflecting the status of the CNS homeostasis (International Association of Chiefs of
Police [IACP], 2018c).
20. Medical Rule Out – DRE opinion based on the DIE that a subject’s impairment is more
likely associated with a medical issue then an impairing drug substance (International
Association of Chiefs of Police [IACP], 2018c).
21. Miosis – Abnormally small (constricted) pupils (International Association of Chiefs of
Police [IACP], 2018c).
22. Miss Rate – is the proportion of all drug positive cases that are judged by DREs to be
drug free (Beirness et al., 2007).
23. Multivariate Analysis – Analysis used to determine if there is a relationship between two
or more variables (Maxfield & Babbie, 2017; Meier et al., 2014; Porath-Waller &
Beirness, 2019; Porath-Waller et al., 2021).
24. Mydriasis – Abnormally large (dilated) pupils (International Association of Chiefs of
Police [IACP], 2018c).
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25. Narcotic – A drug derived from Opium, or produced synthetically, that relieves pain but
also induces euphoria, alters mood, and produces sedation (International Association of
Chiefs of Police [IACP], 2018c).
26. On the Nod – A semi-conscious state of deep relaxation. Subject appears to be asleep but
can easily respond to questions (International Association of Chiefs of Police [IACP],
2018c).
27. Ptosis – Droopy eyelids (International Association of Chiefs of Police [IACP], 2018c).
28. Rebound Dilation – A period of pupillary constriction followed by a period of pupillary
dilation where the pupil steadily increases in size and does not return to its original
constricted size (International Association of Chiefs of Police [IACP], 2018c).
29. Resting Nystagmus – Involuntary jerking of the eyes as they look straight ahead
(International Association of Chiefs of Police [IACP], 2018c).
30. Sensitivity – is the number of drug-positive cases identified by DREs, also known as the
hit rate or true positive rate (Beirness et al., 2007).
31. Sign – An observable or detectable indicator of drug influence (International Association
of Chiefs of Police (IACP), 2018a, session 7, p. 6).
32. Specificity – refers to the number of drug-negative cases identified by DREs, also known
as the correct rejection rate (Beirness et al., 2007).
33. Standardized – Conforming to a model in comparative applications (International
Association of Chiefs of Police [IACP], 2018c).
34. Standardized Field Sobriety Tests (SFSTs) – Standardized divided attention (mental and
physical) tests validated by NHTSA. The three tests consist of HGN, walk and turn, and
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one leg stand (Jones et al., 2019; International Association of Chiefs of Police [IACP],
2018c).
35. Symptom – A subjective indicator of drug influence reported by the drug-impaired subject
(International Association of Chiefs of Police (IACP), 2018a, session 7, p. 6).
36. Systematic – Done or acting according to a fixed plan or system; methodical
(International Association of Chiefs of Police [IACP], 2018c).
37. Tolerance – An adjustment of the drug user’s body and brain to the repeated presence of
a drug (International Association of Chiefs of Police [IACP], 2018c).
38. Type I Error – Error occurs when one rejects a true null hypothesis (Maxfield & Babbie,
2017; Meier et al., 2014; Porath-Waller et al., 2021).
39. Vertical Gaze Nystagmus (VGN) – Involuntary jerking of the eyes, up-and-down, which
occurs as the eyes are held at maximum elevation (International Association of Chiefs of
Police [IACP], 2018c).

21
CHAPTER 2: LITERATURE REVIEW
Overview
Empirical research of the drug evaluation and classification program (DECP) contains
three time periods, each with its particular study area. First, the primary source foundational
studies of the program are from the mid-1980s to the early 1990s. The primary studies focused
on the 12-steps of the DRE process, and researchers examined the validation requirements
needed for court purposes. The early studies in the program assisted law enforcement officers
and prosecutors in entering the judicial system as a valid process to detect drug-impaired drivers.
The second period of empirical studies was conducted from 2000 to 2015 and focused on
individual drugs and their signs and symptomology. Researchers examined how drugs affected
the human body and compared these results with the DECP curriculum for validation (Bramness
et al., 2003; Bramness et al., 2009; Declues et al., 2018; Downey et al., 2015; Hartman et al.,
2016; Heishman et al., 1998; Khiabani et al., 2007; Perry et al., 2015; Silber et al., 2005). The
final period of empirical research in the DECP overlapped the second period from 2013 to the
present, focusing on the accuracy rates of the DRE opinions conducted in Canada (Porath-Waller
& Beirness, 2013; Porath-Waller et al., 2009; Porath & Beirness, 2019). This literature review
examined previous peer-reviewed journal articles and government-sponsored research, which
focused on creating the drug evaluation and classification program, drug recognition expert 12step protocol, seven drug categories identified in the DECP, and the validation studies conducted
on the DRE accuracy rates.
Theoretical Framework
Program evaluation theory's function is to ascertain the theoretical sensibility of the
program being evaluated (Sharpe, 2011). A program evaluation theory consists of a set of
statements that describe a particular program, explain why, how, and under what conditions the
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program effects occur, predict the outcomes of the program, and specify the requirements
necessary to bring about the desired program effects (Sedani & Sechrest, 1999; Sharpe, 2011).
Programs implemented in criminal justice need to have evaluations completed throughout the
program's life span to ensure the goals identified by policymakers and designers are being met
(Braga & Weisburd, 2013; Janeksela, 1977; Reichert & Gatens, 2019). According to Reichert &
Gatens (2019), an "evaluation in criminal justice is vital to improving program effectiveness,
increasing efficiency, and improving public safety" (p. 1).
Criminal Justice programs are primarily funded through local, state, or federal
government assistance. Government-funded criminal justice programs must provide proof of
their legitimacy, efficiency, and effectiveness to justify the program's existence (Braga &
Weisburd, 2013; Janeksela, 1977; Reichert & Gatens, 2019). Program evaluation theory answers
the dilemma of ascertaining if a particular program effectively achieves the goals of a particular
criminal justice program. Program evaluations are a systematic assessment of a program's
outcomes compared to the implicit or explicit standards to improve a program (Vito & Higgins,
2014). Chen (2005) stated, "an evaluation that examines how a program's structure,
implementation procedures, and causal mechanisms actually work in the field will provide
information that can be very useful in program improvement" (p. 37).
Criminal justice programs are implemented and sustained through limited resources.
Program evaluation theory assists policymakers in determining if the limited resources being
utilized by a program are justified. Evaluations of a criminal justice program assist policymakers
in making informed decisions on program improvement and contain accountability to the
utilization of the limited resources of the program (Chen, 2005). The Office of Justice Programs
(OJP) has devoted an entire division to the research of criminal justice programs to ensure grant
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programs are spending taxpayer dollars wisely (Office of Justice Programs, 2022). "OJP's
Evidence Integration Initiative is focused on improving the synthesis and translation of social
science research findings to inform practice and policy in criminal justice" (Office of Justice
Programs, 2022, para. 6).
The overall goal of the DECP is to help prevent crashes, deaths, and injuries by
improving enforcement of drug-impaired driving offenses (International Association of Chiefs of
Police [IACP], 2018c). International Association of Chiefs of Police, Drug recognition expert
course - instructor guide (2018) identifies three additional goals of the DECP training program,
which include:
1. Determine if the subject is impaired.
2. Determine if the impairment is resulting from an injury, illness, or drugs.
3. Determine, if drug-related, what category (or categories) of drugs is (or are) the likely
cause of the subject's impairment (p. 5).
Utilizing program evaluation theory of the DECP, this dissertation explained how the
program enabled a certified DRE to determine whether a suspect is under the influence of
alcohol and or drugs and, if so, by what category of drugs to achieve the program's overall goals.
Program evaluation theory of the DECP also assists the research in identifying the detailed
process the DECP uses to achieve the three secondary goals of the program. A detailed
description of the process and mechanisms of the DECP was examined in the literature review of
this dissertation. Program evaluation theory of the DECP assist in defining the critical inputs of
the program's components and how these components are delivered. Program evaluation theory
of the DECP assist in defining the amount of treatment required to induce the outcome and
outline the required aspects vital in producing the expected outcomes (Sharpe, 2011).
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In order to achieve the goals of the DECP, a DRE conducts the 12-step DRE protocol
DIE of individuals suspected of impairment after being arrested for Driving Under the Influence
(DUI). The DIE contains over one-hundred data points documented on a DIE face sheet and
narrative report. These data points are the critical inputs needed to influence the opinion made by
the DRE to achieve the three secondary goals of the DECP. This literature review examined
previous peer-reviewed journal articles and government-sponsored research, which focused on
creating the DECP, the DRE 12-step protocol, seven drug categories identified in the DECP, and
the validation studies conducted on the DRE accuracy rates.
Related Literature
Drugs in Society
The use of psychoactive drugs can be traced back several centuries to the beginning of
recorded history (Mann, 2017). Psychoactive substances have been used for religious
ceremonies, medicinal reasons, and recreational use (Crocq, 2007; Mann, 2017). For example,
priests and shamans have induced dissociative trances for religious purposes by ingesting
psychoactive plants. The use of amanita muscaria, a psychedelic mushroom, can be traced back
4,000 years in Central Asia which was used in religious rituals. In present times individuals use
the psilocybe mushrooms, which contain a psychoactive compound of psilocin and psilocybin, to
induce the same effects used over 4,000 years ago (Crocq, 2007).
Healers throughout history have used psychoactive substances for medicinal use, which is
evident in the 9th century BC Homer's Odyssey, where opium use is described as a potion to lull
all pain and anger (Crocq, 2007). In current society, cannabis has evolved into the largest
medicinal used plant, which contains the psychoactive substance delta-9-tetrahydrocannabinol
(THC) and can produce a variety of physical and mental effects, including euphoria, change in
perception, changes in appetite, and changes in memory (Behere et al., 2017). Cocaine for
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medicinal use appeared in 1860 when German chemist Albert Nieman isolated cocaine from
coca leaves (Goldstein et al., 2009). Doctors and healers used cocaine for its analgesic effect on
blocking nerves numbing effect for various medical procedures. Cocaine was sold over the
counter to the public in the United States until 1916 (Goldstein et al., 2019). Sigmund Freud was
known to use cocaine for depression and indigestion issues which assisted the drug to become
more commonplace in society (Goldstein et al., 2009).
As new drugs are developed or discovered from natural plants, individuals have utilized
them for their psychoactive effects on the human body for no other reason than personal
satisfaction (Behere et al., 2017; Crocq, 2007; Goldstein et al., 2007). Some of the most widely
abused drugs throughout history are alcohol, nicotine, and caffeine (Khan & Aslam, 2020). As
these drugs evolved, they became socially acceptable in most societies. For example, according
to the Bible, one of Noah's first actions after coming out of the Ark was to plant a vineyard; he
drank some of its wine and became drunk (New King James Version, 1997, Genesis 9:20-21).
Drug use has become the social norm either for religious ceremonies, medicinal, or
recreational uses. Although most drugs begin their journey into our society for legitimate
purposes, individuals have taken advantage of the drug's psychoactive properties for personal
pleasures or addiction. Furthermore, as pharmaceutical companies develop more drugs, the
psychoactive properties become more potent, increasing consumers' likelihood of abuse (Valeriy
& Tregubenko, 2019). Substance Abuse and Mental Health Services Administration (SAMHSA)
published the Key substance use and mental health indicators in the United States: Results from
the 2020 National Survey on Drug Use and Health (2021) which indicated “58.7 percent or
162.5 million people aged twelve or older self-reported the use of tobacco, alcohol, or illicit drug
in the past month” (p. 1).
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Drug-Related Legislation in the United States
The Hague Convention of 1912 required countries to regulate opium traffic into their
respective borders. During the same period as the Hague Convention, there was also an increase
in drug abuse levels. The federal government held hearings to determine the best course of the
regulation (Sacco, 2014). As a result, United States Congress passed the Harrison Narcotic Act
in 1914, establishing prescriptions for products exceeding the allowable limit of narcotics and
mandated an increase of physicians and pharmacists to maintain dispensing records (Olsen,
2022; Sacco, 2014). The Harrison Narcotic Act sought to regulate and control drugs through
taxation. The Narcotic Division of the Internal Revenue Bureau sent thousands of physicians and
pharmacists to federal penitentiaries for violations under the Harrison Narcotic Act (Olsen, 2022;
Sacco, 2014). As the United States moved into the prohibition era of the 1920s, several other
congressional acts were passed to enforce and regulate the sell, transportation, and use of drugs.
One of these acts was the Marihuana Tax Act of 1937, requiring a high-cost transfer tax stamp
for every sale of marijuana. The federal government issued the marijuana tax stamps, and the
issuance was rare. In response to the Act of 1937, all of the states made the possession of
marijuana illegal. Over the next several decades, Congress implemented several Drug Acts to
increase penalties and provide stricter criminalization laws for drug-related offenses (Sacco,
2014).
In 1970, Congress passed the Comprehensive Drug Abuse Prevention and Control Act
(CDAPCA), including the Controlled Substance Act (CSA). CDAPCA moved the drug laws
from a taxation enforcement concept to a regulation and law enforcement function. The Act was
designed to place the various drug laws under a single comprehensive statute (Redford, 2017;
Sacco, 2014). CSA helped establish a framework for the federal government to regulate the
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lawful production, possession, and distribution of controlled substances (Redford, 2017; Sacco,
2014). In addition, CSA enacted the scheduling of controlled substances in the United States. In
1973, the Drug Enforcement Administration (DEA) was created to enforce the CSA (Redford,
2017; Sacco, 2014). CDAPCA and CSA was the first step in the “War on Drugs” that would last
to present-day enforcement and legislation (Redford, 2017).
In the 1980s, other anti-drug abuse Acts were passed through congress, including the
Comprehensive Crime Control Act of 1984, the Anti-Drug Abuse Act of 1986 and 1988, and the
Chemical Diversion and Trafficking Act of 1988. These different Acts were developed to combat
the growing number of drug-related criminal offenses occurring in the United States by
increasing the mandatory sentencing guidelines and expanding the number of illegal substances
(Sacco, 2014). Throughout the 1990s and 2000s, the United States government expanded the
various drug Acts to include synthetic compounds and prescription drug abuse control.
Drugs and Impairment
As illustrated above, drug use in society has a long history dating back several centuries.
Natural plants with psychoactive properties were initially used for religious and medicinal
purposes, which have become an addiction and dependency for individuals in society. The
advancement of the pharmaceutical field has only increased the addictive and dependence cycle
plaquing or society. "Addiction is a chronic disease characterized by drug seeking and use that is
compulsive, or difficult to control, despite harmful consequences" (National Institute on Drug
Abuse, 2018, p. 1). Repeated and chronic use of drugs can lead to changes in the human brain,
making it more difficult to stop using drugs (Herman & Roberto, 2015; National Institute on
Drug Abuse, 2018). Drugs affect various critical neurotransmitters, for example, gammaaminobutyric acid, glutamate, dopamine, opioid peptides, serotonin (Herman & Roberto, 2015;
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International Association of Chiefs of Police [IACP], 2018c). One of the most common
neurotransmitters linked to illegal drugs is dopamine (Solinas et al., 2019). Dopamine is a
chemical messenger, a neurotransmitter, associated with the brain's reward and pleasure circuits,
causing a sense of euphoria, which increases an individual's motivation to repeat the behaviors
associated with drug use (National Institute on Drug Abuse, 2018).
Some drugs mimic the action of neurotransmitters associated with sympathetic and
parasympathetic nerves causing messages to be transmitted in the autonomic nervous system.
Sympathomimetic drugs can cause the elevation of blood pressure, pupils dilate, sweat glands
activate, and blood vessels of the skin constrict. Parasympathomimetic drugs can cause the
pupils to constrict, heartbeat to slow, peripheral blood vessels to dilate, and blood pressure to
decrease (International Association of Chiefs of Police [IACP], 2018c). When drugs are ingested
into the human body, the body reacts to the presence of these drugs by producing more
chemicals to bring the body back to a homeostasis level. The artificial creation of the body's
reaction to these messages is generally associated with neurotransmitters and hormones. When
an individual is ingesting a more significant than the average therapeutic dose of a drug, the body
"may produce greatly exaggerated simulations of the natural action of the hormones and
neurotransmitters" (International Association of Chiefs of Police [IACP], 2018c, p. 254).
American Psychological Association (APA) (2022) defines a psychoactive drug as "any
drug that has significant effects on psychological process, such as thinking, perception, and
emotion" (para. 1). Psychoactive drugs include the classification of drugs that produce an altered
state of consciousness affecting an individual's mental abilities and psychomotor skills
(International Association of Chiefs of Police [IACP], 2018c).
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Drugs and Driving
In 2020, there were 228 million licensed drivers in the United States (Carlier, 2022).
With the increase of licensed drivers and the corresponding self-reported surveys of drugged
impaired driving, law enforcement organizations needed to adapt to alcohol-only impaired
driving to include the identification of drugged impaired drivers. According to the 2018 National
Survey on Drug Use and Health, 20.5 million people aged sixteen or older drove under the
influence of alcohol in the past year of 2018, and 12.6 million drove under the influence of an
illicit drug (National Institute on Drug Abuse, 2019).
The legalization of cannabis has only increased the number of drivers under the influence
of drugs. It has become more common in some cases than driving under the influence of alcohol
(Cordelier et al., 2021). The legalization of cannabis capitulated literature on the relationship and
comparison of drugged driving versus alcohol driving (Yockey et al., 2020). Drugged-related
surveys and research indicate a problem occurring in the United States related to the significant
increase in drug driving traffic crashes (Thomas et al., 2020). According to the Office of
Behavioral Safety Research (2021), based on a 2020 study conducted at trauma centers in the
United States, during the last quarter of 2020, fifty-six percent of drivers involved in a serious
injury crash tested positive for at least one drug. (Thomas et al., 2020). In 2015, more people lost
their lives in drugged driving crashes than alcohol driving crashes (Governors Highway Safety
Association [GHSA], 2017). GHSA (2018) estimated that forty-three percent of drivers in 2016
who tested positive for illegal drugs in their system were involved in fatal related crashes.
The DECP was developed to assist law enforcement officers with detecting and gathering
evidence of drug-impaired drivers. With the increase in drug-related traffic crashes, specialized
law enforcement officers are needed to assist in detecting and identifying individuals who may
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be under the influence of drugs while operating a motor vehicle. The DECP was created to assist
with the specialized training needed to increase the level of knowledge of law enforcement in
detecting drugged driving (International Association of Chiefs of Police [IACP], 2018c).
Drug Evaluation and Classification Program
LAPD was the first organization to examine the problem of drugged-impaired drivers on
the roadways. During the 1970s, LAPD officers noticed that individuals arrested for driving
under the influence had low breath alcohol concentration readings. As a result, the officers
suspected the individuals were under the influence of drugs but lacked the training and
knowledge to support their suspicions in court. As a result, LAPD assigned two sergeants,
Richard Studdard and Len Leeds, to collaborate with medical professionals, toxicologist,
research psychologist, and medical doctors to develop a program to identify drug-influenced
drivers (Beirness & Porath, 2019; Porath-Waller et al., 2008; Porath-Waller & Beirness, 2010;
Talpins et al., 2018). The result of the collaboration was the 12-step systematic and standardized
process which later became the DRE protocol (Beirness & Porath, 2019; Porath-Waller &
Beirness, 2010; Talpins et al., 2018). The DRE protocol consisted of officers examining
individuals through interviews, behavioral tests, physical assessments, and measuring vital signs
and clinical indicators consistent with the effects of psychoactive substances (Beirness & Porath,
2019; Porath-Waller & Beirness, 2010; Talpins et al., 2018). "The LAPD formally recognized
the Program in 1979" (Talpins et al., 2018, p. 11).
Physicians, behavioral researchers, and other scientists held the first DRE school in Los
Angeles in 1980 (Beirness & Porath, 2019). The school gained the attention of NHTSA in the
1980s, and NHTSA, in collaboration with LAPD, conducted several research projects to develop
a standardized methodology. The focus of the research was to create a standardized and
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systematic process that could be taught to law enforcement officers to assist with the recognition,
arrest, and prosecution of suspected drivers under the influence of drugs (International
Association of Chiefs of Police [IACP], 2018c; Talpins et al., 2018). The results of the studies
created the DECP in 1987 with pilot programs in Arizona, Colorado, New York, and Virginia.
Currently all fifty states and several countries participate in the DECP (Beirness & Porath, 2019;
Talpins et al., 2018).
LAPD and NTHSA developed the DIE process into a 12-Step protocol for DREs to
follow in creating, analyzing, and developing opinions of which drug categories are psychoactive
during the evaluation. The DRE protocol addresses three required questions for law enforcement
officers: "Whether the suspect is impaired; and if so, whether the impairment relates to drugs or a
medical condition; and if drugs, the category or combination of categories of drugs that is the
likely cause of the impairment" (International Association of Chiefs of Police [IACP], 2018c, p.
133). The DRE protocol is a standardized and systematic approach to determine the complex
observable signs and symptoms known to be reliable indicators of drug impairment
(International Association of Chiefs of Police [IACP], 2018c; Newmeyer et al., 2017; Papfotiou
et al., 2004; Papfotiou et al., 2005; Schmitt et al., 2003; Scherer et al., 2020; Smith et al., 2002;
Stuster et al., 2006; Talpins et al., 2018; Vaillancourt et al., 2021).
DREs are law enforcement officers who have completed all three phases of the DECP
training requirements for certification established by IACP and NHTSA. Law enforcement
officers are first required to have prerequisites before being accepted into the DECP training.
Officers must have completed the NHTSA twenty-four-hour DUI standardized field sobriety
testing course and the sixteen-hour NHTSA Advanced Roadside Impaired Driving Enforcement
(ARIDE) course. ARIDE was developed to bridge the gap between the DUI alcohol training
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program and the DECP by providing officers with general knowledge related to drug impairment
(International Association of Chiefs of Police, 2022). The next step in the application process is
for officers to receive the recommendation of their organizational leader, the state prosecutor,
and a certified DRE. Applications are then sent to the DECP State Coordinator for approval and
verification of all prerequisite requirements.
Once accepted into the DECP, officers begin phase one training in the sixteen-hour DRE
preliminary school. The goal of the DRE preliminary school is to prepare officers to successfully
complete the second phase of training consisting of the seven-day DRE school. Students are
introduced to the seven drug categories used in the DECP, identify the twelve major components
of the DRE 12-step protocol, administer and interpret the psychophysical tests, conduct eye
examinations used in DIEs, check vital signs, describe the history and physiology of alcohol as a
drug, and list the major signs and symptoms associated with each drug category (International
Association of Chiefs of Police [IACP], 2018a).
Phase two of DECP is the seven-day DRE school which consists of an intensive learning
environment to comprehend and understand the 981-page student manual. Students learn each
component of the DRE 12-step protocol, including the examination procedures, observations,
measurements, the effects of drugs on the body, signs, and symptoms of each drug category. The
training is presented with classroom instruction followed by hands-on training. For example,
students learn how to take blood pressure, pulse rates, and body temperature. Students are also
taught how to estimate pupil sizes in three different lighting conditions. Students are also given
an overview of physiology and drugs, eye examinations (HGN, VGN, LOC), and in-depth
education on how drugs chemically affect the human body. After completing the seven-day
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school training, students must take a final examination with an acceptable passing score of 80%
(International Association of Chiefs of Police [IACP], 2018c).
The third phase of the DECP training consists of field evaluation certifications. Students
are observed and supervised by certified DRE instructors during the certification phase. Students
perform the DRE 12-step protocol on individuals under the influence of drugs. In Florida, the
DECP conducts the certification phase at an outreach clinic in Jacksonville. Volunteers give a
toxicology specimen and are screened by a DRE instructor before being presented to the DRE
student. Students then conduct the DRE 12-step protocol documenting their findings on the DIE
face sheets. Students must complete 12 drug evaluations and identify a minimum of three of the
seven drug categories. DREs then complete the written narrative portion of the DIE and submit it
to a minimum of two DRE instructors for review. Toxicological specimen results are compared
to the DRE opinion, and a passing rate of 75% is required to complete the certification phase.
After the certification phase, students complete a five-part final knowledge examination
(International Association of Chiefs of Police [IACP], 2018c).
DREs are highly trained and experienced officers skilled in detecting and identifying
subjects under the influence of drugs and identifying the categories of drugs causing the
impairment (International Association of Chiefs of Police, 2022). In 2020, the United States had
an estimated 696,644 law enforcement officers providing services to their communities (Statista,
2021). According to IACP, there are an estimated 8,000 certified DREs in the United States,
equating to certified DREs being only 1.1% of the law enforcement officer community. Florida
had an estimated 38,580 active certified law enforcement officers in 2020 (U.S. Bureau of Labor
Statistics, 2022). According to IACP, in 2019, Florida employed 405 DREs, equating to only 1%
of employed law enforcement officers.
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DRE 12-Step Protocol
The DRE 12-step evaluation protocol consists of a breath test, interview of arresting
officer by the DRE, preliminary examination, pulse rates, eye examination, divided attention
psychophysical tests, vital signs, dark room examinations, examination of muscle tone, check for
injection sites, subject's statements and other observations, opinion of the evaluator, and
toxicological examination (International Association of Chiefs of Police [IACP], 2018c; Scherer
et al., 2020; Talpins et al., 2018; Vaillancourt et al., 2021). Several of the steps contained in the
DRE evaluation protocol are not new concepts, and creators of the DECP utilized trusted and
proven methods of assessment in the medical community (International Association of Chiefs of
Police [IACP], 2018c). Therefore, the individual tests performed during the evaluation have a
strong foundation in the medical community as reliable and validated (Talpins et al.,
2018). DREs document the 12-step protocol on a DIE face sheet that contains over one hundred
different elements in numerical, narrative, and pictorial forms (Porath-Waller et al., 2021). DREs
then create a written narrative that can range from one to ten pages in length, submitted to the
State Attorney's Office as evidence for prosecution.
Breath Alcohol Test. The first step in the DRE protocol consists of obtaining a breath
test from the subject. Florida Administrative Code (FAC) 11D-8 outlines the requirements of the
Florida Department of Law Enforcement (FDLE) alcohol testing program. FAC 11D-8 requires
subjects to provide two valid breath samples, within fifteen minutes of each other, utilizing CMI,
Inc. Intoxilyzer 8000 to complete the breath test (Florida Department of State, 2015). A breath
alcohol test gives an accurate concentration level of the subject's alcohol content contained in the
breath sample (Porath-Waller et al., 2021; Talpins et al., 2018). In addition, the breath test assists
the DRE in determining if the impairment level observed in the subject is consistent with the
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measured alcohol level (Porath-Waller et al., 2021). The inconsistency of the impairment level
and breath alcohol levels identified in the sample is required to determine if a medical condition
mimicking impairment is the cause of the observed impairment or if drugs are possibly causing
the observed impairment (International Association of Chiefs of Police [IACP], 2018c; Talpins
et al., 2018).
Interview Arresting Officer. The second step in the DRE protocol is interviewing the
arresting officer. The DREs inquire about the behaviors, impairment, appearance, driving
pattern, smells, and any other identifiers that could indicate the subject being under the influence
of drugs (International Association of Chiefs of Police [IACP], 2018c; Porath-Waller et al.,
2021; Talpins et al., 2018). The interviewing process is critical because DRE evaluations are, on
average, 54 minutes after the subject's arrest (Porath-Waller et al., 2021). For example, due to
psychoactive drug periods, an officer on the traffic stop scene might observe indicators of drug
categories. However, when the subject is presented to the DRE for an evaluation, the drug could
no longer be psychoactive. The subject would then display different outward indicators than they
did on the traffic stop scene.
Preliminary Examination. The third step in the DRE protocol is known as the "fork in
the road" (International Association of Chiefs of Police [IACP], 2018c). This step is critical in
determining the first question for the DRE of whether the subject is impaired or having a medical
emergency (Porath-Waller et al., 2021; Talpins, 2018). A preliminary examination and first pulse
reading are conducted in the third step. Next, the DRE will ask the subject a series of questions
relating to the subject's health, medical history, drug use, and ingestion of food. DREs observe
the subject's appearance, attitude, speech, smells, coordination, breath, and face color. DREs will
also estimate if the subject's pupils are within a .05-millimeter difference. Finally, the DRE will

36
determine if the subject's eyes can track and obtain an estimation of the angle of onset for
Horizontal Gaze Nystagmus (HGN) if present. The preliminary eye examination aims to
determine if the subject is possibly suffering from a neurological disorder, disease, or brain
injury (International Association of Chiefs of Police [IACP], 2018c; Talpins et al., 2018).
Eye Examination. The fourth step in the DRE protocol is the eye examination. The DRE
will conduct the Horizontal Gaze Nystagmus (HGN), Vertical Gaze Nystagmus (VGN), and
Lack of Convergence (LOC) test during this step (Porath-Waller et al., 2021; Talpins et al.,
2018). Central nervous system depressants, inhalants, and dissociative anesthetics may cause
horizontal gaze nystagmus and lack of convergence. Cannabis alone may also cause a lack of
convergence for the eyes. Nystagmus is the involuntary jerking of the eyes. Horizontal Gaze
Nystagmus (HGN) is the involuntary jerking of the eyes occurring as the eyes gaze to the side
(Bertolli et al., 2007; International Association of Chiefs of Police [IACP], 2018c; Talpins et al.,
2018).
HGN has been established and validated through multiple studies as a strong indicator of
a subject's breath alcohol content level (Burns & Anderson, 1995; Burns & Dioquino, 1997;
Stuster, 1998; Stuster, 2006). Nystagmus causes an individual's inability to track a moving
object. This impairing condition restricts an individual's ability to operate a motor vehicle due to
the restriction of tracking moving objects (Talpins et al., 2018). The phenomena caused by
nystagmus indicate that HGN is not only an indicator of impairment; HGN is impairment
(Talpins et al., 2018). Several medical validation studies have shown alcohol impairment is not
the only impairing substance causing HGN, but other known drug categories can also induce
HGN (Dhingra et al., 2019; Kosnoski et al., 1998). For this reason, DECP included the eye
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examinations as step four of the DRE evaluation protocol to help DREs identify and conclude
which drug categories could be causing impairment in individuals.
Vertical Gaze Nystagmus (VGN) is also administered during the eye examination. VGN
will be present if the drug is a high dose for that particular individual's tolerance levels
(International Association of Chiefs of Police [IACP], 2018c; Talpins et al., 2018). VGN is the
involuntary jerking of the eyes, up-and-down, which occurs as the eyes are held at maximum
elevation (International Association of Chiefs of Police [IACP], 2018c).
Finally, the last eye examination test performed to assist DREs in determining which
drug categories are causing impairment is Lack of Convergence (LOC). LOC is the inability of a
subject's eyes to converge, or cross, as the subject attempts to focus on a stimulus moving slowly
towards their nose (International Association of Chiefs of Police [IACP], 2018c).
Divided Attention Psychophysical Tests. The fifth step of the DRE protocol is the
divided attention psychophysical tests, which consist of the Modified Romberg Balance (MRB),
Walk and Turn (WAT), One-Leg Stand (OLS), and Finger to Nose (FTN) (Porath-Waller et al.,
2021; Talpins, 2018). The psychophysical tests aim to determine the subject's impairment
indicators (International Association of Chiefs of Police [IACP], 2018c; Talpins et al., 2018). In
addition, the psychophysical test are modifications of neurologists' performance test in
diagnosing illness and are used by pharmacologists in assessing the psychomotor effects of drugs
(Cowan & Jaffee, 1989; Talpins et al., 2018).
The Standardized Field Sobriety Tests (SFST) were initially developed to assist law
enforcement officers in determining the degree of impairment among alcohol-affected
individuals (Anderson et al., 1983; Burns & Anderson, 1995; Burns & Moskowitz, 1977; Burns
& Dioquino, 1997; Downey et al., 2016; Fiorentino et al., 2020; Porath-Waller & Beirness, 2013;
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Stuster & Burns, 1998; Tharp et al., 1981). Subsequent validation studies were conducted and
suggested the usefulness of identifying drug impairment in individuals (Alder & Burns, 1994;
Downey et al., 2012; Downey et al., 2016; Fiorentino et al., 2020; Ip et al., 2013; Papafotiou et
al., 2005; Perry et al., 2015; Porath-Waller & Beirness, 2013). SFSTs are a series of tasks to
assess an individual's ability levels of divided attention, cognitive functioning, and psychomotor
performance (Downey et al., 2016).
Modified Romberg Balance. The Modified Romberg Balance (MRB) is a modified
version of Moritz Heinrich Romberg, a German neurologist, balance test which evaluates
neurological function detecting the individual's inability to maintain a steady standing posture
with eyes closed, divided attention and time sense impairment (Hartman et al., 2016). The
participants are asked to estimate the passing of thirty seconds with their eyes closed, standing
with their feet together and head tilted back. An individual's internal timing estimates can slow
down or speed up depending on a particular drug category that may be psychoactive at the time
of the evaluation (International Association of Chiefs of Police [IACP], 2018c).
MRB is divided into the instructional and balance stages. DREs evaluate the subject for
several indicators of impairment in the two stages (International Association of Chiefs of Police
[IACP], 2018c). First, subjects are instructed to stand straight with their feet together and arms
down by their side. The subject is to remain in this position while the DRE continues with the
instructions for the test. Next, evaluated subjects are instructed not to begin the test until told by
the DRE. The DRE instructs the subject that once they are told to begin the test, they are to tilt
their head back, close their eyes, and estimate the passage of thirty seconds. When the subject
believes the passage of thirty seconds occurs, they are to tilt their head forward, open their eyes,
and say stop (International Association of Chiefs of Police [IACP], 2018c).
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DREs document on the DIE face sheet if they observe body or eyelid tremors, swaying of
the subject, and the time it took for the subject to conduct the test. Each clue exhibited by the
subject correlates to one or more of the drug categories symptomologies on the drug-matrix,
assisting DREs in determining which drug category is causing impairment in the subject
(International Association of Chiefs of Police [IACP], 2018c).
Walk and Turn. The second divided attention test in the 12-Step DRE protocol is the
Walk and Turn (WAT) test (International Association of Chiefs of Police [IACP], 2018c). The
WAT divides a subject's mental ability such as short-term memory, judgment, and decision
making with physical activity such as balance, muscle control, and coordination (International
Association of Chiefs of Police [IACP], 2018a; International Association of Chiefs of Police
[IACP], 2018b). The WAT test was one of the first validated tests used to assess a subject's
alcohol impairment (Anderson et al., 1983; Burns & Anderson, 1995; Burns & Moskowitz,
1977; Burns & Dioquino, 1997; Stuster & Burns, 1998; Tharp et al., 1981).
WAT is divided into the instructional and walking stages. DREs evaluate the subject for
eight indicators of impairment in the two stages (International Association of Chiefs of Police
[IACP], 2018c). According to the DRE instructor manual (International Association of Chiefs of
Police [IACP], 2018a), the test begins with the DRE instructing the subject to place their right
foot on a line, the left foot directly in front of the right foot with their left heel touching their
right toes on the line. The subject is then instructed to place their arms down by their side and
stay in this position while the DRE finishes giving all the instructions. This first set of
instructions is called the instructional stage, and DREs are looking to see if the subject can
maintain their balance in this position as the first clue of impairment. The second indicator of
impairment is to see if the subject begins the test prior to being told to start. The DREs then
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complete the rest of the instructions telling the subjects to walk nine heel-to-toe steps down the
line, turn in a prescribed manner and return nine heel-to-toe steps down the line. DREs evaluate
the subject for six additional indicators of impairment, including does not touch heel-to-toe, steps
off the line, using arms for balance, improper turn, incorrect number of steps, and stops walking
to steady themselves.
While performing the WAT test, DREs evaluate the subject's ability to divide their
attention between physical actions such as walking on the line and mental actions such as shortterm memory of the instructions for the required number of steps and turning instructions. DREs
document each clue of impairment on the DIE face sheet, including a pictogram of the subject's
performance (International Association of Chiefs of Police [IACP], 2018c).
One Leg Stand. The third divided attention test in the 12-Step DRE protocol is the One
Leg Stand (OLS) test (International Association of Chiefs of Police [IACP], 2018c). The OLS
divides a subject's mental ability, such as short-term memory and information processing, with
physical activity such as balance, muscle control, and coordination (International Association of
Chiefs of Police [IACP], 2018b). The OLS test is also one of the original validated tests used to
assess a subject's alcohol impairment (Anderson et al., 1983; Burns & Anderson, 1995; Burns &
Moskowitz, 1977; Burns & Dioquino, 1997; Stuster & Burns, 1998; Tharp et al., 1981).
One Leg Stand (OLS) is divided into the instructional stage and balance and counting
stage. DREs evaluate the subject for four indicators of impairment in the two stages
(International Association of Chiefs of Police [IACP], 2018c). According to the DRE instructor
manual (International Association of Chiefs of Police [IACP], 2018a), the test begins with the
DRE instructing the subject to stand with their feet together and arms by their sides. Next, the
DRE instructs the subject to raise their left foot six inches off the ground, keeping their foot
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parallel to the ground and counting aloud by one thousand while keeping their arms down by
their side. Finally, the DRE times the test for thirty seconds before instructing the subject to
place their foot down. The exact timing of the test is essential for the DRE during the evaluation
due to the original research showed subjects were able to stand on one leg for up to twenty-five
seconds, but most were not able to keep their foot raised for a full thirty seconds (Burns &
Moskowitz, 1977; International Association of Chiefs of Police [IACP], 2018b).
The DRE then instructs the subject to perform the same test using the right foot raised off
the ground. The DRE evaluation of the OLS differs from alcohol-related OLS test on the
roadside due to having the subject perform the test twice, once with each raised foot. The
purpose of administering the test twice for both the left and right legs is to assist the DRE in
making comparisons and identifying potential medical conditions that may be present
(International Association of Chiefs of Police [IACP], 2018a). DREs are evaluating the subject
for four clues of impairment which include the subject swaying while balancing, using their arms
to balance, hopping, and placing their foot down (Anderson et al., 1983; Burns & Anderson,
1995; Burns & Moskowitz, 1977; Burns & Dioquino, 1997; International Association of Chiefs
of Police [IACP], 2018a; International Association of Chiefs of Police [IACP], 2018b;
International Association of Chiefs of Police [IACP], 2018c, Stuster & Burns, 1998; Tharp et al.,
1981).
While performing the OLS test, DREs evaluate the subject's ability to divide their
attention between physical actions such as the balancing task and mental actions such as the
information processing needed to conduct the test. DREs document each clue of impairment on
the DIE face sheet, including a pictogram of the subject's performance (International Association
of Chiefs of Police [IACP], 2018c).
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Finger-to-Nose. The fourth divided attention test in the 12-Step DRE protocol is the
Finger-to-nose (FTN) test (International Association of Chiefs of Police [IACP], 2018c). The
FTN divides a subject's mental ability, such as information processing, with physical activity
such as muscle control and coordination (International Association of Chiefs of Police [IACP],
2018b). The subject is instructed to touch their nose six times in a systematic sequence. Their
eyes are closed, and the two hands are outstretched to the sides (International Association of
Chiefs of Police [IACP], 2018a; Shinar & Schechtman, 2005). DREs document each placement
of the subject's index finger to the nose on the DIE face sheet, which includes a pictogram of the
subject's performance (International Association of Chiefs of Police [IACP], 2018c). DREs also
observe the subject for any indication of swaying during the test, body tremors, and eyelid
tremors (International Association of Chiefs of Police [IACP], 2018a).
Vital Signs. The sixth step in the DRE protocol is the vital signs. DREs obtain a subject's
blood pressure, pulse rate, and body temperature (Porath-Waller et al., 2021; Talpins et al.,
2018). Subjects under the influence of specific drug categories can raise or lower vital signs. The
results of the vital signs assist DREs in identifying which drug category is currently psychoactive
at the time of the evaluation (International Association of Chiefs of Police [IACP], 2018a;
International Association of Chiefs of Police [IACP], 2018c). DREs document the results of the
vital signs on the DIE face sheets to determine the possible drug category associated with the
results of the subject's blood pressure, pulse rate, and body temperature.
DREs use a standard manual sphygmomanometer with a stethoscope to record the
systolic and diastolic pressures to obtain the subject's blood pressure. The subject's blood
pressure is obtained at the brachial artery pulse point on the left arm. The DRE average range is
120-140 systolic and 70-90 diastolic. A subject's blood pressure above the average range is
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considered raised, and if below the average range, it is considered lowered (International
Association of Chiefs of Police [IACP], 2018c).
DREs obtain a subject's pulse measurement manually at the radial artery pulse point. The
average DRE pulse rate is sixty to ninety beats per minute. The pulse is measured with a
mechanical timepiece for thirty seconds and then times by two. If the pulse rate is above ninety
beats per minute, it is considered raised. If the pulse is below sixty beats per minute, it is
considered lowered (International Association of Chiefs of Police [IACP], 2018c). DREs obtain
a subject's body temperature using an oral thermometer. The average DRE range for body
temperature is 98.6 degrees Fahrenheit plus or minus one-degree Fahrenheit (International
Association of Chiefs of Police [IACP], 2018c).
Drugs affect human physiology and indicators of possible impairment may be present and
assessed in this evaluation stage. For example, central nervous system stimulants, hallucinogens,
and dissociative anesthetics can increase a subject's blood pressure, pulse rate, and body
temperature. Conversely, central nervous system depressant and narcotic analgesic drugs can
lower a subject's blood pressure and pulse rate (International Association of Chiefs of Police
[IACP], 2018a; International Association of Chiefs of Police [IACP], 2018c). Depending on
what type of drug a subject ingests prior to driving a vehicle and that drug being psychoactive in
the body determines the different physiological responses observed. The sixth step of taking vital
signs is a critical component of the DRE protocol (International Association of Chiefs of Police
[IACP], 2018c).
Dark Room Examination. The seventh step of the 12-step DRE protocol is the
darkroom examinations. The subject's pupil sizes are estimated with a pupilometer in three
different lighting conditions room light, near-total darkness, and direct light (Porath-Waller et al.,
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2021; Talpins et al., 2018). Specific drug categories cause an individual's pupils to be constricted
or dilated (International Association of Chiefs of Police [IACP], 2018a; International Association
of Chiefs of Police [IACP], 2018c; Shinar & Schechtman, 2005;). DREs also assess how the
subject's pupils react to light's introduction under near-total darkness conditions (Porath-Waller
et al., 2021; Talpins et al., 2018).
DREs utilize a room for this step that can be turned into a near-total darkness
environment to estimate the subject's pupil size. DREs use a pupilometer containing a series of
circles or semi-circles with diameters ranging from 1.0mm to 10.0mm in half-millimeter
increments (International Association of Chiefs of Police [IACP], 2018a; International
Association of Chiefs of Police [IACP], 2018c). According to the DRE Instructor Manual
(International Association of Chiefs of Police [IACP], 2018a), the first estimation of the subject's
pupils occurs in the room with normal lighting conditions with an average DRE range of 2.5mm
to 5.0mm. Once the room light estimate has been obtained, the room is placed into a near-total
darkness environment for ninety seconds before the second estimation of the pupil sizes. The
DRE average range of near-total darkness is 5.0mm to 8.5mm. An estimate of direct light pupil
size then occurs with the DRE turning on a penlight directly into the eyes of the subject, one eye
at a time. The average DRE range for direct light is 2.0mm to 4.5mm. The DRE is also
estimating the reaction of the subject's pupils to the direct light to determine if the reaction is
slow, normal, or none (International Association of Chiefs of Police [IACP], 2018c).
Specific drug categories can dilate a subject's pupils when they are psychoactive at the
evaluation time. For example, central nervous system stimulants and hallucinogens can dilate the
pupils. In contrast, a narcotic analgesic can constrict a subject's pupils (International Association
of Chiefs of Police [IACP], 2018a; International Association of Chiefs of Police [IACP], 2018c).
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Therefore, examining the pupils under controlled lighting conditions provides essential evidence
of possible drug influence due to the various manifestations of the drug's psychoactive
properties. After the estimations are gathered, the DRE then checks the nose and mouth of the
subject for other signs of drug use (International Association of Chiefs of Police [IACP], 2018a;
International Association of Chiefs of Police [IACP], 2018c; Porath-Waller et al., 2021; Talpins
et al., 2018).
Muscle Tone and Injection Sites. The eighth step of the DRE process is the examination
of muscle tone. DREs examine the subject's skeletal muscle tone to assess whether the muscles
are rigid, flaccid, or normal (International Association of Chiefs of Police [IACP], 2018a;
International Association of Chiefs of Police [IACP], 2018c; Porath-Waller et al., 2021; Talpins
et al., 2018). The ninth step is conducted simultaneously as the muscle tone examination. DREs
observed the subject body for injection sites to indicate drug use. The third pulse rate is also
taking in the nineth step (International Association of Chiefs of Police [IACP], 2018c; PorathWaller et al., 2021; Talpins et al., 2018).
Interrogation, Statements, and Observations. The tenth step in the DRE process is to
interview the subject and record any statements. Observations of the subject's behavior and
mannerisms are also documented during this step (Porath-Waller et al., 2021; Talpins et al.,
2018). DREs ask a series of questions about the subject's history of drug use and attempt to
determine if they confirm the use of drugs prior to operating a vehicle. The statements and
observations are documented on the DIE face sheets (Talpins et al., 2018).
Opinion of Evaluator. Step eleven is for the DRE to formulate their opinion of which
drug category or categories they believe the subject is currently under the influence
(International Association of Chiefs of Police [IACP], 2018a; International Association of Chiefs
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of Police [IACP], 2018c; Porath-Waller et al., 2021; Talpins et al., 2018). The opinion made by
the DRE is based on the totality of the evidence and observations noted during the evaluation.
The DRE opinion is to determine if the subject is impaired, and if so, then by which drug
category or combination of drug categories is causing the impairment (Porath-Waller et al.,
2021). The subsequent opinion by the DRE is to determine if the subject’s impairment is
affecting the subject's ability to operate a vehicle safely (International Association of Chiefs of
Police [IACP], 2018a; International Association of Chiefs of Police [IACP], 2018c).
Toxicology Examination. The final step in the DRE process is the toxicology
examination. It is dependent on the DREs jurisdiction as to whether urine, blood, or both are
collected and sent for examination (International Association of Chiefs of Police [IACP], 2018c;
Porath-Waller et al., 2021; Talpins et al., 2018). The toxicology examination can occur months
after the DRE completes the evaluation and is used as a toxicological confirmation of the DRE's
opinion.
DRE 12-Step Protocol Validation Studies
NHTSA and LAPD focused on developing a standardized and systematic process for a
law enforcement officer to determine if drugs impair suspected individuals under arrest for
driving under the influence. Accordingly, NHTSA and LAPD conducted a two-phase validation
study in 1984 and 1985 (International Association of Chiefs of Police [IACP], 2018c). The first
phase was a laboratory validation research study where individuals ingested selected drugs and
then performed field sobriety tests. The laboratory evaluation study was conducted at Johns
Hopkins University in Maryland in 1984 (Bigelow et al., 1985; International Association of
Chiefs of Police [IACP], 2018c). After the laboratory study was completed, NHTSA and LAPD
officers moved into the second phase by conducting a field validation study commonly referred

47
to as the 173 study (International Association of Chiefs of Police [IACP], 2018c). These two
primary studies set the foundation for the DECP and admissibility in the criminal justice system.
John Hopkins Study. Bigelow et al. (1985) enlisted the assistance of four DREs from
LAPD: Richard Studdard, Jerry Powell, Pat Russell, and Doug Laird. Volunteers were given a
"pill" and smoked a "cigarette" in a controlled laboratory. The pill contained either a placebo,
secobarbital, diazepam, or d-amphetamine. The cigarette contained either a placebo or delta-9tetrahydrocannabinol (THC). The laboratory study was a double-blind experiment where neither
the DREs nor the volunteers knew which pill or cigarette they received contained any drugs or
was a placebo. The dosage units were increased from the normal therapeutic doses for this study
due to researchers trying to identify individuals who were impaired by the drugs. The normal
daily dose is "secobarbital- 100mg, diazepam- 4-40mg, and d-amphetamine-15mg for
therapeutic purposes. The doses administered for this study are secobarbital- 300mg, diazepamweak-15mg and strong- 30mg, d-amphetamine- weak-15mg and strong-30mg, marijuana- weak
1.3% THC and strong-2.8% THC” (International Association of Chiefs of Police [IACP], 2018c,
p. 115).
The four DREs were presented with 80 volunteers, and each DRE evaluated all the
volunteers. The evaluations were conducted independently by a single DRE, and the other three
DREs were unaware of the conclusions from their partners who also examined the same
volunteers. Each DRE was allotted 20 minutes to evaluate to determine if the volunteer was
impaired and if impaired by which drug category was causing the impairment. DREs had no
contact with the volunteers prior to the evaluation and did not contact other DREs until the
evaluations were completed (Bigelow et al., 1985). Due to the allotted time only being 20
minutes, DREs used a modified evaluation compared to a field evaluation which usually lasts
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approximately one hour. The core procedures did not change, and only those items which
seemed irrelevant to the experimental context were removed. The modified evaluation
procedures consisted of three components.
First, the DREs conducted a brief interview to determine the volunteer's medical history,
drug history, eating and sleeping habits, and alcohol use. The second component was the clinical
evaluation which consisted of pulse rate, blood pressure, body temperature, pupil size, pupil
reaction to light, nystagmus, perspiration, and salivation observations. The third component was
the field sobriety testing (psychomotor tests) which consisted of standing steadiness and time
perception, line test, one-foot balance, and hand-to-nose test (Bigelow et al., 1985). These four
psychomotor tests would later be the modified Romberg balance, walk and turn, one-leg stand,
and finger to nose tests. (International Association of Chiefs of Police [IACP], 2018c).
DREs correctly identify 95% of the subjects who received placeboes as not impaired. In
addition, the DREs correctly identified 98.7% of subjects who received secobarbital or
substantial doses of marijuana, diazepam, or d-amphetamine. The DREs also identified the
correct category of drugs causing the impairment in 90% of the subjects (Bigelow et al., 1985;
International Association of Chiefs of Police [IACP], 2018c).
"173 Study". The second phase of the validation process was to conduct a field
validation study in Los Angeles. The study was based on 173 individuals arrested on suspicion of
driving under the influence of drugs in Los Angeles (International Association of Chiefs of
Police [IACP], 2018c). The study consisted of twenty-five different DREs trained in the LAPD
DRE program. Researchers narrowed the field down to 173 participants by excluding any
suspects who refused to provide a toxicological sample, were involved in a traffic crash, or were
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found in possession of drugs (Compton, 1986; International Association of Chiefs of Police
[IACP], 2018c).
Compton (1986) conducted the field validation study over three months in 1985.
Individuals arrested for suspicion of driving under the influence were brought to the jail facility,
where a DRE evaluated those whose alcohol breath samples were not consistent with their level
of impairment. The DREs used the 12-step protocol to conduct the evaluations, which consisted
of an interview, physiological symptoms, and behavioral tests (Compton, 1986). Once the
evaluation was completed, each DRE gave their opinion on whether or not the individual was
impaired and if impaired by which drug category was causing the impairment. The subjects were
then asked to provide a toxicological blood sample sent to a private laboratory for analysis. Two
hundred one subjects were evaluated, and only one-hundred and seventy-three subjects agreed to
provide a blood sample (Compton, 1986).
"Thirty-seven (21%) of the subjects were found to have only one drug other than alcohol,
eighty-two (47%) had two drugs and forty-three (25%) had three or more drugs including
alcohol" (International Association of Chiefs of Police [IACP], 2018c, Session 3 p. 15). Thus, a
total of 125 subjects had ingested two or more drugs. The DREs were able to identify 94% of
subjects being impaired by at least one drug, which was confirmed through blood toxicological
analysis. DREs then gave an opinion on which drug category they believed was causing the
subject's impairment. The DREs were able to identify one or more drugs correctly in 87% of the
subjects (Compton, 1986).
Arizona Study. The two-phase validation studies conducted at Johns Hopkins University
and the Los Angeles Police Department set the standard for future researchers to examine the
DRE protocol and its effectiveness in identifying individuals under the influence of specific drug
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categories. The last primary source and foundational study performed was conducted in
Arizona, Drug recognition expert (DRE) validation study: Final report to Governor's office of
highway safety state of Arizona, in 1994 by Eugene Adler and Marcelline Burns.
Adler & Burns (1994) reviewed over five-hundred drug influence evaluations over fiftythree months and the corresponding toxicological analyses of the suspect's specimens. This was
the first validation study of the DECP since the 1985 John Hopkins and 173 studies were
conducted. Ten years have passed since the original research, and Adler & Burns wanted to
examine if the prediction rates of DREs have changed with the increase of experience of officers
in the program. The objective of the study was to "evaluate the validity of the DRE methodology
with records from an established program, to examine relationships between drug signs and
symptoms and drug presence in specimens, and to study arrestee characteristics and drug
choices" (Alder & Burns, 1994, p. viii). Five hundred drug influence evaluations were collected
from Phoenix Police Department and Arizona Department of Public Safety Laboratory from
January 1989 to May 1993. Researchers utilized the Foxplus software to conduct a descriptive
statistics analysis of data extracted from the five hundred drug influence evaluations and
toxicological results (Alder & Burns, 1994). The study results indicated DREs with the Phoenix
Police Department had an accuracy rate of 85%, agreeing with Compton's previous field
validation study in 1986 (Alder & Burns, 1994).
DRE Seven Drug Categories
DREs refer to a symptomology drug matrix (Appendix B) to assist with determining an
opinion of drug classification. The symptomology drug matrix directly correlates to the DIE face
sheet used to document the evaluation results in the 12-step DRE protocol. The symptomology
drug matrix contains signs and symptoms observed in the DIE and places these observations into
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one of the respective drug categories. DREs define a sign as "an observable or detectable
indicator of drug influence" (International Association of Chiefs of Police [IACP], 2018a,
session 7, p. 6). For example, dilated pupils, high blood pressure, and raised body temperature
are considered a sign for DRE evaluations. DREs define a symptom as "a subjective indicator of
drug influence reported by the drug-impaired subject" (International Association of Chiefs of
Police [IACP], 2018a, session 7, p. 6). For example, "I feel nauseous" is considered a symptom
by DREs.
Drugs are categorized based on their symptomatology or effects on the human body
associated with each category's long-standing, medically accepted facts (Talpins et al., 2018).
Each category contains drugs that affect a person's body, impairing their normal faculties and
ability to operate a vehicle safely (International Association of Chiefs of Police [IACP], 2018a;
Talpins et al., 2018). The 12-step DRE protocol evaluation is designed to assist DREs in
identifying which possible drug category is causing impairment in the evaluated subjects who
have been placed under arrest for driving under the influence (International Association of
Chiefs of Police [IACP], 2018c). The seven drug categories of the DECP are central nervous
system (CNS) depressants, central nervous system (CNS) stimulants, hallucinogens, dissociative
anesthetics, narcotic analgesics, inhalants, and cannabis (International Association of Chiefs of
Police [IACP], 2018a; International Association of Chiefs of Police [IACP], 2018c; Porath &
Beirness, 2019; Porath-Waller et al., 2021; Talpins et al., 2018).
CNS Depressants. Central Nervous System (CNS) Depressants are the first category on
the DRE symptomology drug matrix (Porath & Beirness, 2019; Talpins et al., 2018). CNS
Depressants contain a classification of drugs that affect the human body by slowing down a
person's brain and central nervous system (Logan et al., 2017; Talpins et al., 2018). The six
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major subcategories of CNS Depressants other than alcohol are barbiturates, non-barbiturates,
anti-anxiety tranquilizers, antidepressants, anti-psychotic tranquilizers, and combinations
(International Association of Chiefs of Police [IACP], 2018c).
HGN and LOC are usually present in subjects who have ingested a CNS Depressant drug,
while VGN may be present if it is a high dose for that particular subject (Logan et al., 2017). A
subject's pupil size will be normal. However, Soma, Quaaludes, and some antidepressants will
dilate the pupils (International Association of Chiefs of Police [IACP], 2018c). A subject's
reaction to light will usually be slowed when estimated in the darkroom evaluation (Dargan et
al., 2013; Stephenson et al., 2013). Pulse rate and blood pressure tend to be lower in subjects
under the influence of a CNS Depressant (Dargan et al., 2013; Snozek, 2020; Stephenson et al.,
2013). Quaaludes, alcohol, and some antidepressants could elevate a subject's pulse rate
(International Association of Chiefs of Police [IACP], 2018c). The subject's body temperature is
usually normal, and their muscle tone will be flaccid (Snozek, 2020; Stephenson et al., 2013).
Subjects that ingested above a standard therapeutic dose of CNS Depressants can show
signs and symptoms of having a drunk like behavior, drowsiness, ptosis, disoriented, unsteady
walking, slow or sluggish reactions, thick or slurred speech, and be uncoordinated (Dargan et al.,
2013; Logan et al., 2017; International Association of Chiefs of Police [IACP], 2018c; Snozek,
2020; Stephenson et al., 2013).
CNS Stimulants. Central Nervous System (CNS) Stimulants are the second category on
the DRE symptomology drug matrix (Porath & Beirness, 2019; Talpins et al., 2018). CNS
Stimulants contain a classification of drugs that affect the human body by speeding up a person's
brain and central nervous system (Talpins et al., 2018). The three major subcategories of CNS
Stimulants are cocaine, amphetamines, and others (International Association of Chiefs of Police
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[IACP], 2018c). All three subcategories exhibit the same signs and symptoms associated with the
CNS Stimulant drug category for the DRE evaluation.
HGN, VGN, and LOC will not be present in the DRE evaluation for the subjects who
only have ingested a CNS Stimulant drug (International Association of Chiefs of Police [IACP],
2018c). The subject's pupils will be dilated above the average DRE range, and the pupil's
reaction to light will be slow (Dhingra et al., 2019; Porath & Beirness, 2019). CNS Stimulants
will raise a subject's pulse rate, blood pressure, and body temperature when the drug is consumed
over the standard therapeutic dose prescribed for the subject (Caplan et al., 2007; Porath &
Beirness, 2019). Subjects can also show signs and symptoms of having body tremors, anxiety,
dry mouth, euphoria, exaggerated reflexes, exited, eyelid tremors, bruxism, increased alertness,
insomnia, irritability, restlessness, and talkative (Caplan et al., 2007; Chang et al., 2019;
International Association of Chiefs of Police [IACP], 2018c; Porath & Beirness, 2019).
Hallucinogens. The third drug category on the DRE symptomology drug matrix is
Hallucinogens (Porath & Beirness, 2019; Talpins et al., 2018). Hallucinogens “are drugs that
affect a person’s perceptions, sensations, thinking, self-awareness, and emotions” (International
Association of Chiefs of Police [IACP], 2018c, p. 458). DECP divides hallucinogen drugs into
two subcategories of natural and synthetic hallucinogens (International Association of Chiefs of
Police [IACP], 2018c). Natural hallucinogens consist of drugs that occur in nature such as
peyote, psilocybin, salvia divinorum, nutmeg, jimson weed, morning glory seeds, and bufotenine
(Barrett et al., 2018; Garcia-Romeu & Richards, 2018; Nitescu & Alexandrescu, 2019).
Synthetic hallucinogens are made in a laboratory and consist of lysergic acid diethylamide
(LSD), N,N-dimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA)
(Barrett et al., 2018; De Gregorio, 2021; Garcia-Romeu & Richards, 2018; Waters, 2021).
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Hallucinogens are known for their psychedelic and psychomimetic properties causing mindrevealing or psychosis-mimicking (Waters, 2021).
HGN, VGN, and LOC will not be present in the DRE evaluation for the subjects who
only have ingested a hallucinogen drug (International Association of Chiefs of Police [IACP],
2018c). The subject's pupils will be dilated above the average DRE range, and the pupil's
reaction to light will be normal (Dhingra et al., 2019). Hallucinogen’s will raise a subject's pulse
rate, blood pressure, and body temperature when the drug is consumed over the standard
therapeutic dose prescribed for the subject (Vizeli & Liechti, 2017). Subjects can also show signs
and symptoms of having body tremors, dazed appearance, difficulty in speech, disorientation,
flashbacks, hallucinations, memory loss, paranoia, perception of time and distance distortion,
synesthesia, and uncoordinated (Ellenhorn et al., 1999; International Association of Chiefs of
Police [IACP], 2018c; Porath & Beirness, 2019).
Dissociative Anesthetic. Dissociative Anesthetics are the fourth category on the DRE
symptomology drug matrix (Porath & Beirness, 2019; Talpins et al., 2018). Dissociative
anesthetic drugs give a subject a state where they feel detached from their environment and
contains a stimulant, depressant, hallucinogenic, and analgesic property (Lee & Stout, 2020).
Drugs identified as dissociative anesthetics are Phenyl Cyclohexyl Piperidine (PCP), ketamine,
methoxetamine, and dextromethorphan (DXM) (Lee & Stout, 2020; International Association of
Chiefs of Police [IACP], 2018c).
HGN, VGN, and LOC will be present in the DRE evaluation for the subjects who only
have ingested a dissociative anesthetic drug with a possible early onset of HGN (International
Association of Chiefs of Police [IACP], 2018c). The subject's pupils’ size and reaction to light
will be normal (Lee & Stout, 2020). Dissociative anesthetics will raise a subject's pulse rate,
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blood pressure, and body temperature when the drug is consumed over the standard therapeutic
dose prescribed for the subject (Lee & Stout, 2020; Morris & Wallach, 2014; Riva-Posse et al.,
2018). Subjects can also show signs and symptoms of having blank stare, confused, cyclic
behavior disoriented, hallucinations, increased pain threshold, non-communicative, perspiring,
possibly violent, sensory distortions, and slurred speech (Lee & Stout, 2020; Morris & Wallach,
2014; International Association of Chiefs of Police [IACP], 2018c).
Narcotic Analgesics. The fifth drug category on the DRE symptomology drug matrix is a
narcotic analgesic (Porath & Beirness, 2019; Talpins et al., 2018). A Narcotic “is a drug derived
from Opium, or produced synthetically, that relieves pain but also induces euphoria, alters mood,
and produces sedation” (International Association of Chiefs of Police [IACP], 2018c, p. 577).
An Analgesic “is a medication or drug that relieves pain” (International Association of Chiefs of
Police [IACP], 2018c, p. 577). Narcotic analgesics are divided into two subcategories of opiates
and synthetics (International Association of Chiefs of Police [IACP], 2018c). Commonly used
drugs in the narcotic analgesic category are heroin, morphine, codeine, dilaudid, hydrocodone,
thebaine, oxycodone, oxymorphone, demerol, methadone, fentanyl, and buprenorphine (Talpins
et al., 2018).
HGN, VGN, and LOC will not be present in the DRE evaluation for the subjects who
only have ingested a narcotic analgesic drug (International Association of Chiefs of Police
[IACP], 2018c). The narcotic analgesic drug category is unique because it is the only DRE drug
category that causes miosis (Armenian et al., 2018; Edwards, 2019; Finegan, 2021). Miosis is
abnormally small (constricted) pupils (International Association of Chiefs of Police [IACP],
2018c). A subject’s pupillary reaction to light under the influence of a narcotic analgesic will be
little to none visible during a DRE evaluation (Dhingra et al., 2019). Narcotic analgesics will
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lower a subject’s pulse rate, blood pressure, and body temperature when the drug is consumed
over the standard therapeutic prescribed dose for the subject (Finegan, 2021; Gupta & Edwards,
2018; Patel et al., 2021).
A common side effect of narcotic analgesics is sedation, which may impact cognition,
psychomotor performance, and driving ability (Ferreira et al., 2018). Subjects can also show
signs and symptoms of having depressed reflexes, ptosis, drowsiness, dry mouth, euphoria,
itching, low, raspy speech, and slowed breathing (Armenian et al., 2018; Finegan, 2021). A
common sign DREs observe during an evaluation of a subject under the influence of a narcotic
analgesic is called “on-the-nod.” On-the-nod is a semi-conscious state of deep relaxation. The
subject appears to be asleep but can efficiently respond to questions (International Association of
Chiefs of Police [IACP], 2018c).
Inhalants. Inhalants are the sixth drug category on the DRE symptomology drug matrix
(Porath & Beirness, 2019; Talpins et al., 2018). Inhalants drug category is named after the
primary method of ingestion for breathable chemicals (Talpins et al., 2018). Inhalants are divided
into three subcategories of volatile solvents, aerosols, and anesthetic gases (International
Association of Chiefs of Police [IACP], 2018c). Volatile solvents are toluene, acetone, benzene,
spray paint, paint thinners, lighter fluid, model airplane glue, gasoline, and kerosene
(Braunscheidel et al., 2019; Crossin et al., 2018; Cruz & Bowen, 2021; Howard et al., 2011).
Aerosols include hair sprays, insecticides, and freeze sprays (Cruz & Bowen, 2021; Howard et
al., 2011). Anesthetic gases include ether, nitrous oxide, amyl nitrite, and butyl nitrite (Cruz &
Bowen, 2021; Howard et al., 2011; Shelton, 2016).
HGN and LOC are usually present in subjects who have ingested an Inhalant, while VGN
may be present if it is a high dose for that particular subject (International Association of Chiefs
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of Police [IACP], 2018c). Pupillary reaction to light is slow, and pupil size is normal but may be
dilated in some subjects. Inhalants will increase pulse rates in subjects (Taylor et al., 2021).
Subjects' blood pressure will be down for anesthetic gases and up with volatile solvents and
aerosols (International Association of Chiefs of Police [IACP], 2018c). Inhalant impairment is
similar to alcohol intoxication signs and symptoms of slurred speech, euphoria, incoordination,
lethargy, slowed reflexes, blurred vision, bloodshot watery eyes, confusion, disoriented, and lack
of muscle control (Cruz & Bowen, 2021; Howard et al., 2011; International Association of
Chiefs of Police [IACP], 2018c). Additional effects of the inhalant drug category include intense
headaches, slow, thick speech, and a flushed face (Bowen et al., 2016).
Cannabis. The last category on the DRE symptomology drug matrix is Cannabis (Porath
& Beirness, 2019; Talpins et al., 2018). The psychoactive ingredient in Cannabis is delta-9
tetrahydrocannabinol (THC) (Subramaniam et al., 2019; Talpins et al., 2018). Cannabis is also
known more commonly as marijuana. The drug category of Cannabis also includes the various
forms of marijuana, cannabinoids, and synthetic drugs like Marinol (International Association of
Chiefs of Police [IACP], 2018c). Cannabis is becoming the most socially acceptable drug after
alcohol in the United States. It is currently legalized in more than thirty-seven states, four
territories, and the District of Columbia (Garcia & Hanson, 2022).
HGN and VGN are not present in subjects under the influence of Cannabis. Cannabis is
the only drug category in the DEC program that LOC will be present in the absence of HGN and
VGN (International Association of Chiefs of Police [IACP], 2018c). Pupils will be dilated for
most subjects, but at times they can be normal in size (Dhingra et al., 2019). Pupillary reaction to
light will be normal, but subjects may have rebound dilation in the darkroom examination
(Dhingra et al., 2019; International Association of Chiefs of Police [IACP], 2018c). Cannabis
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causes an increase in blood pressure and pulse rate (Subramaniam et al., 2019). Subjects can also
show signs and symptoms of altered time and distance perception, eyelid tremors, body tremors,
drowsiness, disorientation, impaired memory function, increased appetite, lack of concentration,
possible paranoia, and lack of concentration (Curran et al., 2016; International Association of
Chiefs of Police [IACP], 2018c; Prini et al., 2020).
Signs and Symptoms of Drugs
The primary source studies of Bigelow et al. (1985), Compton (1986), and Alder & Burns
(1994) set the foundation of research validation for the DECP in the United States. The literature
addressing the validation of the DECP has been lacking since the publication of the Arizona
study in 1994. Researchers examining the DECP turned their attention to the effects of individual
drugs signs and symptoms related to the DRE protocol over the next twenty years. Several
studies have been conducted on drug identification performance's observable signs and
symptoms.
Heishman et al. (1998) conducted a research study of DECP related to the use of
alprazolam, d-amphetamine, codeine, and marijuana. The purpose of the study was to determine
if there is a need to refine the DECP evaluations by determining which variables are the best
predictors of drug intake across a range of drug classes in order to aid the DREs in the detection
process (Heishman et al., 1998; Shinar & Schechtman, 2005; Porath-Waller et al., 2021). Fortyeight volunteers participated in the study and were dosed with either a placebo, alprazolam, damphetamine, codeine, or delta-9-tetrahydrocannabinol (THC). The study was conducted under
double-blinded conditions according to a randomized, Latin-square design (Heishman et al.,
1998). Thirty DREs from eight states participated in the study as evaluators. DREs were
instructed only to ask two questions related to physical defects and vision problems. DREs
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completed the 12-step protocol except for the interview step on all forty-eight volunteers and
then rendered their opinion on impairment and the drug category causing the impairment if
present (Heishman et al., 1998).
Heishman et al. (1998) concluded that the DREs in this study could firmly predict the
volunteers were impaired and under the influence of a drug but struggled to classify the same
drug category causing the impairment. The purpose of the study was to identify select variables
to assist DREs in their prediction of drug category classifications. To this objective, researchers
were able to identify two to seven variables of the DECP evaluation that predicted the presence
or absence of alprazolam, d-amphetamine, and marijuana with moderate sensitivity. Codeine
revealed a sensitivity as low, and false-negative rates were extremely high (Heishman et al.,
1998).
Shinar & Schechtman (2005) conducted a research study solely based on a subject's
performance on the psychophysical tests and a limited number of clinical indicators. The study
reanalyzed the data previously collected in the Heishman et al. (1998) study. Shinar &
Schechtman (2005) utilized the results of the Heishman et al. (1998) study to determine if DRE
predictability could be achieved through the use of only the psychophysical test, blood pressures,
pulse rates, nystagmus, pupil estimations, and body temperature for the four categories of central
nervous system depressants, central nervous system stimulants, narcotic analgesics, and
cannabis. "The results suggested that DREs formed their opinion about the category of drug
consumed based on only one or two pivotal signs and symptoms while ignoring others, even if
contradictory to their judgment" (Porath-Waller et al., 2021, p. 4).
Other literature during this period focused on individual drugs and their association with
the psychophysical test performed during an everyday driving under the influence investigation
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and not associated with the DRE protocol. For example, Bramness et al. (2003) completed a
study on the performance of individuals dosed with benzodiazepine when administered the field
sobriety test of the modified Romberg balance, walk and turn, one-leg stand, and the finger to
nose test. In 2005, Silber et al. completed another psychophysical study after dosing subjects
with d-amphetamines. Downey et al. (2012) completed their study of psychophysical indicators
of impairment on the field sobriety tests after dosing volunteers with dl-3,4methylenedioxymethamphetamine (MDMA). Ip et al. (2013) published their findings of
individuals' results of meeting field sobriety test indicators after being dosed with levels of
trazodone. Finally, in 2014, Perry et al. conducted a double-blinded study of the subject's
performance on field sobriety tests after being dosed with various levels of dextromethorphan.
All of the studies contributed to the curriculum of the DRE school as it was revised over the
years to assist students with obtaining additional knowledge of how individuals' performance on
field sobriety tests related to certain drugs (International Association of Chiefs of Police [IACP],
2018c). The issue with all the research studies being devoted to the psychophysical test is that it
is only one step in the 12-step DRE protocol.
A group of researchers in Canada picked up where Alder & Burns left off in 1994 and
began to publish DECP validation studies in 2009. These studies concentrated on drug influence
evaluations obtained in Canada from 2009 to 2019. The research literature and studies were
spearheaded by Amy J. Porath-Waller and Douglas J. Beirness. One of the first studies
completed by Beirness et al. (2009) examined 1,349 cases in which 92.1% of DRE opinions were
confirmed through toxicological analysis. Thirty-six cases returned no psychoactive drugs
present and were correctly opinioned by the DREs as having no impairment. The overall
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accuracy of the DRE opinions with drugs presents and no drugs present was 94.8% as being
correctly identified (Beirness et al., 2009).
Porath-Waller et al. (2009) examined 1576 Canadian DEC evaluations from 1995 to
2008. The study aimed to enhance officers' training in the DECP by focusing on a smaller set of
critical signs and symptoms when developing an opinion as to which drug category is causing
impairment. Statistical analysis was performed to simplify the process used by DREs to predict
the best four classes of drugs, including central nervous system stimulants, central nervous
system depressants, narcotic analgesics, and cannabis (Porath-Waller et al., 2009). This was one
of the first studies to use statistical analysis of univariate relationships and a multinomial logistic
regression model to identify signs and symptoms in the DECP to assist the DREs in forming
opinions of drug categories. The results of the study indicated a statistical model that includes
nine clinical indicators of pulse rate, condition of eyes, eyelids, lack of convergence, hippus,
rebound dilation, reaction to light, injection sites, and systolic blood pressure significantly
predicted the correct drug category (Porath-Waller et al., 2009).
Porath-Waller et al.'s (2009) study focused on distinct drug categories and their
relationship with signs and symptoms. Porath-Waller et al. (2010) study continued by examining
3,489 additional evaluations to determine the signs and symptoms that best predict three
common drug combinations. As a result, Porath-Waller et al. (2010) identified eleven clinical
indicators that significantly predicted the correct drug combinations. These indicators were the
condition of eyes, lack of convergence, rebound dilation, reaction to light, mean pulse rate,
injection sites, horizontal gaze nystagmus, pupil size in near-total darkness, one-leg stand test,
walk and turn test, and muscle tone.
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Amy J. Porath-Waller and Douglas J. Beirness's research studies over the past two
decades have been the only studies to use statistical analysis that coded the DIE face sheet and
narratives in order to extract data for analysis. They performed several statistical studies that
identified which signs and symptoms from the DRE protocol have strong predictability in
determining which drug category or drug categories cause impairment (Beirness et al., 2009;
Beirness et al., 2013; Porath-Waller et al., 2009; Porath-Waller et al., 2010; Porath-Waller et al.,
2013; Porath-Waller et al., 2019; Porath-Waller et al., 2021). Their research indicated that DREs
in Canada reported an overall accuracy rate of ninety-five percent (Beirness et al., 2009). The
research examined over one hundred quantified indicators from DIE face sheets and narratives.
Until recently, all of Dr. Porath-Waller and Dr. Beirness collaborative research focused
on Canada's DECP. In May of 2021, Porath-Waller & Beirness published a research project
funded through the National Highway Traffic Safety Administration, Exploring the predictive
validity of drug evaluation and classification program evaluations, which focused on drug
influence evaluations in the United States collected from April 2000 to December 2012. The
study's primary objective was to "determine which combinations of drug-related signs and
symptoms from the DEC protocol can most efficiently and effectively predict the drug category
or combination used by the subject" (Porath-Waller & Beirness, 2021, p. v). "Research built on
previous work conducted by Porath-Waller and colleagues by examining all of the information
recorded during the DEC evaluations and assessing additional drug categories and combinations"
(Porath-Waller & Beirness, 2021, p. 6).
The majority of the research conducted on the DECP is focused first on the development
of the program, second on the validation of the DRE opinions, third on the individual drug
effects on the body, and finally on the identifying predictors in the DECP evaluations. There is a
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significant gap in the literature identifying common themes or predictors that indicate missed or
incorrect opinions of DRE evaluations. The majority of the literature identified is over fifteen
years old. New literature does not address the incorrect opinions of DREs or the validation of
DREs in the State of Florida. The predictability study conducted in 2021 by Porath-Waller et al.
utilized ten- to twenty-year-old data.
Summary
Program evaluation theory’s function is to ascertain the theoretical sensibility of the
program being evaluated (Sharpe, 2011). The Drug Evaluation and Classification Program was
developed to assist with training law enforcement officers in identifying and detecting arrested
subjects who operated a motor vehicle under the influence of drugs. Drug-related DUIs have
increased significantly over the past several decades due to increased recreational use of licit and
illicit drugs (Cordelier et al., 2021). Drug use in society is not a new phenomenon and has been
used for religious ceremonies, medical reasons, and recreational purposes for several centuries
(Crocq, 2007; Mann, 2017). In order to combat the rising levels of drug abuse, the United States
has enacted multiple drug-related legislation over the past one hundred years (Olsen, 2022;
Sacco, 2014).
The ingestion of drugs causes several impairing effects on the human body when taken in
excess of the recommended therapeutic dose; most notably, drugs affect the central nervous
system and brain functions (American Psychological Association, 2022). In order to identify and
detect drivers under the influence of drugs, law enforcement officers use the 12-step DRE
protocol (International Association of Chiefs of Police [IACP], 2018c). The 12-step drug
influence evaluation process became known as the Drug Recognition Expert (DRE) protocol
(Beirness & Porath, 2019; Porath-Waller & Beirness, 2010; Talpins et al., 2018). DREs are
trained in recognizing the signs and symptoms associated with seven drug categories of central
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nervous system depressants, central nervous system stimulants, hallucinogens, dissociative
anesthetics, narcotic analgesics, inhalants, and cannabis (International Association of Chiefs of
Police [IACP], 2018c; Porath-Waller et al., 2021). After the evaluation is completed, DREs
develop an opinion based on the signs and symptoms exhibited by participants. DREs will then
classify which of the seven-drug category or categories is currently psychoactive during the
evaluation (International Association of Chiefs of Police [IACP], 2018c; Porath-Waller et al.,
2021).
Several validation studies were conducted in the 1980s and early 1990s to give
creditability to the DECP (Bigelow et al., 1985; Compton, 1986; Alder & Burns, 1994). From
2000 to 2015, researchers examined how drugs affected the human body and compared these
results with the DECP curriculum for validation (Bramness et al., 2003; Bramness et al., 2009;
Declues et al., 2018; Downey et al., 2015; Hartman et al., 2016; Heishman et al., 1998; Khiabani
et al., 2007; Perry et al., 2015; Silber et al., 2005). In addition, research has been completed on
the DECP in Canada, examining the accuracy rates of DRE opinions, but data is lacking for the
United States. This literature review provided an overview of drug use in society and the history
of the DECP. It also identified the DECP systematic and standardized evaluation process and the
seven drug categories that are known to impair individuals. This literature review served as a
foundation for this study's design, data collection, and analysis portions.
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CHAPTER THREE: METHODS
Overview
The purpose of this study was to evaluate the drug evaluation and classification program
(DECP) in Florida to determine the accuracy rates of drug recognition experts (DREs) and
determine which core set of measurements (signs and symptoms) from the Drug Influence
Evaluation (DIE) face sheets correspond to each of the seven drug categories, and to determine if
any common themes or indicators from the DIEs are identified with the inaccuracies of DRE
opinions. This chapter presents the methodological issues and procedures of the study. First, the
research design, research questions, and hypotheses are presented. Next, the study setting,
instrumentation, and procedures are described. Finally, the data analysis approach is outlined.
Design
This study was a quantitative cross-sectional descriptive and predictive examination of
Florida's DECP. The purpose of a cross-sectional design is to perform a descriptive or inferential
analysis of observations from a single period of time (Rezigalla, 2020). This type of design is the
most appropriate choice for this study because the purpose of the study was to examine drug
influence evaluations performed in Florida in a single year (2019). Cross-sectional research can
be further classified as descriptive when the study involves determining the rate or prevalence of
an outcome (Rezigalla, 2020). A portion of this study was considered descriptive because one
goal of the study was to determine the accuracy rate of DRE opinions in Florida. This study also
was considered predictive because the study was to determine which measures from the drug
influence evaluations are related to (i.e., predictive of) toxicology results and DRE opinions.
Predictive designs are appropriate to use when a goal of the study is to examine if an outcome
can be determined by a set of variables or measures (Howell, 2013).
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Research Questions
RQ1: What is the accuracy rate of DRE opinions compared to the toxicology results for
drug influence evaluations completed by DREs in Florida during 2019?
RQ2: What set of measures (signs and symptoms) from the drug influence evaluations
that completed by DREs in Florida during 2019 significantly predict the drug categories?
RQ3: Among the inaccurate drug influence evaluations (missed opinions) completed by
DREs in Florida during 2019, what set of measures (signs and symptoms) significantly predict
the drug categories inaccurately determined by the DREs?
Hypotheses
H01: The accuracy rate of DRE opinions for drug influence evaluations completed by
DREs in Florida during 2019 will not be significantly different from accuracy rates found in
previous studies.
Ha1: The accuracy rate of DRE opinions for drug influence evaluations completed by
DREs in Florida during 2019 will be significantly different from accuracy rates found in
previous studies.
H02: No set of measures (signs and symptoms) from the drug influence evaluations
completed by DREs in Florida during 2019 significantly predict the drug categories determined
by toxicology results.
Ha2: A set of measures (signs and symptoms) from the drug influence evaluations
completed by DREs in Florida during 2019 significantly predict the drug categories determined
by toxicology results.
H03: No set of measures (signs and symptoms) significantly predict the drug categories
inaccurately determined by the DREs in Florida during 2019.
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Ha3: No set of measures (signs and symptoms) significantly predict the drug categories
inaccurately determined by the DREs in Florida during 2019.
Participants and Setting
The population for this study was comprised of the enforcement drug influence
evaluation and toxicological results for 2019 in the state of Florida. The DECP comprises of
DREs who conduct a standardized and systematic 12-step protocol evaluation of subjects
suspected to be under the influence of drugs. The DIEs are documented on a DIE face sheet and
transferred to a national database maintained by the International Association Chiefs of Police
(IACP) and the National Highway Traffic and Safety Administration (NHTSA). The DIEs and
toxicological results are maintained in the IACP-NHTSA DRE database and are available due to
Florida’s public information requirements. Therefore, DRE enforcement DIEs with
corresponding toxicological results were obtained for the purpose of this study.
According to the IACP-NHTSA database (2021), a total of 1,480 DIEs were completed
in 2019. Of the 1,480 DIEs completed, 986 are considered to be enforcement evaluations.
Enforcement evaluations are conducted in the field when an officer has arrested a subject for
DUI, and the alcohol breath test does not correspond to the subject’s level of impairment. The
remaining DIEs are considered to be training evaluations and were excluded from this study.
A target sample size calculation was conducted using G*Power 3.1.9.6 (Faul et al.,
2020). The calculation was conducted for a logistic regression analysis assuming a medium
effect size, a power level of .80, and an alpha level of .05 based on the recommendations of
Cohen (1988). Lipsy & Hurley (1998) recommended an odds ratio of 1.72 as an appropriate
medium effect size in a logistic regression. The results of the sample size calculation using these
parameters was that 177 cases were needed for analysis.
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Instrumentation
Two primary sources of research documents were used in this study: the DIE face sheets
and corresponding toxicological results. The first research source used for this study was the
DECP drug influence evaluation form. The drug influence evaluation was documented on a DIE
face sheet which consists of the possibility for over one-hundred data points. The evaluation
included basic information about the incident and person who was examined (i.e., age, gender,
race, type of crash, date, and time of the evaluation), breath test results, health and physiological
information (i.e., whether the person has eaten or drank that day, the last time the person has
slept, whether the person is sick or injured, whether the person is diabetic or epileptic, has
physical disabilities, is under the care of a doctor, or is taking medications), and attitude. The
evaluation also included several observations and tests such as eye examinations, divided
attention tests (modified Romberg balance, walk and turn, one leg stand, and finger to nose),
vital signs, pupil size, muscle tone, injection sites, and other notes and observations. At the end
of the evaluation, the DRE provided an opinion about what drug category or categories the
subject was under the influence of at the time of the evaluation. The DRE opinion options are
rule out (no impairment), medical rule out, alcohol, CNS depressant, CNS stimulant,
hallucinogen, dissociative anesthetic, narcotic analgesic, inhalant, and cannabis. The DIE face
sheet is used by all certified DREs across the nation and is a standardized form for the
documentation of the DRE 12-step protocol (International Association of Chiefs of Police
[IACP], 2018c).
The second research source used for this study was the toxicological results self-reported
to the IACP-NHTSA DRE database for the corresponding DIE face sheets. A toxicological
examination is the last step in the 12-step DRE protocol. Either the arresting officer or the DRE
supervises the collection of the biological sample to ensure collection procedures follow Florida
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Department of Law Enforcement (FDLE) Crime Laboratory Evidence Submission
Manual (2021). Blood sample collections follow Florida Administrative Code 11D-8, which
defines which professionals are qualified to collect a blood sample for analysis. Whole blood
samples can be collected up to twenty-four hours after an incident utilizing an FDLE-approved
evidence collection kit (Florida Department of Law Enforcement [FDLE], 2021). Urine samples
can be collected up to 72 hours after the incident because detecting drugs in urine is longer than
in blood (Florida Department of Law Enforcement [FDLE], 2021). Biological samples collected
from subjects are then transported to an FDLE laboratory for testing. Toxicologists will only
analyze the biological samples for drugs controlled under Florida Statute 893. The commonly
abused drugs FDLE laboratories analyze for are amphetamines, methamphetamine, ecstasy,
barbiturates, benzodiazepines, carisoprodol, cocaine, methadone, heroin, oxycodone, codeine,
morphine, hydrocodone, and Tetrahydrocannabinols. Over-the-counter medications and many
prescription medications are not routinely included in drug analysis (Florida Department of Law
Enforcement [FDLE], 2021).
Procedures
A sample of DRE DIE face sheets were collected on suspected drug-impaired drivers in
the state of Florida during 2019. The DIEs contained over one-hundred data points documented
by DREs while performing evaluations. DREs documented the evaluations on DIE face sheets
and are entered into a national database with corresponding toxicology results. IACP is the
custodian agency for the DRE national database. In addition, every state is assigned a DECP
State Coordinator as a point of contact and administrator of the DECP. Employed by the
University of North Florida, Tim Cornelius is the State of Florida DECP State Coordinator for
IACP and NHTSA.
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Florida law requires any documents produced by a law enforcement agency to be
available to the public upon request. Florida State Statutes define public records as
all documents, papers, letters, maps, books, tapes, photographs, films, sound recordings,
data processing software, or other material, regardless of the physical form,
characteristics, or means of transmission, made or received pursuant to law or ordinance
or in connection with the transaction of official business by any agency (Section 119.01112, F.S.).
The DIE face sheets and the information contained in the IACP database are subject to Florida's
public record laws. The data for this study was collected by making a public records request to
the custodian of the IACP database. The request was for all enforcement DIE face sheets and
corresponding toxicological results. The DIE face sheets were redacted to eliminate any
identifying data of subjects being evaluated except for the age and gender.
DREs enter into the database enforcement evaluations conducted in the field by trained
DREs on individuals who have been arrested for suspected drug-impaired driving offenses.
DREs also enter into the database training evaluations that occur across the state at various times
in order for DREs to stay current with the standardized and systematic 12-step DRE protocol for
evaluations. Training evaluations were excluded from this study due to the evaluations not
occurring in the field and are under strict supervision by a DRE instructor.
IACP DRE database was changed in 2020, and evaluations after 2020 are being entered
into the program with the one-hundred data points documented on the DIE face sheets and DRE
narratives. The database currently only contains information on the DRE opinions and
toxicology results for cases prior to 2020. Mr. Cornelius recommended that an email be sent to
all active certified DREs that conducted evaluations in 2019 and request the DIE face sheets for
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enforcement evaluations. DREs also maintain an active “rolling log,” which contains information
on drug influence evaluations conducted by each DRE. The rolling log contains the case number,
DRE evaluation log number, enforcement or training type, DRE opinion, and toxicological
results. An email was sent to the DREs requesting a copy of the rolling log in order to identify
the toxicological results.
After receiving the requested DIE face sheets and toxicological results, an exclusion
sorting of the information was conducted to determine which evaluations were excluded from the
study. Exclusion for evaluations included cases with no corresponding toxicological results,
cases where the subject refused to continue participation in the evaluation, medical rule-out
cases, and alcohol-only cases. The DIE face sheets (Appendix A) were then coded using the drug
influence evaluation coding instrument (Appendix C). Dr. Porath-Waller developed and used the
coding instrument in several research studies on the DECP over the past ten years (Porath-Waller
et al., 2009; Porath-Waller & Beirness, 2010; Porath & Beirness, 2019; Porath-Waller et al.,
2021). The foundational coding instrument provided by Dr. Porath-Waller was adjusted to
include additional variables documented on the DIE face sheets to provide an accurate coding
instrument for the study.
Data Analysis
Research Question 1
Research Question 1 asks: What is the accuracy rate of DRE opinions compared to the
toxicology results for drug influence evaluations completed by DREs in Florida during 2019? To
answer this research question, accuracy rates were computed from the DRE opinions and
toxicology results, and the rates were reported.
Beirness et al. (2007) conducted a critical review of primary source laboratory and field
validation studies of Bigelow et al. (1985), Compton (1986), Preusser et al. (1992), Hardin et al.
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(1993), Adler & Burns (1994), Heishman et al. (1998), Smith et al. (2002), and Shinar &
Schechtman (2005). Beirness et al. (2007) identified that the previous studies all attempted to
determine the degree of correspondence between the opinion of the DRE and the actual use of
drugs. Each study examined by Beirness et al. (2007) used different measurements to indicate the
criteria for matches or confirmations of DRE opinions and toxicological results. Beirness et al.
(2007) developed a standard set of measures based on comparing DRE opinions and toxicology
results. This study utilized Beirness et al. (2007) model of standard psychometric measures to
analyze the accuracy rates of DRE opinions compared to toxicology results for the drug
influence evaluations obtained from Florida for 2019.
Beirness et al. (2007; 2009) model of standard psychometric measures contains six
measures: sensitivity, specificity, false alarm rate, miss rate, corroboration rate, and overall
accuracy. Beirness et al. (2007) added additional measures (corroboration rate and overall
accuracy) to the standard psychometric measures used by previous researchers and the medical
environment. Beirness et al. (2007) identify four types of measurement units: true-positive, truenegative, false-positive, and false-negative. True positives (T.P.) are the number of drug-positive
cases correctly identified by DREs. True negatives (T.N.) are the number of drug-negative cases
correctly identified by DREs. A false positive (F.P.) and false-negative (F.N.) are the numbers of
drug positive or negative cases not correctly identified by DREs.
Sensitivity is also known as the hit rate or true positive and refers to a number of drugpositive cases identified by DREs. "This measure is defined as the number of drug-positive cases
correctly identified by the DRE (T.P.) divided by the total number of drug-positive cases
identified by the toxicology (TP+FN)" (Beirness et al., 2007, p. 369). The next measure is
specificity, also known as the correct rejection rate, refers to the number of drug-negative cases
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identified by DREs. "The number of cases the DRE specifies as being drug negative (T.N.)
divided by the total number of drug negative cases identified by toxicology (TN+FP)" (Beirness
et al., 2007, p. 369). False alarm rate is the next measure in Beirness et al. (2007; 2009) model
and is the proportion of all true drug-negative cases where the DRE opinioned the subject was
impaired (FP+TN).
The miss rate "is the proportion of all drug positive cases that are judged by the DRE to
be drug free and is represented by (FN/TP+FN)" (Beirness et al., 2007, p. 369). The fifth
measure identified by Beirness et al. (2007) is corroboration rate or positive detection rate and is
defined as "the proportion of all persons identified by DRE procedure as being under the
influence of a given substance that are subsequently confirmed by the toxicology as being
correctly identified" (p. 370). The corroboration rate is T.P./(TP+FP). The corroboration rate is
what most legal representatives in the criminal justice court system reference when examining
validation studies. The last measure is overall accuracy and is "the proportion of all cases that are
either correct or correct rejections (TP+TN)/(TP+FP+TN+FN)" (Beirness et al., 2007, p. 370).
The conclusion of Beirness et al. (2007) study of previous research studies indicated the
DECP reported the overall accuracy of DRE evaluations was appropriately 80%. Beirness et al.
(2009) conducted an additional study in Canada, examining 1,349 drug influence evaluations and
determining the overall accuracy rates of Canadian DRE evaluations was appropriately 95%
(Beirness et al.., 2009). Beirness et al. (2007) standard psychometric measure model has been
used by various researchers when analyzing the DECP (Porath-Waller et al., 2021). This study
examined the sensitivity, specificity, false alarm rate, miss rate, corroboration rate and overall
accuracy of the drug influence evaluations completed in Florida for 2019. Each accuracy
measure was reported, and z-tests of proportions were performed to test the null hypothesis (H01)
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and determine if the overall accuracy in Florida for 2019 is similar to the overall accuracy found
in previous studies.
Research Question 2
Research Question 2 asks: What set of measures (signs and symptoms) from the drug
influence evaluations completed by DREs in Florida during 2019 significantly predict the drug
categories determined by toxicology results? To answer this research question, a binary logistic
regression analysis was performed. Binary logistic regression is appropriate to perform when the
aim of the analysis is to determine if a set of variables significantly predict membership in a
category (Field, 2017). In this analysis, the goal was to use measures from the DIE face sheets to
predict the drug category determined by the toxicology results. Therefore, the dependent
(criterion) variable in the analysis was the drug category determined by the toxicology results.
The independent (predictor) variables were the signs and symptoms documented on the DIE face
sheets.
Due to the large number of variables available from the DIE face sheets, a stepwise
method was used to select the variables to include in the final regression model. In a stepwise
selection method, variables are entered (or removed) from the model based on their level of
statistical significance (e.g., significant predictors are added or non-significant predictors are
removed). For this analysis, the forward entry method was used, meaning that at each step, the
most significant predictor from the list of possible predictors were added to the model. Predictors
continued to be added until there were no predictors remaining that contribute significantly to the
model. The level of significance (alpha) used for this procedure was .05. If the forward entry
procedure selected one or more measures as contributing significantly to the prediction of drug
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category, then the null hypothesis (H02) may be rejected. The odds ratio was reported as a
measure of effect size for each significant predictor in the model.
Research Question 3
Research Question 3 asks: Among the inaccurate drug influence evaluations (missed
opinions) completed by DREs in Florida during 2019, what set of measures (signs and
symptoms) significantly predict the drug categories inaccurately determined by the DREs? To
answer this research question, another binary logistic regression analysis was performed. In this
analysis, the goal was to use the measures from the DIE face sheets to predict the drug category
opinion of the DREs among cases in which the DRE opinion was inaccurate based on the
toxicology results. Therefore, only cases with missed DRE opinions were included in this
analysis. The dependent (criterion) variable in the analysis was the drug category opinion of the
DRE. The independent (predictor) variables were the signs and symptoms documented on the
DIE face sheets. As with the previous analysis, the forward entry method was used to select the
predictor variables, meaning that at each step, the most significant predictor from the list of
possible predictors were added to the model. Predictors continued to be added until there were no
predictors remaining that contributed significantly to the model. The level of significance (alpha)
used for this procedure was .05. If the forward entry procedure selected one or more measures as
contributing significantly to the prediction of drug category opinion, then the null hypothesis
(H03) may be rejected. The odds ratio was reported as a measure of effect size for each
significant predictor in the model.
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CHAPTER FOUR: FINDINGS
Overview
The purpose of this study was to evaluate the drug evaluation and classification program
(DECP) in Florida to determine the accuracy rates of drug recognition experts (DREs) and
determine which core set of measurements (signs and symptoms) from the Drug Influence
Evaluation (DIE) face sheets correspond to each of the seven drug categories, and to determine if
any common themes or indicators from the DIEs are identified with the inaccuracies of DRE
opinions. This chapter presents a description of the collected data and the analyses performed on
the data to answer the research questions. The research questions and hypotheses are as follows:
RQ1: What is the accuracy rate of DRE opinions compared to the toxicology results for
drug influence evaluations completed by DREs in Florida during 2019?
H01: The accuracy rate of DRE opinions for drug influence evaluations completed by
DREs in Florida during 2019 will not be significantly different from accuracy rates found in
previous studies.
Ha1: The accuracy rate of DRE opinions for drug influence evaluations completed by
DREs in Florida during 2019 will be significantly different from accuracy rates found in
previous studies.
RQ2: What set of measures (signs and symptoms) from the drug influence evaluations
that completed by DREs in Florida during 2019 significantly predict the drug categories?
H02: No set of measures (signs and symptoms) from the drug influence evaluations
completed by DREs in Florida during 2019 significantly predict the drug categories determined
by toxicology results.
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Ha2: A set of measures (signs and symptoms) from the drug influence evaluations
completed by DREs in Florida during 2019 significantly predict the drug categories determined
by toxicology results.
RQ3: Among the inaccurate drug influence evaluations (missed opinions) completed by
DREs in Florida during 2019, what set of measures (signs and symptoms) significantly predict
the drug categories inaccurately determined by the DREs?
H03: No set of measures (signs and symptoms) significantly predict the drug categories
inaccurately determined by the DREs in Florida during 2019.
Ha3: No set of measures (signs and symptoms) significantly predict the drug categories
inaccurately determined by the DREs in Florida during 2019.
Descriptive Statistics
A total of 236 DRE face sheets were collected for this study. Twenty-two face sheets
were excluded because the subjects refused to provide a toxicological sample. An additional nine
face sheets were excluded because the DRE called a medical impairment. Finally, 10 additional
face sheets were excluded because they were incomplete. A final total of 195 face sheets were
entered into an SPSS data file and included in the analysis.
Table 1 displays frequencies and percentages for the active drug categories identified
based on the DRE opinion and toxicology results across the 195 cases. In 59% of the cases, a
single active drug category was identified, with the most prevalent category being cannabis (n =
51, 26%). In approximately 29% of the cases, more than one active drug category was identified,
with the most prevalent combination being CNS depressant and cannabis (n = 20, 10%). No
active drug was identified in approximately 12% of the cases (n = 23).
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Table 1
Active Drug Categories Identified Based on DRE Opinion and Toxicology Results
Drug Category
No Drug Found
CNS Depressant
CNS Stimulant
Narcotic Analgesic
Cannabis
CNS Stimulant/Narcotic Analgesic
CNS Depressant/Narcotic Analgesic
CNS Depressant/CNS Stimulant
Narcotic Analgesic/Cannabis
CNS Stimulant/Cannabis
CNS Depressant/Cannabis
CNS Depressant/CNS Stimulant/Cannabis
CNS Depressant/CNS Stimulant/Narcotic Analgesic/Cannabis

Frequency
23
22
20
23
51
5
9
8
6
3
20
4
1

Percent
11.8
11.3
10.3
11.8
26.2
2.6
4.6
4.1
3.1
1.5
10.3
2.1
0.5

Characteristics
Table 2 displays characteristics of the study data. The ages of the subjects ranged from 18
to 86 years (M = 36.06, SD = 14.07). Most subjects were men (n = 133, 68.2%), and 79% of the
subjects (n = 154) were identified as White. Approximately 80.5% of the cases involved no
crash, but the most common type of crash was property (n = 32, 16.4%). A large majority of the
chemical tests were urine tests (n = 185, 94.9%).
Table 2
Data Characteristics
Characteristic
Gender
Male
Female
Race
White
Black
Hispanic

Frequency

Percent

133
62

68.2
31.8

154
33
7

79.0
16.9
3.6

79
Other

1

0.5

Type of Crash
None
Fatal
Injury
Property

157
2
4
32

80.5
1.0
2.1
16.4

Chemical Test
Urine
Blood

185
10

94.9
5.1

Results
Hypothesis 1
The focus of Hypothesis 1 was the accuracy rate of DRE opinions compared to the
toxicology results. To answer the research question and test the hypothesis, measures of accuracy
were computed. In order to compute the accuracy measures, each case was classified as either a
true positive, true negative, false positive, or false negative. The DRE opinion was considered
correct (true positive) if the DRE called one or two drug categories and the toxicology result
contained at least one of the called categories. If the DRE called three or more drug categories,
the opinion was considered correct if the toxicology result contained at least two of the called
categories. The DRE opinion was also considered correct if the DRE called no drug categories
and no drugs were found in the toxicology result (i.e., true negative) (International Association
of Chiefs of Police [IACP], 2018c; Smith et al., 2002). Table 3 presents the number of true
positives, true negatives, false positives, and false negatives observed in the data.
Table 3
Count of True Positives, True Negatives, False Positives, and False Negatives
Result
True positive
True negative

Count
167
5
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False positive
False negative

17
6

There were 172 correct opinions and 23 missed opinions, resulting in an overall accuracy
rate of approximately 88%. The overall accuracy in this study is higher than the 80% reported by
Beirness et al. (2007) but lower than the 95% found in 1,349 Canadian DRE evaluations
(Beirness et al., 2009). A z-test of proportions shows that the accuracy rate in this study was
significantly lower than the Canadian study (z = -3.80, p < .001); therefore, the null hypothesis
that the accuracy rate would be similar to previous studies may be rejected.
In addition to overall accuracy, other measures of accuracy were computed. The
sensitivity was approximately 97%. The specificity was approximately 23%. The false alarm rate
was approximately 77%. The miss rate was approximately 3%. Finally, the corroboration rate
was approximately 91%.
Hypothesis 2
The focus of Hypothesis 2 was determining what set of measures (signs and symptoms)
from the face sheet significantly predict the active drug categories. To answer the research
question and test the hypothesis, logistic regression models were performed. Due to the low
frequencies of specific combinations of active drug categories, binary logistic regressions were
performed to predict each active drug category observed in the data (CNS depressant, CNS
stimulant, narcotic analgesic, and cannabis). A logistic regression was performed for each drug
category with the outcome being coded as 1 if the drug category was active and 0 if the drug
category was not active. Before conducting each regression, bivariate tests (i.e., chi-square tests)
were performed to determine which factors from the face sheets were significantly associated
with the drug category and to test the assumption of adequate expected frequencies. Factors
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significantly associated with the drug category at alpha = .05 in the bivariate tests were
considered for inclusion in the regression model. Factors with more than 20% of cells with
expected frequencies less than five were excluded from the regression model (Porath-Waller &
Beirness, 2010; Porath-Waller et al., 2021). Included factors were entered into the regression
using a forward (conditional) stepwise procedure to select the factors that contribute most
significantly to the prediction of the drug category.
CNS Depressants
Table 4 displays crosstabulations of each factor with the identification of CNS depressant
as an active drug category. Factors significantly associated with CNS depressants were abnormal
speech, bloodshot eye appearance, lack of smooth pursuit and maximum deviation (both eyes),
30 to 45 degree angle of onset (both eyes), vertical gaze nystagmus, putting foot down on right
OLS, starting WAT before instructions are finished, stepping off line in WAT1, both pupil size
in near total darkness (NTD) was within normal ranges, abnormal reaction to light, below range
blood pressure, and flaccid muscle tone.
Table 4
Crosstabulation of Face Sheet Measures with Active CNS Depressant
Variable

Value

Have you eaten today

Not available
No
Yes
Not available
No
Yes
Not available
10 minutes or less
difference
11 to 30 minutes
difference

Have you drank today

Est. time vs. actual time

CNS Depressant
Not Active
Active
n (%)
n (%)
5 (3.8)
0 (0)
25 (19.1)
18 (28.1)
101 (77.1)
46 (71.9)
4 (3.1)
0 (0)
28 (21.4)
20 (31.3)
99 (75.6)
44 (68.8)
7 (5.3)
5 (7.8)
31 (23.7)
11 (17.2)
28 (21.4)

14 (21.9)

Bivariate Test Result
χ2 (2) = 4.19, p = 0.123

χ2 (2) = 3.93, p = 0.140

χ2 (4) = 1.38, p = 0.847
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Duration of last sleep

Sick or injured
Diabetic or epileptic

Physical disabilities
Under care of doctor or
dentist

Taking medications or
drugs

Coordination
Breath
Face

Speech
Eyes appearance

Blindness
Eye tracking stimulus
Ability to follow stimulus
Eyelids

31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
Not available
No
Yes
No
Yes
Not available

37 (28.2)

19 (29.7)

28 (21.4)

15 (23.4)

10 (7.6)
20 (15.3)
86 (65.6)
15 (11.5)
97 (74)
34 (26)
1 (0.8)
125 (95.4)
5 (3.8)
100 (76.3)
31 (23.7)
1 (0.8)

9 (14.1)
9 (14.1)
34 (53.1)
12 (18.8)
47 (73.4)
17 (26.6)
0 (0)
62 (96.9)
2 (3.1)
43 (67.2)
21 (32.8)
0 (0)

No
Yes
Not available

85 (64.9)
45 (34.4)
2 (1.5)

32 (50)
32 (50)
0 (0)

No
Yes
Fair/good
Other
Normal
Other
Not available
Normal
Other
Normal
Other
Not available
Normal
Bloodshot
Watery
Bloodshot and watery
None
Right eye
Equal
Unequal
No
Yes
Not available
Normal
Droopy

37 (28.2)
92 (70.2)
33 (25.2)
98 (74.8)
68 (51.9)
63 (48.1)
0 (0)
55 (42)
76 (58)
38 (29)
93 (71)
2 (1.5)
22 (16.8)
21 (16)
24 (18.3)
62 (47.3)
130 (99.2)
1 (0.8)
130 (99.2)
1 (0.8)
7 (5.3)
124 (94.7)
1 (0.8)
40 (30.5)
90 (68.7)

14 (21.9)
50 (78.1)
10 (15.6)
54 (84.4)
42 (65.6)
22 (34.4)
1 (1.6)
27 (42.2)
36 (56.3)
8 (12.5)
56 (87.5)
0 (0)
6 (9.4)
25 (39.1)
8 (12.5)
25 (39.1)
64 (100)
0 (0)
64 (100)
0 (0)
4 (6.3)
60 (93.8)
1 (1.6)
14 (21.9)
49 (76.6)

χ2 (3) = 4.62, p = 0.202

χ2 (1) = 0.01, p = 0.928
χ2 (2) = 0.56, p = 0.758

χ2 (1) = 1.84, p = 0.175
χ2 (2) = 4.74, p = 0.093

χ2 (2) = 2.01, p = 0.366

χ2 (1) = 2.29, p = 0.130
χ2 (1) = 3.29, p = 0.070
χ2 (2) = 2.07, p = 0.355

χ2 (1) = 6.50, p = 0.011
χ2 (4) = 13.84, p = 0.008

χ2 (1) = 0.49, p = 0.483
χ2 (1) = 0.49, p = 0.483
χ2 (1) = 0.07, p = 0.797
χ2 (2) = 1.81, p = 0.406
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Pulse

Left eye lack of smooth
pursuit

Left eye maximum
deviation

Eye angle of onset

Right eye lack of smooth
pursuit

Right eye maximum
deviation

Vertical gaze nystagmus
Lack of convergence

Completion of one leg
stand (left)

Completion of one leg
stand (right)

Left OLS sways while
balancing

Left OLS uses arms to
balance

Left OLS hopping

Left OLS puts foot down

χ2 (2) = 5.19, p = 0.075

Below range
Within range
Above range
Unable to perform

11 (8.4)
61 (46.6)
59 (45)
1 (0.8)

11 (17.2)
33 (51.6)
20 (31.3)
1 (1.6)

No
Yes or present
Unable to perform

79 (60.3)
51 (38.9)
1 (0.8)

6 (9.4)
57 (89.1)
1 (1.6)

No
Yes or present
Unable to Perform
Not present
30 to 45 Degrees
Immediate on-set
Unable to perform

84 (64.1)
46 (35.1)
1 (0.8)
90 (68.7)
40 (30.5)
0 (0)
1 (0.8)

5 (7.8)
58 (90.6)
1 (1.6)
10 (15.6)
51 (79.7)
2 (3.1)
1 (1.6)

No
Yes or present
Unable to perform

79 (60.3)
51 (38.9)
1 (0.8)

6 (9.4)
57 (89.1)
1 (1.6)

No
Yes or present
No
Yes
Unable to perform
Absent
Present
Not attempted

84 (64.1)
46 (35.1)
121 (92.4)
10 (7.6)
1 (0.8)
38 (29)
92 (70.2)
6 (4.6)

5 (7.8)
58 (90.6)
42 (65.6)
22 (34.4)
0 (0)
10 (15.6)
54 (84.4)
3 (4.7)

Attempted but stopped
Attempted and completed
Not attempted

4 (3.1)
121 (92.4)
8 (6.1)

0 (0)
61 (95.3)
6 (9.4)

χ2 (2) = 0.99, p = 0.611

Attempted but stopped
Attempted and completed
Not attempted/completed

1 (0.8)
122 (93.1)
8 (6.1)

1 (1.6)
57 (89.1)
3 (4.7)

χ2 (2) = 1.72, p = 0.424

Not present
Present
Not attempted/completed

18 (13.7)
105 (80.2)
8 (6.1)

5 (7.8)
56 (87.5)
3 (4.7)

χ2 (2) = 2.10, p = 0.351

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

47 (35.9)
76 (58)
8 (6.1)
101 (77.1)
22 (16.8)
8 (6.1)

17 (26.6)
44 (68.8)
3 (4.7)
50 (78.1)
11 (17.2)
3 (4.7)

χ2 (2) = 45.36, p <.001

χ2 (2) = 54.98, p <.001

χ2 (3) = 50.24, p <.001

χ2(2) = 45.36, p <.001

χ2(2) = 54.98, p <.001

χ2(1) = 22.41, p <.001
χ2 (2) = 4.77, p = 0.092

χ2 (2) = 2.00, p = 0.369

χ2 (2) = 0.16, p = 0.922

χ2 (3) = 4.74, p = 0.192
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Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front
to back

MRB swaying left to
back

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors
WAT completion

0
1
More than 2
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

52 (39.7)
38 (29)
33 (25.2)
18 (13.7)
27 (20.6)
79 (60.3)
7 (5.3)
9 (6.9)

16 (25)
25 (39.1)
20 (31.3)
8 (12.5)
16 (25)
35 (54.7)
5 (7.8)
6 (9.4)

Not present
Present
Not attempted/completed

25 (19.1)
97 (74)
9 (6.9)

6 (9.4)
52 (81.3)
6 (9.4)

χ2 (2) = 3.19, p = 0.203

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

42 (32.1)
80 (61.1)
9 (6.9)
100 (76.3)
22 (16.8)
9 (6.9)

18 (28.1)
40 (62.5)
7 (10.9)
44 (68.8)
13 (20.3)
6 (9.4)

χ2 (2) = 0.58, p = 0.748

0
1
More than 2
Not attempted/completed
0-14
15-29
30 or more
0

54 (41.2)
28 (21.4)
40 (30.5)
18 (13.7)
23 (17.6)
79 (60.3)
11 (8.4)
27 (20.6)

11 (17.2)
26 (40.6)
21 (32.8)
12 (18.8)
15 (23.4)
33 (51.6)
4 (6.3)
14 (21.9)

χ2 (3) = 13.62, p = 0.003

Less than 2 inches
2 inches or more

32 (24.4)
72 (55.0)

17 (26.6)
33 (51.6.1)

0

33 (25.2)

21 (32.8)

Less than 2 inches
2 inches or more

30 (22.9)
68 (51.9)

10 (15.6)
33 (51.6)

Not attempted/completed
0-24
25-35
36 or higher
No

3 (2.3)
40 (30.5)
53 (40.5)
35 (26.7)
80 (61.1)

0 (0)
12 (18.8)
26 (40.6)
26 (40.6)
48 (75)

Yes
No

51 (38.9)
102 (77.9)

16 (25)
55 (85.9)

Yes
Not attempted

29 (22.1)
4 (3.1)

9 (14.1)
4 (6.3)

χ2 (3) = 1.08, p = 0.781

χ2 (2) = 1.50, p = 0.473

χ2 (3) = 2.29, p = 0.514

χ2 (2) = 2.03, p = 0.904

χ2 (2) = 2.01, p = 3.66

χ2 (3) = 6.36, p = 0.095

χ2 (1) = 3.70, p = 0.054

χ2 (1) = 1.79, p = 0.181
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WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT turn

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

Attempted but stopped
Attempted and completed

4 (3.1)
123 (93.9)

1 (1.6)
59 (92.2)

Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
Less than 9
9
More than 9
Not attempted/completed
Proper turn
Improper turn
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1

6 (4.6)
48 (36.6)
63 (48.1)
14 (10.7)
6 (4.6)
104 (79.4)
20 (15.3)
1 (0.8)
6 (4.6)
75 (57.3)
30 (22.9)
20 (15.3)
6 (4.6)
58 (44.3)
20 (15.3)
47 (35.9)
6 (4.6)
73 (55.7)
30 (22.9)
22 (16.8)
6 (4.6)
53 (40.5)
37 (28.2)
35 (26.7)
6 (4.6)
19 (14.5)
84 (64.1)
22 (16.8)
13 (9.9)
36 (27.5)
82 (62.6)
9 (6.9)
80 (61.1)
27 (20.6)
15 (11.5)
9 (6.9)
48 (36.6)
25 (19.1)
49 (37.4)
9 (6.9)
76 (58.0)
28 (21.4)

4 (6.3)
14 (21.9)
33 (51.6)
13 (20.3)
4 (6.3)
38 (59.4)
21 (32.8)
1 (1.6)
4 (6.3)
30 (46.9)
14 (21.9)
16 (25)
4 (6.3)
17 (26.6)
15 (23.4)
28 (43.8)
4 (6.3)
22 (34.4)
18 (28.1)
20 (31.3)
4 (6.3)
19 (29.7)
18 (28.1)
23 (35.9)
4 (6.3)
7 (10.9)
36 (56.3)
17 (26.6)
7 (11.1)
14 (22.2)
42 (66.7)
5 (7.8)
34 (53.1)
15 (23.4)
10 (15.6)
5 (7.8)
18 (28.1)
13 (20.3)
28 (43.8)
5 (7.8)
29 (45.3)
13 (20.3)

χ2 (2) = 1.46, p = 0.483

χ2 (3) = 6.16, p = 0.104

χ2 (3) = 9.16, p = 0.027

X2(3) = 3.32, p = 0.345

χ2 (3) = 6.03, p = 0.110

χ2 (3) = 8.91, p = 0.031

χ2 (3) = 2.81, p = 0.421

χ2 (3) = 3.13, p = 0.372

χ2 (2) = 0.63, p = 0.732

χ2 (3) = 1.26, p = 0.738

χ2 (3) = 1.45, p = 0.695

χ2 (3) = 5.30, p = 0.151
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WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD

2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
Less than 9
9
More than 9
Not attempted
0
1
2
3
4
5
6
Not available
No
Yes
Not available
No
Yes
Not available

18 (13.7)
9 (6.9)
52 (39.7)
38 (29)
32 (24.4)
9 (6.9)
10 (7.6)
90 (68.7)
22 (16.8)
6 (4.6)
51 (38.9)
12 (9.2)
16 (12.2)
15 (11.5)
8 (6.1)
9 (6.9)
14 (10.7)
5 (3.8)
62 (47.3)
64 (48.9)
5 (3.8)
115 (87.8)
11 (8.4)
5 (3.8)

17 (26.6)
5 (7.8)
23 (35.9)
12 (18.8)
24 (37.5)
5 (7.8)
3 (4.7)
38 (59.4)
18 (28.1)
3 (4.7)
27 (42.2)
11 (17.2)
9 (14.1)
5 (7.8)
3 (4.7)
0 (0)
6 (9.4)
3 (4.7)
31 (48.4)
30 (46.9)
3 (4.7)
53 (82.8)
8 (12.5)
3 (4.7)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

97 (74)
29 (22.1)
5 (3.8)
106 (80.9)
20 (15.3)
5 (3.8)
96 (73.3)
30 (22.9)
5 (3.8)
111 (84.7)
15 (11.5)
5 (3.8)

50 (78.1)
11 (17.2)
2 (3.1)
51 (79.7)
11 (17.2)
3 (4.7)
49 (76.6)
12 (18.8)
3 (4.7)
57 (89.1)
4 (6.3)
3 (4.7)

χ2 (2) = 0.69, p = 0.709

No
Yes
Not available
Below range
Within range
Above range
Not available

122 (93.1)
4 (3.1)
1 (0.8)
16 (12.2)
94 (71.8)
20 (15.3)
2 (1.5)

59 (92.2)
2 (3.1)
0 (0)
3 (4.7)
51 (79.7)
10 (15.6)
0 (0)

χ2 (2) = 0.08, p = 0.959

χ2 (3) = 4.53, p = 0.209

χ2 (3) = 3.87, p = 0.275

χ2 (7) = 7.76, p = 0.355

χ2 (2) = 0.13, p = 0.939

χ2 (2) = 0.95, p = 0.623

χ2 (2) = 0.17, p = 0.921

χ2 (2) = 0.49, p = 0.784

χ2 (2) = 1.37, p = 0.505

χ2 (3) = 3.36, p = 0.340
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Left pupil size DL1

Left pupil size DL2

Right pupil size RL

Right pupil size NTD

Right pupil size DL1

Right pupil size DL2

Rebound dilation
Reaction to light

Nasal area

Oral cavity
Left arm injection sites

Right arm injection sites

Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
No
Yes
Not available
Normal
Slow
Little to none
Not available
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
Both
None
Old
Fresh
Both

40 (30.5)
83 (63.4)
6 (4.6)
1 (0.8)
13 (9.9)
104 (79.4)
13 (9.9)
94 (71.8)
30 (22.9)
7 (5.3)
2 (1.5)
16 (12.2)
92 (70.2)
21 (16)
3 (2.3)
40 (30.5)
79 (60.3)
9 (6.9)
2 (1.5)
13 (9.9)
103 (78.6)
13 (9.9)
94 (71.8)
30 (22.9)
7 (5.3)
89 (67.9)
42 (32.1)
3 (2.3)
54 (41.2)
52 (39.7)
22 (16.8)
1 (0.8)
90 (68.7)
40 (30.5)
47 (35.9)
84 (64.1)
108 (82.4)
11 (8.4)
11 (8.4)
1 (0.8)
111 (84.7)
10 (7.6)
9 (6.9)
1 (0.8)

9 (14.1)
49 (76.6)
6 (9.4)
0 (0)
1 (1.6)
59 (92.2)
4 (6.3)
55 (85.9)
7 (10.9)
2 (3.1)
0 (0)
3 (4.7)
51 (79.7)
10 (15.6)
0 (0)
9 (14.1)
49 (76.6)
6 (9.4)
0 (0)
1 (1.6)
59 (92.2)
4 (6.3)
55 (85.9)
7 (10.9)
2 (3.1)
50 (78.1)
14 (21.9)
0 (0)
21 (32.8)
39 (60.9)
4 (6.3)
0 (0)
46 (71.9)
18 (28.1)
31 (48.4)
33 (51.6)
51 (79.7)
4 (6.3)
9 (14.1)
0 (0)
58 (90.6)
3 (4.7)
3 (4.7)
0 (0)

χ2 (3) = 8.33, p = 0.040

χ2 (3) = 6.18, p = 0.103

χ2 (2) = 4.83, p = 0.089

χ2 (3) = 4.01, p = 0.261

χ2 (3) = 8.19, p = 0.042

χ2 (3) = 6.78, p = 0.079

χ2 (2) = 4.83, p = 0.089

χ2 (1) = 2.18, p = 0.140
χ2 (3) = 10.00, p = 0.019

χ2 (2) = 0.64, p = 0.728

χ2 (1) = 2.83, p = 0.093
χ2 (3) = 2.13, p = 0.546

χ2 (3) = 1.55, p = 0.670
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BP systolic

BP diastolic

Body temperature

Muscle tone

Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

1 (0.8)
24 (18.3)
59 (45)
47 (35.9)
1 (0.8)
11 (8.4)
87 (66.4)
32 (24.4)
0 (0)
57 (43.5)
71 (54.2)
3 (2.3)
1 (0.8)
65 (49.6)
49 (37.4)
16 (12.2)

0 (0)
22 (34.4)
30 (46.9)
12 (18.8)
0 (0)
16 (25)
41 (64.1)
7 (10.9)
3 (4.7)
31 (48.4)
29 (45.3)
1 (1.6)
0 (0)
22 (34.4)
38 (59.4)
4 (6.3)

χ2 (3) = 9.39, p = 0.025

χ2 (3) = 13.00, p = 0.005

χ2 (3) = 7.15, p = 0.067

χ2 (3) = 8.87, p = 0.031

The forward stepwise regression procedure selected three predictors, and the model was
significant, χ2(8) = 42.02, p < .001, indicating that a set of face sheet measures significantly
predicted CNS depressants. Table 5 displays a classification table for the model’s predictive
effectiveness. The overall prediction accuracy was approximately 74%.
Table 5
Classification Table for Regression Predicting CNS Depressant
Observed
CNS depressant not active
CNS depressant active
Overall % Correct

Predicted
CNS depressant not active CNS depressant active
117
14
37
27

% Correct
89.3
42.2
73.8

Table 6 displays the regression coefficient results for the model predicting CNS depressants.
Bloodshot eye appearance (OR = 5.49, p = .005), vertical gaze nystagmus (OR = 5.89, p < .001),
and WAT1 steps off line of 2 or higher (OR = 3.83, p = .003) were associated with higher odds
of CNS depressant being an active drug category.
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Table 6
Coefficients for Regression Predicting CNS Depressant
95% CI OR
Lower Upper

Variable
B
SE
Wald
Sig.
OR
Eyes appearance [ref: Normal]
Not available
-19.28 28142.11 0.00
.999
0.00
0.00
.
Bloodshot
1.70
0.60
7.97
.005
5.49
1.68
17.90
Watery
0.27
0.67
0.17
.683
1.31
0.36
4.83
Bloodshot and watery
0.55
0.56
0.96
.326
1.73
0.58
5.18
Vertical gaze nystagmus
1.77
0.46
15.06 < .001 5.89
2.40
14.44
WAT1 steps off line [ref: 0]
Not attempted/completed
0.93
0.80
1.35
.246
2.54
0.53
12.24
1
0.69
0.44
2.61
.106
2.00
0.86
4.64
2 or higher
1.33
0.56
9.09
.003
3.83
1.59
8.99
Note. The upper bound of the 95% CI for eye appearance not available approaches infinity and is
not reported.
CNS Stimulants
Table 7 displays crosstabulations of each factor with the identification of CNS stimulant
as an active drug category. Factors significantly associated with CNS stimulants were less ability
to follow stimulus, above range pulse, faster MRB internal clock, no MRB eyelid tremors,
stopping walking on WAT2, left and right pupil size NTD, no rebound dilation, slow reaction to
light, abnormal nasal area, and rigid muscle tone.
Table 7
Crosstabulation of Face Sheet Measures with Active CNS Stimulant
Variable

Value

Have you eaten today

Not available
No
Yes
Not available
No
Yes
Not available

Have you drank today

Est. time vs. actual time

CNS Stimulant
Not Active
Active
n (%)
n (%)
5 (3.2)
0 (0)
35 (22.7)
8 (19.5)
114 (74)
33 (80.5)
4 (2.6)
0 (0)
40 (26)
8 (19.5)
110 (71.4)
33 (80.5)
9 (5.8)
3 (7.3)

Bivariate Test Result
χ2 (2) = 1.66, p = 0.436

χ2 (2) = 1.98, p = 0.372

χ2 (4) = 6.29, p = 0.179
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Duration of last sleep

Sick or injured
Diabetic or epileptic

Physical disabilities
Under care of doctor or
dentist

Taking medications or
drugs

Coordination
Breath
Face

Speech
Eyes appearance

Blindness
Eye tracking stimulus
Ability to follow stimulus

10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
Not available
No
Yes
No
Yes
Not available

38 (24.7)

4 (9.8)

35 (22.7)

7 (17.1)

41 (26.6)

15 (36.6)

31 (20.1)

12 (29.3)

15 (9.7)
25 (16.2)
96 (62.3)
18 (11.7)
118 (76.6)
36 (23.4)
1 (0.6)
147 (95.5)
6 (3.9)
111 (72.1)
43 (27.9)
1 (0.6)

4 (9.8)
4 (9.8)
24 (58.5)
9 (22)
26 (63.4)
15 (36.6)
0 (0)
40 (97.6)
1 (2.4)
32 (78)
9 (22)
0 (0)

No
Yes
Not available

94 (61)
59 (38.3)
2 (1.3)

23 (56.1)
18 (43.9)
0 (0)

No
Yes
Fair/good
Other
Normal
Other
Not available
Normal
Other
Normal
Other
Not available
Normal
Bloodshot
Watery
Bloodshot and watery
None
Right eye
Equal
Unequal
No
Yes

42 (27.3)
110 (71.4)
34 (22.1)
120 (77.9)
84 (54.5)
70 (45.5)
1 (0.6)
62 (40.3)
91 (59.1)
38 (24.7)
116 (75.3)
2 (1.3)
21 (13.6)
37 (24)
26 (16.9)
68 (44.2)
154 (100)
0 (0)
154 (100)
0 (0)
6 (3.9)
148 (96.1)

9 (22)
32 (78)
9 (22)
32 (78)
26 (63.4)
15 (36.6)
0 (0)
20 (48.8)
21 (51.2)
8 (19.5)
33 (80.5)
0 (0)
7 (17.1)
9 (22)
6 (14.6)
19 (46.3)
40 (97.6)
1 (2.4)
40 (97.6)
1 (2.4)
5 (12.2)
36 (87.8)

χ2 (3) = 3.45, p = 0.327

χ2 (1) = 2.93, p = 0.087
χ2 (2) = 0.47, p = 0.789

χ2 (1) = 0.59, p = 0.442
χ2 (2) = 0.65, p = 0.721

χ2 (2) = 1.08, p = 0.583

χ2 (1) = 0.00, p = 0.986
χ2 (1) = 1.04, p = 0.309
χ2 (2) = 1.18, p = 0.556

χ2 (1) = 0.48, p = 0.489
χ2 (4) = 0.99, p = 0.911

χ2 (1) = 3.78, p = 0.052
χ2 (1) = 3.78, p = 0.052
χ2 (1) = 4.19, p = 0.041
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Eyelids

Pulse

Left eye lack of smooth
pursuit

Left eye maximum
deviation

Eye angle of onset

Right eye lack of smooth
pursuit

Right eye maximum
deviation

Vertical gaze nystagmus
Lack of convergence

Completion of one leg
stand (left)

Completion of one leg
stand (right)

Left OLS sways while
balancing

Left OLS uses arms to
balance

Left OLS hopping

χ2 (2) = 4.60, p = 0.100

Not available
Normal
Droopy
Below range
Within range
Above range
Unable to perform

1 (0.6)
38 (24.7)
115 (74.7)
21 (13.6)
76 (49.4)
57 (37)
2 (1.3)

1 (2.4)
16 (39)
24 (58.5)
1 (2.4)
18 (43.9)
22 (53.7)
0 (0)

No
Yes or present
Unable to perform

70 (45.5)
82 (53.2)
2 (1.3)

15 (36.6)
26 (63.4)
0 (0)

No
Yes or present
Unable to Perform
Not present
30 to 45 Degrees
Immediate on-set
Unable to perform

71 (46.1)
81 (52.6)
2 (1.3)
80 (51.9)
70 (45.5)
2 (1.3)
2 (1.3)

18 (43.9)
23 (56.1)
0 (0)
20 (48.8)
21 (51.2)
0 (0)
0 (0)

No
Yes or present
Unable to perform

70 (45.5)
82 (53.2)
2 (1.3)

15 (36.6)
26 (63.4)
0 (0)

No
Yes or present
No
Yes
Unable to perform
Absent
Present
Not attempted

71 (46.1)
81 (52.6)
130 (84.4)
24 (15.6)
1 (0.6)
33 (21.4)
120 (77.9)
6 (3.9)

18 (43.9)
23 (56.1)
33 (80.5)
8 (19.5)
0 (0)
15 (36.6)
26 (63.4)
3 (7.3)

Attempted but stopped
Attempted and completed
Not attempted

4 (2.6)
144 (93.5)
10 (6.5)

0 (0)
38 (92.7)
4 (9.8)

χ2 (2) = 1.58, p = 0.454

Attempted but stopped
Attempted and completed
Not attempted/completed

1 (0.6)
143 (92.9)
8 (5.2)

1 (2.4)
36 (87.8)
3 (7.3)

χ2 (2) = 1.19, p = 0.551

Not present
Present
Not attempted/completed

20 (13)
126 (81.8)
8 (5.2)

3 (7.3)
35 (85.4)
3 (7.3)

χ2 (2) = 0.49, p = 0.784

Not present
Present
Not attempted/completed

52 (33.8)
94 (61)
8 (5.2)

12 (29.3)
26 (63.4)
3 (7.3)

χ2 (2) = 0.28, p = 0.869

χ2 (2) = 6.01, p = 0.049

χ2 (2) = 1.72, p = 0.423

χ2 (2) = 0.64, p = 0.726

χ2 (3) = 1.36, p = 0.715

χ2 (2) = 1.72, p = 0.423

χ2 (2) = 0.64, p = 0.726

χ2 (1) = 0.36, p = 0.546
χ2 (2) = 4.20, p = 0.123

χ2 (2) = 1.89, p = 0.389
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Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front
to back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors

Not present
Present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

120 (77.9)
26 (16.9)
8 (5.2)
57 (37)
49 (31.8)
40 (26)
20 (13)
31 (20.1)
94 (61)
9 (5.8)
11 (7.1)

31 (75.6)
7 (17.1)
3 (7.3)
11 (26.8)
14 (34.1)
13 (31.7)
6 (14.6)
12 (29.3)
20 (48.8)
3 (7.3)
4 (9.8)

Not present
Present
Not attempted/completed

27 (17.5)
116 (75.3)
11 (7.1)

4 (9.8)
33 (80.5)
4 (9.8)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

49 (31.8)
94 (61)
12 (7.8)
115 (74.7)
27 (17.5)
11 (7.1)

11 (26.8)
26 (63.4)
4 (9.8)
29 (70.7)
8 (19.5)
4 (9.8)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
None

50 (32.5)
45 (29.2)
48 (31.2)
24 (15.6)
28 (18.2)
89 (57.8)
13 (8.4)
33 (21.4)

15 (36.6)
9 (22)
13 (31.7)
6 (14.6)
10 (24.4)
23 (56.1)
2 (4.9)
8 (19.5)

< 2 inches
2 inches or more
None
< 2 inches
2 inches or more
Not attempted/completed
0-24
25-35
36 or higher
No

37 (24)
84 (54.5)
44 (28.6)
29 (18.8)
81 (52.6)
2 (1.3)
33 (21.4)
69 (44.8)
50 (32.5)
93 (60.4)

12 (29.3)
21 (51.2)
10 (24.4)
11 (26.8)
20 (48.8)
1 (2.4)
19 (46.3)
10 (24.4)
11 (26.8)
35 (85.4)

Yes
No

61 (39.6)
124 (80.5)

6 (14.6)
33 (80.5)

Yes

30 (19.5)

8 (19.5)

χ2 (3) = 1.67, p = 0.644

χ2 (3) = 2.24, p = 0.524

χ2 (2) = 1.63, p = 0.442

χ2 (2) = 0.58, p = 0.749

χ2 (2) = 0.29, p = 0.865

χ2 (3) = 1.07, p = 0.784

χ2 (3) =1.21, p = 0.751

χ2 (2) = .477, p = 0.788

χ2 (2) = 1.31, p = 0.521

χ2 (3) = 11.47, p = 0.009

χ2 (1) = 8.96, p = 0.003

χ2 (1) = 0.00, p = 0.996

93
WAT completion

WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT turn

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

Not attempted
Attempted but stopped
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted/completed
Proper turn
Improper turn
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0

5 (3.2)
4 (2.6)
145 (94.2)
7 (4.5)
49 (31.8)
76 (49.4)
22 (14.3)
7 (4.5)
115 (74.7)
30 (19.5)
2 (1.3)
7 (4.5)
86 (55.8)
36 (23.4)
25 (16.2)
7 (4.5)
62 (40.3)
26 (16.9)
59 (38.3)
7 (4.5)
79 (51.3)
40 (26)
28 (18.2)
7 (4.5)
62 (40.3)
42 (27.3)
43 (27.9)
7 (4.5)
18 (11.7)
97 (63)
32 (20.8)
14 (9.2)
43 (28.1)
96 (62.7)
10 (6.5)
97 (63)
32 (20.8)
15 (9.7)
10 (6.5)
50 (32.5)
32 (20.8)
63 (40.9)
10 (5.8)
86 (55.8)

3 (7.3)
1 (2.4)
37 (90.2)
3 (7.3)
13 (31.7)
20 (48.8)
5 (12.2)
3 (7.3)
27 (65.9)
11 (26.8)
0 (0)
3 (7.3)
19 (46.3)
8 (19.5)
11 (26.8)
3 (7.3)
13 (31.7)
9 (22)
16 (39)
3 (7.3)
16 (39)
8 (19.5)
14 (34.1)
3 (7.3)
10 (24.4)
13 (31.7)
15 (36.6)
3 (7.3)
8 (19.5)
23 (56.1)
7 (17.1)
6 (14.6)
7 (17.1)
28 (68.3)
4 (9.8)
17 (41.5)
10 (24.4)
10 (24.4)
4 (9.8)
17 (41.5)
6 (14.6)
14 (34.1)
4 (9.8)
19 (46.3)

χ2 (2) = 1.36, p = 0.506

χ2 (3) = 0.590, p = 0.899

χ2 (3) = 2.19, p = 0.533

χ2 (3) = 3.21, p = 0.360

χ2 (3) = 1.57, p = 0.667

χ2 (3) = 5.87, p = 0.118

χ2 (3) = 3.74, p = 0.291

χ2 (3) = 2.44, p = 0.486

χ2 (2) = 2.63, p = 0.269

χ2 (3) = 8.66, p = 0.034

χ2 (3) = 2.37, p = 0.499

χ2 (3) = 5.74, p = 0.125
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WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
2
3
4
5
6
Not available
No
Yes
Not available
No
Yes
Not available

35 (22.7)
23 (14.9)
10 (6.5)
64 (41.6)
39 (25.3)
41 (26.6)
10 (6.5)
10 (6.5)
103 (66.9)
31 (20.1)
8 (5.2)
64 (41.6)
17 (11)
18 (11.7)
15 (9.7)
9 (5.8)
7 (4.5)
16 (10.4)
7 (4.5)
73 (47.4)
74 (48.1)
7 (4.5)
129 (83.8)
18 (11.7)
7 (4.5)

6 (14.6)
12 (29.3)
4 (9.8)
11 (26.8)
11 (26.8)
15 (36.6)
4 (9.8)
3 (7.3)
25 (61)
9 (22)
1 (2.4)
14 (34.1)
6 (14.6)
7 (17.1)
5 (12.2)
2 (4.9)
2 (4.9)
4 (9.8)
1 (2.4)
20 (48.8)
20 (48.8)
1 (2.4)
39 (95.1)
1 (2.4)
1 (2.4)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

116 (75.3)
31 (20.1)
6 (3.9)
124 (80.5)
24 (15.6)
7 (4.5)
112 (72.7)
35 (22.7)
7 (4.5)
133 (86.4)
14 (9.1)
7 (4.5)

31 (75.6)
9 (22)
1 (2.4)
33 (80.5)
7 (17.1)
1 (2.4)
33 (80.5)
7 (17.1)
1 (2.4)
35 (85.4)
5 (12.2)
1 (2.4)

No
Yes
Not available
Below range
Within range
Above range

142 (92.2)
5 (3.2)
1 (0.6)
19 (12.3)
109 (70.8)
25 (16.2)

39 (95.1)
1 (2.4)
0 (0)
0 (0)
36 (87.8)
5 (12.2)

χ2 (3) = 3.45, p = 0.327

χ2 (3) = 7.38, p = 0.864

χ2 (7) = 2.33, p = 0.939

χ2 (2) = 0.37, p = 0.832

χ2 (2) = 3.68, p = 0.159

χ2 (2) = 0.40, p = 0.818

χ2 (2) = 0.24, p = 0.888

χ2 (2) = 1.09, p = 0.579

χ2 (2) = 0.67, p = 0.714

χ2 (2) = 0.45, p = 0.799

χ2 (3) = 6.93, p = 0.074
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Left pupil size NTD

Left pupil size DL1

Left pupil size DL2

Right pupil size RL

Right pupil size NTD

Right pupil size DL1

Right pupil size DL2

Rebound dilation
Reaction to light

Nasal area

Oral cavity
Left arm injection sites

Right arm injection sites

Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
No
Yes
Not available
Normal
Slow
Little to none
Not available
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
Both
None
Old
Fresh

1 (0.6)
46 (29.9)
98 (63.6)
9 (5.8)
1 (0.6)
12 (7.8)
125 (81.2)
16 (10.4)
114 (74)
33 (21.4)
7 (4.5)
1 (0.6)
19 (12.3)
108 (70.1)
26 (16.9)
1 (0.6)
46 (29.9)
95 (61.7)
12 (7.8)
1 (0.6)
12 (7.8)
125 (81.2)
16 (10.4)
114 (74)
33 (21.4)
7 (4.5)
104 (67.5)
50 (32.5)
2 (1.3)
68 (44.2)
59 (38.3)
25 (16.2)
0 (0)
114 (74)
40 (26)
65 (42.2)
89 (57.8)
127 (82.5)
11 (7.1)
15 (9.7)
1 (0.6)
132 (85.7)
12 (7.8)
9 (5.8)

1 (2.4)
3 (7.3)
34 (82.9)
3 (7.3)
0 (0)
2 (4.9)
38 (92.7)
1 (2.4)
35 (85.4)
4 (9.8)
2 (4.9)
1 (2.4)
0 (0)
35 (85.4)
5 (12.2)
2 (4.9)
3 (7.3)
33 (80.5)
3 (7.3)
1 (2.4)
2 (4.9)
37 (90.2)
1 (2.4)
35 (85.4)
4 (9.8)
2 (4.9)
35 (85.4)
6 (14.6)
1 (2.4)
7 (17.1)
32 (78)
1 (2.4)
1 (2.4)
22 (53.7)
18 (43.9)
13 (31.7)
28 (68.3)
32 (78)
4 (9.8)
5 (12.2)
0 (0)
37 (90.2)
1 (2.4)
3 (7.3)

χ2 (3) = 9.46, p = 0.024

χ2 (3) = 3.51, p = 0.319

χ2 (2) = 2.88, p = 0.237

χ2 (3) = 7.54, p = 0.056

χ2 (3) = 12.07, p = 0.007

χ2 (3) = 4.06, p = 0.255

χ2 (2) = 2.88, p = 0.237

χ2 (1) = 5.03, p = 0.025
χ2 (3) = 22.03, p <.001

χ2 (2) = 9.18, p = 0.010

χ2 (1) = 1.49, p = 0.223
χ2 (3) = 0.82, p = 0.844

χ2 (3) = 1.85, p = 0.604
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BP systolic

BP diastolic

Body temperature

Muscle tone

Both
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

1 (0.6)
1 (0.6)
38 (24.7)
69 (44.8)
46 (29.9)
1 (0.6)
26 (16.9)
99 (64.3)
28 (18.2)
3 (1.9)
66 (42.9)
82 (53.2)
3 (1.9)
1 (0.6)
69 (44.8)
76 (49.4)
8 (5.2)

0 (0)
0 (0)
8 (19.5)
20 (48.8)
13 (31.7)
0 (0)
1 (2.4)
29 (70.7)
11 (26.8)
0 (0)
22 (53.7)
18 (43.9)
1 (2.4)
0 (0)
18 (43.9)
11 (26.8)
12 (29.3)

X2(3) = 0.78, p = 0.854

χ2 (3) = 6.56, p = 0.087

χ2 (3) = 2.23, p = 0.527

χ2 (3) = 22.25, p <.001

The forward stepwise regression procedure selected one predictor, and the model was
significant, χ2(3) = 18.28, p < .001, indicating that a set of face sheet measures significantly
predicted CNS stimulants. Table 8 displays a classification table for the model’s predictive
effectiveness. The overall prediction accuracy was approximately 79%.
Table 8
Classification Table for Regression Predicting CNS Stimulant
Observed
CNS stimulant not active
CNS stimulant active
Overall % Correct

Predicted
CNS stimulant not active
CNS stimulant active
154
0
41
0

% Correct
100.0
0.0
79.0

Table 9 displays the regression coefficient results for the model predicting CNS
stimulants. Having MRB eyelid tremors (OR = 2.38, p = .003) was associated with higher odds
of CNS stimulant.
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Table 9
Coefficients for Regression Predicting CNS Stimulant
Variable
Pulse [ref: Within range]
Below range
Above range
MRB eyelid tremors

B

SE

Wald

Sig.

OR

-1.64
0.59
1.44

1.06
0.38
0.48

2.39
2.50
8.98

.122
.114
.003

0.19
1.81
2.38

95% CI OR
Lower Upper
0.02
0.87
0.09

1.55
3.78
0.60

Narcotic Analgesics
Table 10 displays crosstabulations of each factor with the identification of narcotic
analgesic as an active drug category. Factors significantly associated with narcotic analgesics
were being sick or injured, being diabetic or epileptic, being under the care of a doctor or dentist,
abnormal coordination, abnormal speech, droopy eyelids, no lack of smooth pursuit and no
maximum deviation (both eyes), angle of onset not present (both eyes), lack of convergence
absent, difficulty on OLS, MRB swaying front to back, no MRB eyelid tremors, stopping
walking on WAT2, miss heel to toe on WAT2, stepping off the line on WAT2, steps taken on
WAT2, no FTN eyelid tremors, left and right pupil size (all lights), no rebound dilation,
abnormal reaction to light, arm injection sites, and flaccid muscle tone.
Table 10
Crosstabulation of Face Sheet Measures with Active Narcotic Analgesic
Variable

Value

Have you eaten today

Not available
No
Yes
Not available
No
Yes
Not available

Have you drank today

Est. time vs. actual time

Narcotic Analgesic
Not Active
Active
n (%)
n (%)
3 (2)
2 (4.5)
34 (22.5)
9 (20.5)
114 (75.5)
33 (75)
2 (1.3)
2 (4.5)
34 (22.5)
14 (31.8)
115 (76.2)
28 (63.6)
8 (5.3)
4 (9.1)

Bivariate Test Result
χ2 (2) = 0.94, p = 0.626

χ2 (2) = 3.65, p = 0.161

χ2 (4) = 7.06, p = 0.133
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Duration of last sleep

Sick or injured
Diabetic or epileptic

Physical disabilities
Under care of doctor or
dentist

Taking medications or
drugs

Coordination
Breath
Face

Speech
Eyes appearance

Blindness
Eye tracking stimulus
Ability to follow stimulus

10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
Not available
No
Yes
No
Yes
Not available

34 (22.5)

8 (18.2)

33 (21.9)

9 (20.5)

48 (31.8)

8 (18.2)

28 (18.5)

15 (34.1)

14 (9.3)
18 (11.9)
97 (64.2)
22 (14.6)
119 (78.8)
32 (21.2)
1 (0.7)
148 (98)
2 (1.3)
113 (74.8)
38 (25.2)
1 (0.7)

5 (11.4)
11 (25)
23 (52.3)
5 (11.4)
25 (56.8)
19 (43.2)
0 (0)
39 (88.6)
5 (11.4)
30 (68.2)
14 (31.8)
0 (0)

No
Yes
Not available

99 (65.6)
51 (33.8)
2 (1.3)

18 (40.9)
26 (59.1)
0 (0)

No
Yes
Fair/good
Other
Normal
Other
Not available
Normal
Other
Normal
Other
Not available
Normal
Bloodshot
Watery
Bloodshot and watery
None
Right eye
Equal
Unequal
No
Yes

45 (29.8)
104 (68.9)
39 (25.8)
112 (74.2)
81 (53.6)
70 (46.4)
1 (0.7)
70 (46.4)
80 (53)
43 (28.5)
108 (71.5)
0 (0)
20 (13.2)
37 (24.5)
24 (15.9)
70 (46.4)
150 (99.3)
1 (0.7)
150 (99.3)
1 (0.7)
9 (6)
142 (94)

6 (13.6)
38 (86.4)
4 (9.1)
40 (90.9)
29 (65.9)
15 (34.1)
0 (0)
12 (27.3)
32 (72.7)
3 (6.8)
41 (93.2)
2 (4.5)
8 (18.2)
9 (20.5)
8 (18.2)
17 (38.6)
44 (100)
0 (0)
44 (100)
0 (0)
2 (4.5)
42 (95.5)

χ2 (3) = 5.12, p = 0.163

χ2 (1) = 8.53, p = 0.003
χ2 (2) = 10.17, p = 0.006

χ2 (1) = 0.77, p = 0.380
χ2 (2) = 9.27, p = 0.010

χ2 (2) = 5.42, p = 0.067

χ2 (1) = 5.55, p = 0.018
χ2 (1) = 2.09, p = 0.149
χ2 (2) = 5.56, p = 0.062

χ2 (1) = 8.87, p = 0.003
χ2 (4) = 8.24, p = 0.083

χ2 (1) = 0.29, p = 0.588
χ2 (1) = 0.29, p = 0.588
χ2 (1) = 0.13, p = 0.720
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Eyelids

Pulse

Left eye lack of smooth
pursuit

Left eye maximum
deviation

Eye angle of onset

Right eye lack of smooth
pursuit

Right eye maximum
deviation

Vertical gaze nystagmus
Lack of convergence

Completion of one leg
stand (left)

Completion of one leg
stand (right)

Left OLS sways while
balancing

Left OLS uses arms to
balance

Left OLS hopping

χ2 (2) = 15.68, p <.001

Not available
Normal
Droopy
Below range
Within range
Above range
Unable to perform

1 (0.7)
52 (34.4)
98 (64.9)
15 (9.9)
70 (46.4)
66 (43.7)
1 (0.7)

1 (2.3)
2 (4.5)
41 (93.2)
7 (15.9)
24 (54.5)
13 (29.5)
1 (2.3)

No
Yes or present
Unable to perform

58 (38.4)
92 (60.9)
1 (0.7)

27 (61.4)
16 (36.4)
1 (2.3)

No
Yes or present
Unable to Perform
Not present
30 to 45 Degrees
Immediate on-set
Unable to perform

58 (38.4)
92 (60.9)
1 (0.7)
67 (44.4)
82 (54.3)
1 (0.7)
1 (0.7)

31 (70.5)
12 (27.3)
1 (2.3)
33 (75)
9 (20.5)
1 (2.3)
1 (2.3)

χ2 (2) = 8.69, p = 0.013

No
Yes or present
Unable to perform

58 (38.4)
92 (60.9)
1 (0.7)

27 (61.4)
16 (36.4)
1 (2.3)

χ2 (2) = 15.76, p <.001

No
Yes or present
No
Yes
Unable to perform
Absent
Present
Not attempted

58 (38.4)
92 (60.9)
124 (82.1)
27 (17.9)
0 (0)
33 (21.9)
118 (78.1)
5 (3.3)

31 (70.5)
12 (27.3)
39 (88.6)
5 (11.4)
1 (2.3)
15 (34.1)
28 (63.6)
4 (9.1)

Attempted but stopped
Attempted and completed
Not attempted

2 (1.3)
144 (95.4)
8 (5.3)

2 (4.5)
38 (86.4)
6 (13.6)

χ2 (2) = 4.07, p = 0.131

Attempted but stopped
Attempted and completed
Not attempted/completed

2 (1.3)
141 (93.4)
6 (4)

0 (0)
38 (86.4)
5 (11.4)

χ2 (2) = 4.50, p = 0.106

Not present
Present
Not attempted/completed

20 (13.2)
125 (82.8)
6 (4)

3 (6.8)
36 (81.8)
5 (11.4)

χ2 (2) = 9.41, p = 0.009

Not present
Present
Not attempted/completed

57 (37.7)
88 (58.3)
6 (4)

7 (15.9)
32 (72.7)
5 (11.4)

χ2 (2) = 13.87, p <.001

χ2 (2) = 3.24, p = 0.198

χ2 (2) = 8.69, p = 0.013

χ2 (2) = 15.76, p <.001

χ2 (3) = 16.32, p <.001

χ2 (1) = 1.06, p = 0.304
χ2 (2) = 6.46, p = 0.040

χ2 (2) = 4.49, p = 0.106
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Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front to
back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors

Not present
Present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

126 (83.4)
19 (12.6)
6 (4)
62 (41.1)
46 (30.5)
37 (24.5)
19 (12.6)
31 (20.5)
91 (60.3)
10 (6.6)
9 (6)

25 (56.8)
14 (31.8)
5 (11.4)
6 (13.6)
17 (38.6)
16 (36.4)
7 (15.9)
12 (27.3)
23 (52.3)
2 (4.5)
6 (13.6)

Not present
Present
Not attempted/completed

28 (18.5)
114 (75.5)
9 (6)

3 (6.8)
35 (79.5)
6 (13.6)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

53 (35.1)
89 (58.9)
9 (6)
115 (76.2)
27 (17.9)
9 (6)

7 (15.9)
31 (70.5)
7 (15.9)
29 (65.9)
8 (18.2)
6 (13.6)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
0

55 (36.4)
42 (27.8)
45 (29.8)
20 (13.2)
30 (19.9)
88 (58.3)
13 (8.6)
36 (23.8)

10 (22.7)
12 (27.3)
16 (36.4)
10 (22.7)
8 (18.2)
24 (54.5)
2 (4.5)
5 (11.4)

< 2 inches
2 inches or more
0
< 2 inches
2 inches or more
Not attempted/completed
0-24
25-35
36 or higher
No

41 (27.2)
74 (49)
43 (28.5)
35 (23.2)
73 (48.3)
1 (0.7)
40 (26.5)
65 (43)
45 (29.8)
90 (59.6)

8 (18.2)
31 (70.5)
11 (25)
5 (11.4)
28 (63.6)
2 (4.5)
12 (27.3)
14 (31.8)
16 (36.4)
38 (86.4)

χ2 (1) = 10.82, p = 0.001

Yes
No

61 (40.4)
120 (79.5)

6 (13.6)
37 (84.1)

χ2 (1) = 0.46, p = 0.496

Yes

31 (20.5)

7 (15.9)

χ2 (3) = 13.11, p = 0.004

χ2 (3) = 1.60, p = 0.660

χ2 (2) = 5.63, p = 0.060

χ2 (2) = 7.42, p = 0.024

χ2 (2) = 4.60, p = 0.100

χ2 (3) = 5.00, p = 0.172

χ2 (3) = 2.86, p = 0.415

χ2 (2) = 6.53, p = 0.038

χ2 (2) = 4.01, p = 0.135

χ2 (3) = 4.88, p = 0.181
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WAT completion

WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

WAT2 raised arms

Not attempted
Attempted but stopped
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed

5 (3.3)
2 (1.3)
144 (95.4)
6 (4)
52 (34.4)
70 (46.4)
23 (15.2)
6 (4)
114 (75.5)
30 (19.9)
1 (0.7)
6 (4)
82 (54.3)
36 (23.8)
27 (17.9)
6 (4)
58 (38.4)
32 (21.2)
55 (36.4)
6 (4)
79 (52.3)
38 (25.2)
28 (18.5)
6 (4)
57 (37.7)
48 (31.8)
40 (26.5)
6 (4)
19 (12.6)
94 (62.3)
32 (21.2)
7 (4.6)
89 (58.9)
38 (25.2)
17 (11.3)
7 (4.6)
58 (38.4)
29 (19.2)
57 (37.7)
7 (4.6)
87 (57.6)
33 (21.9)
24 (15.9)
7 (4.6)

3 (6.8)
3 (6.8)
38 (86.4)
4 (9.1)
10 (22.7)
26 (59.1)
4 (9.1)
4 (9.1)
28 (63.6)
11 (25)
1 (2.3)
4 (9.1)
23 (52.3)
8 (18.2)
9 (20.5)
4 (9.1)
17 (38.6)
3 (6.8)
20 (45.5)
4 (9.1)
16 (36.4)
10 (22.7)
14 (31.8)
4 (9.1)
15 (34.1)
7 (15.9)
18 (40.9)
4 (9.1)
7 (15.9)
26 (59.1)
7 (15.9)
7 (15.9)
25 (56.8)
4 (9.1)
8 (18.2)
7 (15.9)
8 (18.2)
9 (20.5)
20 (45.5)
7 (15.9)
18 (40.9)
8 (18.2)
11 (25)
7 (15.9)

χ2 (2) = 5.33, p = 0.070

χ2 (3) = 5.26, p = 0.154

χ2 (3) = 3.69, p = 0.297

χ2 (3) = 2.37, p = 0.499

χ2 (3) = 6.39, p = 0.094

χ2 (3) = 6.39, p = 0.094

χ2 (3) = 7.29, p = 0.063

χ2 (3) = 2.55, p = 0.466

χ2 (3) = 11.42, p = 0.010

χ2 (3) = 10.69, p = 0.014

χ2 (3) = 9.59, p = 0.022

χ2 (3) = 7.34, p = 0.062
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WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD

0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
2
3
4
5
6
Not available
No
Yes
Not available
No
Yes
Not available

59 (39.1)
42 (27.8)
43 (28.5)
7 (4.6)
8 (5.3)
99 (65.6)
37 (24.5)
6 (4)
61 (40.4)
19 (12.6)
19 (12.6)
15 (9.9)
10 (6.6)
4 (2.6)
17 (11.3)
5 (3.3)
71 (47)
75 (49.7)
5 (3.3)
131 (86.8)
15 (9.9)
5 (3.3)

16 (36.4)
8 (18.2)
13 (29.5)
7 (15.9)
5 (11.4)
29 (65.9)
3 (6.8)
3 (6.8)
17 (38.6)
4 (9.1)
6 (13.6)
5 (11.4)
1 (2.3)
5 (11.4)
3 (6.8)
3 (6.8)
22 (50)
19 (43.2)
3 (6.8)
37 (84.1)
4 (9.1)
3 (6.8)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

114 (75.5)
32 (21.2)
4 (2.6)
120 (79.5)
27 (17.9)
5 (3.3)
107 (70.9)
39 (25.8)
5 (3.3)
129 (85.4)
17 (11.3)
5 (3.3)

33 (75)
8 (18.2)
3 (6.8)
37 (84.1)
4 (9.1)
3 (6.8)
38 (86.4)
3 (6.8)
3 (6.8)
39 (88.6)
2 (4.5)
3 (6.8)

No
Yes
Not available
Below range
Within range
Above range
Not available
Below range
Within range

140 (92.7)
6 (4)
1 (0.7)
5 (3.3)
117 (77.5)
28 (18.5)
1 (0.7)
18 (11.9)
120 (79.5)

41 (93.2)
0 (0)
0 (0)
14 (31.8)
28 (63.6)
2 (4.5)
1 (2.3)
31 (70.5)
12 (27.3)

χ2 (3) = 13.11, p = 0.004

χ2 (7) = 8.48, p = 0.292

χ2 (2) = 1.38, p = 0.501

χ2 (2) = 1.07, p = 0.584

χ2 (2) = 1.17, p = 0.556

χ2 (2) = 3.40, p = 0.183

χ2 (2) = 7.84, p = 0.020

χ2 (2) = 2.64, p = 0.267

χ2 (2) = 2.77, p = 0.250

χ2 (3) = 33.93, p <.001

χ2 (3) = 64.53, p <.001
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Left pupil size DL1

Left pupil size DL2

Right pupil size RL

Right pupil size NTD

Right pupil size DL1

Right pupil size DL2

Rebound dilation
Reaction to light

Nasal area

Oral cavity
Left arm injection sites

Right arm injection sites

BP systolic

Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
No
Yes
Not available
Normal
Slow
Little to none
Not available
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
Both
None
Old
Fresh
Both
Not available
Below range

12 (7.9)
0 (0)
5 (3.3)
129 (85.4)
17 (11.3)
109 (72.2)
33 (21.9)
9 (6)
2 (1.3)
5 (3.3)
115 (76.2)
29 (19.2)
2 (1.3)
18 (11.9)
116 (76.8)
15 (9.9)
1 (0.7)
5 (3.3)
128 (84.8)
17 (11.3)
109 (72.2)
33 (21.9)
9 (6)
99 (65.6)
52 (34.4)
2 (1.3)
67 (44.4)
76 (50.3)
6 (4)
0 (0)
110 (72.8)
41 (27.2)
58 (38.4)
93 (61.6)
130 (86.1)
8 (5.3)
13 (8.6)
0 (0)
136 (90.1)
8 (5.3)
7 (4.6)
0 (0)
1 (0.7)
34 (22.5)

0 (0)
1 (2.3)
9 (20.5)
34 (77.3)
0 (0)
40 (90.9)
4 (9.1)
0 (0)
0 (0)
14 (31.8)
28 (63.6)
2 (4.5)
1 (2.3)
31 (70.5)
12 (27.3)
0 (0)
1 (2.3)
9 (20.5)
34 (77.3)
0 (0)
40 (90.9)
4 (9.1)
0 (0)
40 (90.9)
4 (9.1)
1 (2.3)
8 (18.2)
15 (34.1)
20 (45.5)
1 (2.3)
26 (59.1)
17 (38.6)
20 (45.5)
24 (54.5)
29 (65.9)
7 (15.9)
7 (15.9)
1 (2.3)
33 (75)
5 (11.4)
5 (11.4)
1 (2.3)
0 (0)
12 (27.3)

χ2 (3) = 22.60, p <.001

χ2 (2) = 7.11, p = 0.029

χ2 (3) = 34.33, p = <.001

χ2 (3) = 63.77, p = <.001

χ2 (3) = 19.99, p <.001

χ2 (2) = 7.11, p = 0.029

χ2 (1) = 10.69, p = 0.001
χ2 (3) = 52.17, p = <.001

χ2 (2) = 5.87, p = 0.053

χ2 (1) = 0.70, p = 0.401
χ2 (3) = 11.89, p = 0.008

χ2 (3) = 8.71, p = 0.033

χ2 (3) = 1.51, p = 0.681
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BP diastolic

Body temperature

Muscle tone

Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

72 (47.7)
44 (29.1)
1 (0.7)
20 (13.2)
96 (63.6)
34 (22.5)
3 (2)
68 (45)
76 (50.3)
4 (2.6)
1 (0.7)
78 (51.7)
55 (36.4)
17 (11.3)

17 (38.6)
15 (34.1)
0 (0)
7 (15.9)
32 (72.7)
5 (11.4)
0 (0)
20 (45.5)
24 (54.5)
0 (0)
0 (0)
9 (20.5)
32 (72.7)
3 (6.8)

χ2 (3) = 3.02, p = 0.389

χ2 (3) = 2.16, p = 0.540

χ2 (3) = 18.45, p <.001

The forward stepwise regression procedure selected five predictors, and the model was
significant, χ2(8) = 43.44, p < .001, indicating that a set of face sheet measures significantly
predicted narcotic analgesics. Table 11 displays a classification table for the model’s predictive
effectiveness. The overall prediction accuracy was approximately 81%.
Table 11
Classification Table for Regression Predicting Narcotic Analgesic
Observed
Narcotic analgesic not
active
Narcotic analgesic active
Overall % Correct

Predicted
Narcotic analgesic not
Narcotic analgesic
active
active
143
8
29

15

% Correct
94.7
34.1
81.0

Table 12 displays the regression coefficient results for the model predicting narcotic
analgesics. Being sick or injured (OR = 2.45, p = .037), having abnormal speech (OR = 3.97, p =
.039), and hopping during left OLS (OR = 4.43, p = .002), were associated with higher odds of
narcotic analgesic being an active drug category. Stopping 1 time during WAT2 (OR = 0.20, p =

105
.013) and no rebound dilation (OR = 5.81, p = .003), were associated with lower odds of narcotic
analgesic being an active drug category.
Table 12
Coefficients for Regression Predicting Narcotic Analgesic
Variable
Sick or injured
Abnormal speech
Left OLS hopping [ref: Not present]
Not attempted/completed
Present
WAT2 stops walking [ref: 0]
Not attempted/completed
1
2 or higher
Rebound dilation

95% CI OR
Lower Upper
1.05
5.67
1.07 14.73

B
0.89
1.39

SE
0.43
0.67

Wald
4.34
4.24

Sig.
.037
.039

OR
2.45
3.97

0.51
1.49

0.73
0.49

0.49
9.19

.484
.002

1.67
4.43

0.40
1.70

7.04
11.60

0.20
-1.60
-0.71
-1.76

0.68
0.65
0.59
0.59

0.87
6.17
1.48
8.76

.768
.013
.225
.003

1.23
0.20
0.49
0.17

0.32
0.06
0.16
0.54

4.70
0.71
1.55
0.55

Cannabis
Table 13 displays crosstabulations of each factor with the identification of cannabis as an
active drug category. Factors significantly associated with cannabis were not being sick or
injured, not having a physical disability, not being under the care of a doctor or dentist, abnormal
breath, lack of convergence, less difficulty on OLS, MRB eyelid tremors, MRB body or leg
tremors, not stepping off line in WAT, FTN eyelid and body tremors, left and right pupil size (all
lights), rebound dilation, reaction to light, abnormal oral cavity, within range body temperature,
and normal muscle tone.
Table 13
Crosstabulation of Face Sheet Measures with Active Cannabis
Variable

Value

Have you eaten today

Not available

Cannabis
Not Active
Active
n (%)
n (%)
4 (3.6)
1 (1.2)

Bivariate Test Result
χ2 (2) = 2.25, p = 0.324
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Have you drank today

Est. time vs. actual time

Duration of last sleep

Sick or injured
Diabetic or epileptic

Physical disabilities
Under care of doctor or
dentist

Taking medications or
drugs

Coordination
Breath
Face

Speech
Eyes appearance

No
Yes
Not available
No
Yes
Not available
10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
Not available
No
Yes
No
Yes
Not available

21 (19.1)
85 (77.3)
2 (1.8)
29 (26.4)
79 (71.8)
7 (6.4)
24 (21.8)

22 (25.9)
62 (72.9)
2 (2.4)
19 (22.4)
64 (75.3)
5 (5.9)
18 (21.2)

22 (20)

20 (23.5)

30 (27.3)

26 (30.6)

27 (24.5)

16 (18.8)

7 (6.4)
18 (16.4)
69 (62.7)
16 (14.5)
75 (68.2)
35 (31.8)
0 (0)
104 (94.5)
6 (5.5)
72 (65.5)
38 (34.5)
0 (0)

12 (14.1)
11 (12.9)
51 (60)
11 (12.9)
69 (81.2)
16 (18.8)
1 (1.2)
83 (97.6)
1 (1.2)
71 (83.5)
14 (16.5)
1 (1.2)

No
Yes
Not available

58 (52.7)
52 (47.3)
0 (0)

59 (69.4)
25 (29.4)
2 (2.4)

No
Yes
Fair/good
Other
Normal
Other
Not available
Normal
Other
Normal
Other
Not available
Normal
Bloodshot
Watery
Bloodshot and watery

24 (21.8)
86 (78.2)
21 (19.1)
89 (80.9)
72 (65.5)
38 (34.5)
0 (0)
47 (42.7)
63 (57.3)
23 (20.9)
87 (79.1)
2 (1.8)
21 (19.1)
26 (23.6)
20 (18.2)
41 (37.3)

27 (31.8)
56 (65.9)
22 (25.9)
63 (74.1)
38 (44.7)
47 (55.3)
1 (1.2)
35 (41.2)
49 (57.6)
23 (27.1)
62 (72.9)
0 (0)
7 (8.2)
20 (23.5)
12 (14.1)
46 (54.1)

χ2 (2) = 0.46, p = 0.795

χ2 (4) = 1.20, p = 0.878

χ2 (3) = 3.48, p = 0.323

χ2 (1) = 4.19, p = 0.041
χ2 (2) = 3.79, p = 0.151

χ2 (1) = 8.01, p = 0.005
χ2 (2) = 7.39, p = 0.025

χ2 (2) = 5.40, p = 0.067

χ2 (1) = 1.29, p = 0.257
χ2 (1) = 8.40, p = 0.004
χ2 (2) = 1.32, p = 0.516

χ2 (1) = 1.01, p = 0.316
χ2 (4) = 9.01, p = 0.061
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Blindness
Eye tracking stimulus
Ability to follow stimulus
Eyelids

Pulse

Left eye lack of smooth
pursuit

Left eye maximum
deviation

Eye angle of onset

Right eye lack of smooth
pursuit

Right eye maximum
deviation

Vertical gaze nystagmus
Lack of convergence

Completion of one leg
stand (left)

Completion of one leg
stand (right)

Left OLS sways while
balancing

χ2 (1) = 0.78, p = 0.378

None
Right eye
Equal
Unequal
No
Yes
Not available
Normal
Droopy
Below range
Within range
Above range
Unable to perform

109 (99.1)
1 (0.9)
109 (99.1)
1 (0.9)
8 (7.3)
102 (92.7)
2 (1.8)
34 (30.9)
74 (67.3)
16 (14.5)
51 (46.4)
43 (39.1)
1 (0.9)

85 (100)
0 (0)
85 (100)
0 (0)
3 (3.5)
82 (96.5)
0 (0)
20 (23.5)
65 (76.5)
6 (7.1)
43 (50.6)
36 (42.4)
1 (1.2)

No
Yes or present
Unable to perform

44 (40)
65 (59.1)
1 (0.9)

41 (48.2)
43 (50.6)
1 (1.2)

No
Yes or present
Unable to Perform
Not present
30 to 45 Degrees
Immediate on-set
Unable to perform

47 (42.7)
62 (56.4)
1 (0.9)
54 (49.1)
53 (48.2)
2 (1.8)
1 (0.9)

42 (49.4)
42 (49.4)
1 (1.2)
46 (54.1)
38 (44.7)
0 (0)
1 (1.2)

No
Yes or present
Unable to perform

44 (40)
65 (59.1)
1 (0.9)

41 (48.2)
43 (50.6)
1 (1.2)

No
Yes or present
No
Yes
Unable to perform
Absent
Present
Not attempted

47 (42.7)
62 (56.4)
93 (84.5)
17 (15.5)
1 (0.9)
40 (36.4)
69 (62.7)
8 (7.3)

42 (49.4)
42 (49.4)
70 (82.4)
15 (17.6)
0 (0)
8 (9.4)
77 (90.6)
1 (1.2)

Attempted but stopped
Attempted and completed
Not attempted

1 (0.9)
101 (91.8)
12 (10.9)

3 (3.5)
81 (95.3)
2 (2.4)

χ2 (2) = 5.28, p = 0.071

Attempted but stopped
Attempted and completed
Not attempted/completed

1 (0.9)
97 (88.2)
8 (7.3)

1 (1.2)
82 (96.5)
3 (3.5)

χ2 (2) = 4.10, p = 0.128

χ2 (1) = 0.78, p = 0.378
χ2 (1) = 1.26, p = 0.261
χ2 (2) = 3.06, p = 0.217

χ2 (2) = 2.69, p = 0.261

χ2 (2) = 1.41, p = 0.495

χ2 (2) = 0.94, p = 0.626

χ2 (3) = 1.94, p = 0.585

χ2 (2) = 1.41, p = 0.495

χ2 (2) = 0.94, p = 0.626

χ2 (1) = 0.17, p = 0.682
χ2 (2) = 19.89, p <.001

χ2 (2) = 5.53, p = 0.063
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Left OLS uses arms to
balance

Left OLS hopping

Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front to
back

MRB swaying left to right

MRB internal clock

Not present
Present
Not attempted/completed

9 (8.2)
93 (84.5)
8 (7.3)

14 (16.5)
68 (80)
3 (3.5)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

26 (23.6)
76 (69.1)
8 (7.3)
85 (77.3)
17 (15.5)
8 (7.3)
24 (21.8)
42 (38.2)
36 (32.7)
17 (15.5)
30 (27.3)
58 (52.7)
5 (4.5)
12 (10.9)

38 (44.7)
44 (51.8)
3 (3.5)
66 (77.6)
16 (18.8)
3 (3.5)
44 (51.8)
21 (24.7)
17 (20)
9 (10.6)
13 (15.3)
56 (65.9)
7 (8.2)
3 (3.5)

χ2 (2) = 13.51, p = 0.001

Not present
Present
Not attempted/completed

9 (8.2)
89 (80.9)
12 (10.9)

22 (25.9)
60 (70.6)
3 (3.5)

χ2 (2) = 5.89, p = 0.053

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

28 (25.5)
70 (63.6)
13 (11.8)
77 (70)
20 (18.2)
12 (10.9)

32 (37.6)
50 (58.8)
3 (3.5)
67 (78.8)
15 (17.6)
3 (3.5)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
0

24 (21.8)
31 (28.2)
43 (39.1)
22 (20)
25 (22.7)
59 (53.6)
4 (3.6)
25 (22.7)

41 (48.2)
23 (27.1)
18 (21.2)
8 (9.4)
13 (15.3)
53 (62.4)
11 (12.9)
16 (18.8)

< 2 inches
2 inches or more
0
< 2 inches
2 inches or more
Not attempted/completed
0-24

22 (20)
63 (57.3)
34 (30.9)
16 (14.5)
60 (54.5)
2 (1.8)
33 (30)

27 (31.8)
42 (49.4)
20 (23.5)
24 (28.2)
41 (48.2)
1 (1.2)
19 (22.4)

χ2 (2) = 10.02, p = 0.007

χ2 (2) = 1.51, p = 0.469

χ2 (3) = 19.08, p <.001

χ2 (3) = 6.45, p = .092

χ2 (2) = 4.53, p = 0.104

χ2 (3) = 18.37, p < 0.001

χ2 (3) = 10.89, p = 0.012

χ2 (2) = 3.54, p = 0.170

χ2 (2) = 5.69, p = 0.058

χ2 (3) = 3.85, p = 0.279
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MRB presence eyelid
tremors
MRB presence body or
leg tremors
WAT completion

WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT2 stops walking

WAT2 missed heel to toe

25-35
36 or higher
No

38 (34.5)
37 (33.6)
91 (82.7)

41 (48.2)
24 (28.2)
37 (43.5)

χ2 (1) = 32.67, p <.001

Yes
No

19 (17.3)
97 (88.2)

48 (56.5)
60 (70.6)

χ2 (1) = 9.46, p = 0.002

Yes
Not attempted
Attempted but stopped
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0

13 (11.8)
6 (5.5)
2 (1.8)
102 (92.7)
7 (6.4)
30 (27.3)
60 (54.5)
13 (11.8)
7 (6.4)
79 (71.8)
23 (20.9)
1 (0.9)
7 (6.4)
60 (54.5)
23 (20.9)
20 (18.2)
7 (6.4)
43 (39.1)
20 (18.2)
40 (36.4)
7 (6.4)
43 (39.1)
30 (27.3)
30 (27.3)
7 (6.4)
35 (31.8)
31 (28.2)
37 (33.6)
7 (6.4)
19 (17.3)
60 (54.5)
24 (21.8)
9 (8.2)
58 (52.7)
24 (21.8)
19 (17.3)
9 (7.3)
36 (32.7)

25 (29.4)
2 (2.4)
3 (3.5)
80 (94.1)
3 (3.5)
32 (37.6)
36 (42.4)
14 (16.5)
3 (3.5)
63 (74.1)
18 (21.2)
1 (1.2)
3 (3.5)
45 (52.9)
21 (24.7)
16 (18.8)
3 (3.5)
32 (37.6)
15 (17.6)
35 (41.2)
3 (3.5)
52 (61.2)
18 (21.2)
12 (14.1)
3 (3.5)
37 (43.5)
24 (28.2)
21 (24.7)
3 (3.5)
7 (8.2)
60 (70.6)
15 (17.6)
5 (5.9)
56 (65.9)
18 (21.2)
6 (7.1)
5 (5.9)
30 (35.3)

χ2 (2) = 1.68, p = 0.431

χ2 (3) = 4.57, p = 0.206

χ2 (3) = 0.82, p = 0.844

χ2 (3) = 1.09, p = 0.779

χ2 (3) = 1.07, p = 0.783

χ2 (3) = 10.13, p = 0.018

χ2 (3) = 3.82, p = 0.282

χ2 (3) = 6.11, p = 0.106

χ2 (3) = 5.68, p = 0.128

χ2 (3) = 0.48, p = 0.922

110

WAT2 steps off line

WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
2
3
4
5
6
Not available
No
Yes
Not available
No
Yes
Not available

21 (19.1)
44 (40)
9 (8.2)
51 (46.4)
22 (20)
28 (25.5)
9 (8.2)
37 (33.6)
30 (27.3)
34 (30.9)
9 (8.2)
7 (6.4)
70 (63.6)
24 (21.8)
7 (6.4)
36 (32.7)
18 (16.4)
16 (14.5)
9 (8.2)
5 (4.5)
6 (5.5)
13 (11.8)
6 (5.5)
47 (42.7)
57 (51.8)
6 (5.5)
90 (81.8)
14 (12.7)
6 (5.5)

17 (20)
33 (38.8)
5 (5.9)
54 (63.5)
19 (22.4)
7 (8.2)
5 (5.9)
38 (44.7)
20 (23.5)
22 (25.9)
5 (5.9)
6 (7.1)
58 (68.2)
16 (18.8)
2 (2.4)
42 (49.4)
5 (5.9)
9 (10.6)
11 (12.9)
6 (7.1)
3 (3.5)
7 (8.2)
2 (2.4)
46 (54.1)
37 (43.5)
2 (2.4)
78 (91.8)
5 (5.9)
2 (2.4)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

79 (71.8)
25 (22.7)
6 (5.5)
86 (78.2)
18 (16.4)
6 (5.5)
94 (85.5)
10 (9.1)
6 (5.5)
100 (90.9)
4 (3.6)
6 (5.5)

68 (80)
15 (17.6)
1 (1.2)
71 (83.5)
13 (15.3)
2 (2.4)
51 (60)
32 (37.6)
2 (2.4)
68 (80)
15 (17.6)
2 (2.4)

No
Yes

101 (91.8)
3 (2.7)

80 (94.1)
3 (3.5)

χ2 (3) = 11.02, p = 0.012

χ2 (3) = 2.57, p = 0.464

χ2 (3) = 0.75, p = 0.861

χ2 (7) = 12.64, p = 0.081

χ2 (2) = 3.11, p = 0.211

χ2 (2) = 3.98, p = 0.137

χ2 (2) = 2.15, p = 0.341

χ2 (2) = 2.65, p = 0.266

χ2 (2) = 23.46, p <.001

χ2 (2) = 11.45, p = 0.003

χ2 (2) = 1.25, p = 0.535
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Left pupil size RL

Left pupil size NTD

Left pupil size DL1

Left pupil size DL2

Right pupil size RL

Right pupil size NTD

Right pupil size DL1

Right pupil size DL2

Rebound dilation
Reaction to light

Nasal area

Oral cavity
Left arm injection sites

Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Within range
Above range
No
Yes
Not available
Normal
Slow
Little to none
Not available
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh

0 (0)
16 (14.5)
86 (78.2)
8 (7.3)
1 (0.9)
39 (35.5)
67 (60.9)
3 (2.7)
1 (0.9)
8 (7.3)
95 (86.4)
6 (5.5)
101 (91.8)
8 (7.3)
1 (0.9)
1 (0.9)
16 (14.5)
85 (77.3)
8 (7.3)
2 (1.8)
39 (35.5)
66 (60)
3 (2.7)
2 (1.8)
8 (7.3)
94 (85.5)
6 (5.5)
101 (91.8)
8 (7.3)
1 (0.9)
99 (90)
11 (10)
3 (2.7)
31 (28.2)
55 (50)
21 (19.1)
1 (0.9)
76 (69.1)
33 (30)
54 (49.1)
56 (50.9)
89 (80.9)
10 (9.1)
10 (9.1)

1 (1.2)
3 (3.5)
59 (69.4)
22 (25.9)
1 (1.2)
10 (11.8)
65 (76.5)
9 (10.6)
0 (0)
6 (7.1)
68 (80)
11 (12.9)
48 (56.5)
29 (34.1)
8 (9.4)
1 (1.2)
3 (3.5)
58 (68.2)
23 (27.1)
1 (1.2)
10 (11.8)
62 (72.9)
12 (14.1)
0 (0)
6 (7.1)
68 (80)
11 (12.9)
48 (56.5)
29 (34.1)
8 (9.4)
40 (47.1)
45 (52.9)
0 (0)
44 (51.8)
36 (42.4)
5 (5.9)
0 (0)
60 (70.6)
25 (29.4)
24 (28.2)
61 (71.8)
70 (82.4)
5 (5.9)
10 (11.8)

χ2 (3) = 18.56, p <.001

χ2 (3) = 17.27, p <.001

χ2 (3) = 4.09, p = 0.252

χ2 (2) = 33.56, p <.001

χ2 (3) = 18.35, p <.001

χ2 (3) = 20.15, p <.001

χ2 (3) = 4.80, p = 0.187

χ2 (2) = 33.56, p <.001

χ2 (1) = 43.19, p <.001
χ2 (3) = 16.13, p = 0.001

χ2 (2) = 0.79, p = 0.672

χ2 (1) = 8.69, p = 0.003
χ2 (3) = 1.76, p = 0.623
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Right arm injection sites

BP systolic

BP diastolic

Body temperature

Muscle tone

Both
None
Old
Fresh
Both
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

1 (0.9)
95 (86.4)
6 (5.5)
8 (7.3)
1 (0.9)
0 (0)
25 (22.7)
53 (48.2)
32 (29.1)
0 (0)
10 (9.1)
77 (70)
23 (20.9)
3 (2.7)
54 (49.1)
49 (44.5)
4 (3.6)
1 (0.9)
39 (35.5)
55 (50)
15 (13.6)

0 (0)
74 (87.1)
7 (8.2)
4 (4.7)
0 (0)
1 (1.2)
21 (24.7)
36 (42.4)
27 (31.8)
1 (1.2)
17 (20)
51 (60)
16 (18.8)
0 (0)
34 (40)
51 (60)
0 (0)
0 (0)
48 (56.5)
32 (37.6)
5 (5.9)

χ2 (3) = 1.85, p = 0.605

χ2 (3) = 1.84, p = 0.605

χ2 (3) = 6.25, p = 0.100

χ2 (3) = 8.52, p = 0.036

χ2 (3) = 9.97, p = 0.019

The forward stepwise regression procedure selected four predictors, and the model was
significant, χ2(4) = 75.62, p < .001, indicating that a set of face sheet measures significantly
predicted cannabis. Table 14 displays a classification table for the model’s predictive
effectiveness. The overall prediction accuracy was approximately 76%.
Table 14
Classification Table for Regression Predicting Cannabis
Observed
Cannabis not active
Cannabis active
Overall % Correct

Predicted
Cannabis not active
Cannabis active
88
22
24
61

% Correct
80.0
71.8
76.4

Table 15 displays the regression coefficient results for the model predicting cannabis.
Having abnormal breath (OR = 2.41, p = .015), MRB eyelid tremors (OR = 4.93, p < .001), and
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rebound dilation (OR = 7.41, p < .001) were associated with higher odds of cannabis being an
active drug category. Having a physical disability (OR = 0.37, p = .025) was associated with
lower odds of cannabis being an active drug category.
Table 15
Coefficients for Regression Predicting Cannabis
Variable
Physical disability
Abnormal breath
MRB eyelid tremors
Rebound dilation

B
-1.00
0.88
1.59
2.00

SE
0.45
0.36
0.38
0.41

Wald
5.00
5.96
17.76
23.51

Sig.
.025
.015
< .001
< .001

OR
0.37
2.41
4.93
7.41

95% CI OR
Lower Upper
0.15
0.88
1.19
4.89
2.35
10.34
3.30
16.64

Hypothesis 2 Conclusion
The analyses revealed significant associations between the face sheet measures and the
active drug categories of CNS depressant, CNS stimulant, narcotic analgesic, and cannabis. The
regression models for these drug categories were significant, indicating that there are sets of
measures from the face sheet that can significantly predict active drug categories. Therefore, the
null hypothesis was rejected.
Hypothesis 3
The focus of Hypothesis 3 was determining what set of measures (signs and symptoms)
from the face sheet significantly predict the drug categories inaccurately called by the DREs. To
answer the research question and test the hypothesis, crosstabulations and bivariate tests (i.e.,
chi-square tests) were performed on the cases with missed opinions (n = 23) to determine which
factors from the face sheets were significantly associated with the drug categories that were
called incorrectly. Regressions were not performed due to the small subsample of cases with
missed opinions. There were 13 cases that incorrectly called CNS depressant, three cases that
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incorrected called CNS stimulant, seven cases that incorrectly called narcotic analgesic, one case
that incorrectly called inhalant, and eight cases that incorrectly called cannabis. Because there
was only one incorrect call for inhalant, this drug category was not analyzed further.
Table 16 displays crosstabulations of each factor with the misidentification of CNS
depressant as an active drug category. Factors significantly associated with missed calls of CNS
depressant were lack of smooth pursuit and maximum deviation (both eyes), 30-to-45-degree
angle of onset (both eyes), no FTN eyelid tremors, left and right pupil size DL, and abnormal
nasal area.
Table 16
Crosstabulation of Face Sheet Measures with Missed CNS Depressant Call
Variable

Value

Have you eaten today

Not available
No
Yes
No
Yes
10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
No
Yes
No

Have you drank today
Est. time vs. actual time

Duration of last sleep

Sick or injured
Physical disabilities
Under care of doctor or
dentist

Yes

CNS Depressant
Not Missed
Missed
n (%)
n (%)
1 (10)
0 (0)
0 (0)
5 (38.5)
9 (90)
8 (61.5)
2 (20)
4 (30.8)
8 (80)
9 (69.2)
2 (20)
1 (7.7)
4 (40)

1 (7.7)

3 (30)

8 (61.5)

1 (10)

3 (23.1)

2 (20)
1 (10)
6 (60)
1 (10)
6 (60)
4 (40)
7 (70)
3 (30)
7 (70)

1 (7.7)
2 (15.4)
8 (61.5)
2 (15.4)
11 (84.6)
2 (15.4)
8 (61.5)
5 (38.5)
7 (53.8)

3 (30)

6 (46.2)

Bivariate Test Result
χ2 (2) = 5.77, p = 0.056

χ2 (1) = 0.34, p = 0.560
χ2 (3) = 5.10, p = 0.165

χ2 (3) = 0.91, p = 0.823

χ2 (1) = 1.78, p = 0.183
χ2 (1) = 0.18, p = 0.673
χ2 (1) = 0.62, p = 0.431
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Taking medications or
drugs
Coordination
Breath
Face
Speech
Eyes appearance

Eyelids
Pulse

Left eye lack of smooth
pursuit
Left eye maximum
deviation
Eye angle of onset
Right eye lack of smooth
pursuit
Right eye maximum
deviation
Vertical gaze nystagmus
Lack of convergence
Completion of one leg
stand (left)
Completion of one leg
stand (right)
Left OLS sways while
balancing

χ2 (1) = 0.31, p = 0.580

No

5 (50)

5 (38.5)

Yes
Fair/good
Other
Normal
Other
Normal
Other
Normal
Other
Normal
Bloodshot
Watery
Bloodshot and watery
Normal
Droopy
Below range
Within range
Above range
No

5 (50)
3 (30)
7 (70)
7 (70)
3 (30)
3 (30)
7 (70)
4 (40)
6 (60)
3 (30)
4 (40)
1 (10)
2 (20)
7 (70)
3 (30)
2 (20)
4 (40)
4 (40)
8 (80)

8 (61.5)
2 (15.4)
11 (84.6)
7 (53.8)
6 (46.2)
7 (53.8)
6 (46.2)
3 (23.1)
10 (76.9)
1 (7.7)
3 (23.1)
3 (23.1)
6 (46.2)
6 (46.2)
7 (53.8)
1 (7.7)
6 (46.2)
6 (46.2)
0 (0)

Yes or present
No

2 (20)
8 (80)

13 (100)
0 (0)

Yes or present
Not present
30 to 45 Degrees
No

2 (20)
8 (80)
2 (20)
8 (80)

13 (100)
0 (0)
13 (100)
0 (0)

Yes or present
No

2 (20)
8 (80)

13 (100)
0 (0)

Yes or present
No
Yes
Absent
Present
Not attempted

2 (20)
9 (90)
1 (10)
3 (30)
7 (70)
1 (10)

13 (100)
10 (76.9)
3 (23.1)
2 (15.4)
11 (84.6)
2 (15.4)

Attempted and completed
Not attempted

9 (90)
1 (10)

11 (84.6)
2 (15.4)

χ2 (1) = 0.14, p = 0.704

Attempted and completed
Not attempted/completed

9 (90)
1 (10)

11 (84.6)
2 (15.4)

χ2 (2) = 1.98, p = 0.372

Not present
Present

0 (0)
9 (90)

2 (15.4)
9 (69.2)

χ2 (1) = 0.71, p = 0.400
χ2 (1) = 0.62, p = 0.431
χ2 (1) = 1.31, p = 0.253
χ2 (1) = 0.77, p = 0.382
χ2 (3) = 3.82, p = 0.282

χ2 (1) = 1.31, p = 0.253
χ2 (2) = 0.76, p = 0.686

χ2 (1) = 15.95, p <.001

χ2 (1) = 15.95, p <.001

χ2 (1) = 15.95, p <.001
χ2 (1) = 15.95, p <.001

χ2 (1) = 15.95, p = <.001

χ2 (1) = 0.67, p = 0.412
χ2 (1) = 0.71, p = 0.400
χ2 (1) = 0.14, p = 0.704
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Left OLS uses arms to
balance

Left OLS hopping
Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front to
back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors

Not attempted/completed

1 (10)

2 (15.4)

Not present
Present
Not attempted/completed
Not present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

4 (40)
5 (50)
1 (10)
9 (90)
1 (10)
4 (40)
3 (30)
2 (20)
2 (20)
2 (20)
3 (30)
1 (10)
1 (10)

5 (38.5)
6 (46.2)
2 (15.4)
11 (84.6)
2 (15.4)
5 (38.5)
2 (15.4)
4 (30.8)
3 (23.1)
4 (30.8)
3 (23.1)
1 (7.7)
2 (15.4)

Not present
Present
Not attempted/completed

0 (0)
9 (90)
1 (10)

1 (7.7)
10 (76.9)
2 (15.4)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

1 (10)
8 (80)
1 (10)
8 (80)
1 (10)
1 (10)

5 (38.5)
6 (46.2)
2 (15.4)
10 (76.9)
1 (7.7)
2 (15.4)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
0

3 (30)
2 (20)
2 (20)
1 (10)
2 (20)
7 (70)
0 (0)
5 (50)

3 (23.1)
3 (23.1)
3 (23.1)
2 (15.4)
5 (38.5)
6 (46.2)
0 (0)
4 (30.8)

<2 inches
2 inches or more

1 (40)
4 (40)

4 (30.8)
5 (38.5)

0
< 2 inches
2 inches or more
0-24
25-35
36 or higher
No

4 (40)
1 (10)
5 (50)
3 (30)
2 (20)
5 (50)
6 (60)

4 (30.8)
4 (30.8)
5 (38.5)
4 (30.8)
4 (30.8)
5 (38.5)
9 (69.2)

χ2 (2) = 0.15, p = 0.929

χ2 (1) = 0.14, p = 0.704
χ2 (3) = 0.94, p = 0.817

χ2 (3) = 0.48, p = 0.922

χ2 (2) = 1.01, p = 0.603

χ2 (2) = 2.95, p = 0.229

χ2 (2) = 0.17, p = 0.920

X2(3) = 0.26, p = 0.968

χ2 (2) = 1.38, p = 0.515

χ2 (2) = 1.66, p = 0.436

χ2 (2) = 1.43, p = 0.488

χ2 (2) = 0.43, p = 0.808

χ2 (1) = 0.21, p = 0.645
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MRB presence body or
leg tremors
WAT completion
WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

Yes
No

4 (40)
10 (100)

4 (30.8)
12 (92.3)

Yes
Not attempted
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or more
Not attempted/completed
<9
9
>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher

0 (0)
0 (0)
10 (100)
0 (0)
3 (30)
4 (40)
3 (30)
0 (0)
10 (100)
0 (0)
0 (0)
9 (90)
1 (10)
0 (0)
0 (0)
5 (50)
4 (40)
1 (10)
0 (0)
5 (50)
4 (40)
1 (10)
0 (0)
4 (40)
1 (10)
5 (50)
0 (0)
1 (10)
6 (60)
3 (30)
0 (0)
8 (80)
2 (20)
0 (0)
0 (0)
5 (50)
1 (10)
4 (40)
0 (0)
8 (80)
2 (20)
0 (0)

1 (7.7)
1 (7.7)
12 (92.3)
1 (7.7)
4 (30.8)
7 (53.8)
1 (7.7)
1 (7.7)
10 (76.9)
2 (15.4)
1 (7.7)
5 (38.5)
3 (23.1)
4 (30.8)
1 (7.7)
6 (46.2)
3 (23.1)
3 (23.1)
1 (7.7)
5 (38.5)
6 (46.2)
1 (7.7)
1 (7.7)
7 (53.8)
4 (30.8)
1 (7.7)
1 (7.7)
1 (7.7)
5 (38.5)
6 (46.2)
1 (7.7)
6 (46.2)
3 (23.1)
3 (23.1)
1 (7.7)
4 (30.8)
5 (38.5)
3 (23.1)
1 (7.7)
7 (53.8)
4 (30.8)
1 (7.7)

χ2 (1) = 0.80, p = 0.370

χ2 (1) = 0.80, p = 0.370
χ2 (3) = 2.61, p = 0.455

χ2 (2) = 2.65, p = 0.265

χ2 (3) = 6.87, p = 0.076

χ2 (3) = 2.55, p = 0.466

χ2 (3) = 1.03, p = 0.795

χ2 (3) = 5.97, p = 0.112

χ2 (3) = 1.73, p = 0.631

χ2 (3) = 4.17, p = 0.244

χ2 (3) = 3.59, p = 0.309

χ2 (3) = 2.38, p = 0.497
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WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD
Left pupil size DL1
Left pupil size DL2

Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
4
6
Not available
No
Yes
Not available
No
Yes
Not available

0 (0)
5 (50)
1 (10)
4 (40)
0 (0)
1 (10)
7 (70)
2 (20)
0 (0)
3 (30)
3 (30)
1 (10)
3 (30)
0 (0)
3 (30)
7 (70)
0 (0)
9 (90)
1 (10)
0 (0)

1 (7.7)
6 (46.2)
5 (38.5)
1 (7.7)
1 (7.7)
2 (15.4)
7 (53.8)
3 (23.1)
3 (23.1)
5 (38.5)
3 (23.1)
0 (0)
2 (15.4)
2 (15.4)
4 (30.8)
7 (53.8)
2 (15.4)
8 (61.5)
3 (23.1)
2 (15.4)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

7 (70)
3 (30)
0 (0)
7 (70)
3 (30)
0 (0)
5 (50)
5 (50)
0 (0)
8 (80)
2 (20)
0 (0)

6 (46.2)
5 (38.5)
2 (15.4)
8 (61.5)
3 (23.1)
2 (15.4)
10 (76.9)
1 (7.7)
2 (15.4)
11 (84.6)
0 (0)
2 (15.4)

No
Yes
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range

9 (90)
1 (10)
1 (10)
7 (70)
2 (20)
2 (20)
8 (80)
8 (80)
2 (20)
6 (60)
4 (40)

10 (76.9)
1 (7.7)
1 (7.7)
12 (92.3)
0 (0)
5 (38.5)
8 (61.5)
13 (100)
0 (0)
13 (100)
0 (0)

χ2 (4) = 6.48, p = 0.166

χ2 (4) = 2.23, p = 0.694

χ2 (4) = 4.38, p = 0.357

χ2 (2) = 1.78, p = 0.410

χ2 (2) = 2.71, p = 0.257

χ2 (2) = 2.22, p = 0.329

χ2 (2) = 1.70, p = 0.426

χ2 (2) = 6.05, p = 0.049

χ2 (2) = 4.15, p = 0.125

χ2 (2) = 1.69, p = 0.430

χ2 (2) = 2.98, p = 0.226

χ2 (1) = 0.91, p = 0.340
χ2 (1) = 2.85, p = 0.092
χ2 (1) = 6.30, p = 0.012
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Right pupil size RL

Right pupil size NTD
Right pupil size DL1
Right pupil size DL2
Rebound dilation
Reaction to light

Nasal area
Oral cavity
Left arm injection sites

Right arm injection sites

BP systolic

BP diastolic
Body temperature

Muscle tone

Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
No
Yes
Not available
Normal
Slow
Little to none
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
None
Old
Fresh
Below range
Within range
Above range
Within range
Above range
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

1 (10)
7 (70)
2 (20)
2 (20)
8 (80)
8 (80)
2 (20)
6 (60)
4 (40)
6 (60)
4 (40)
0 (0)
5 (50)
4 (40)
1 (10)
10 (100)
0 (0)
5 (50)
5 (50)
8 (80)
0 (0)
2 (20)
8 (80)
0 (0)
2 (20)
3 (30)
5 (50)
2 (20)
8 (80)
2 (20)
6 (60)
4 (40)
0 (0)
1 (10)
6 (60)
3 (30)
0 (0)

1 (7.7)
12 (92.3)
0 (0)
5 (38.5)
8 (61.5)
13 (100)
0 (0)
13 (100)
0 (0)
12 (92.3)
1 (7.7)
1 (7.7)
5 (38.5)
5 (38.5)
2 (15.4)
8 (61.5)
5 (38.5)
5 (38.5)
8 (61.5)
11 (84.6)
1 (7.7)
1 (7.7)
12 (92.3)
1 (7.7)
0 (0)
3 (23.1)
5 (38.5)
5 (38.5)
9 (69.2)
4 (30.8)
8 (61.5)
2 (15.4)
3 (23.1)
0 (0)
5 (38.5)
7 (53.8)
1 (7.7)

χ2 (2) = 2.98, p = 0.226

χ2 (1) = 0.91, p = 0.340
χ2 (1) = 2.85, p = 0.092
χ2 (1) = 6.30, p = 0.012
χ2 (1) = 3.47, p = 0.063
χ2 (3) = 1.07, p = 0.784

χ2 (1) = 4.92, p = 0.027
χ2 (1) = 0.31, p = 0.580
χ2 (2) = 1.44, p = 0.487

χ2 (2) = 3.47, p = 0.177

χ2 (2) = 0.91, p = 0.634

χ2 (1) = 0.34, p = 0.560
χ2 (2) = 3.62, p = 0.163

χ2 (3) = 3.36, p = 0.340

Table 17 displays crosstabulations of each factor with the misidentification of CNS
stimulant as an active drug category. Factors significantly associated with missed calls of CNS
stimulant were droopy eyelids and slow to no reaction to light.
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Table 17
Crosstabulation of Face Sheet Measures with Missed CNS Stimulant Call
Variable

Value

Have you eaten today

Not available
No
Yes
No
Yes
10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
No
Yes
No

Have you drank today
Est. time vs. actual time

Duration of last sleep

Sick or injured
Physical disabilities
Under care of doctor or
dentist
Taking medications or
drugs
Coordination
Breath
Face
Speech
Eyes appearance

Eyelids

CNS Stimulant
Not Missed
Missed
n (%)
n (%)
1 (5)
0 (0)
4 (20)
1 (33.3)
15 (75)
2 (66.7)
5 (25)
1 (33.3)
15 (75)
2 (66.7)
3 (15)
0 (0)
4 (20)

1 (33.3)

11 (55)

0 (0)

2 (10)

2 (66.7)

3 (15)
3 (15)
11 (55)
3 (15)
15 (75)
5 (25)
13 (65)
7 (35)
12 (60)

0 (0)
0 (0)
3 (100)
0 (0)
2 (66.7)
1 (33.3)
2 (66.7)
1 (33.3)
2 (66.7)

Yes
No

8 (40)
8 (40)

1 (33.3)
2 (66.7)

Yes
Fair/good
Other
Normal
Other
Normal
Other
Normal
Other
Normal
Bloodshot
Watery
Bloodshot and watery
Normal

12 (60)
5 (25)
15 (75)
13 (65)
7 (35)
9 (45)
11 (55)
7 (35)
13 (65)
3 (15)
6 (30)
3 (15)
8 (40)
13 (65)

1 (33.3)
0 (0)
3 (100)
1 (33.3)
2 (66.7)
1 (33.3)
2 (66.7)
0 (0)
3 (100)
1 (33.3)
1 (33.3)
1 (33.3)
0 (0)
0 (0)

Bivariate Test Result
χ2 (2) = 0.39, p = 0.824

χ2 (1) = 0.09, p = 0.759
χ2 (3) = 7.13, p = 0.068

χ2 (3) = 2.22, p = 0.528

χ2 (1) = 0.09, p = 0.759
χ2 (1) = 0.00, p = 0.955
χ2 (1) = 0.05, p = 0.825

χ2 (1) = 0.76, p = 0.385

χ2 (1) = 0.96, p = 0.328
χ2 (1) = 1.10, p = 0.295
χ2 (1) = 0.14, p = 0.704
χ2 (1) = 1.51, p = 0.219
χ2 (3) = 2.22, p = 0.528

χ2 (1) = 4.49, p = 0.034
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Pulse

Left eye lack of smooth
pursuit
Left eye maximum
deviation
Eye angle of onset
Right eye lack of smooth
pursuit
Right eye maximum
deviation
Vertical gaze nystagmus
Lack of convergence
Completion of one leg
stand (left)
Completion of one leg
stand (right)
Left OLS sways while
balancing

Left OLS uses arms to
balance

Left OLS hopping
Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Droopy
Below range
Within range
Above range
No

7 (35)
3 (15)
10 (50)
7 (35)
7 (35)

3 (100)
0 (0)
0 (0)
3 (100)
1 (33.3)

Yes or present
No

13 (65)
7 (35)

2 (66.7)
1 (33.3)

Yes or present
Not present
30 to 45 Degrees
No

13 (65)
7 (35)
13 (65)
7 (35)

2 (66.7)
1 (33.3)
2 (66.7)
1 (33.3)

Yes or present
No

13 (65)
7 (35)

2 (66.7)
1 (33.3)

Yes or present
No
Yes
Absent
Present
Not attempted

13 (65)
16 (80)
4 (20)
4 (20)
16 (80)
3 (15)

2 (66.7)
3 (100)
0 (0)
1 (33.3)
2 (66.7)
0 (0)

Attempted and completed
Not attempted

17 (85)
3 (15)

3 (100)
0 (0)

χ2 (1) = 0.52, p = 0.472

Attempted and completed
Not attempted/completed

17 (85)
3 (15)

3 (100)
0 (0)

χ2 (2) = 0.96, p = 0.619

Not present
Present
Not attempted/completed

2 (10)
15 (75)
3 (15)

0 (0)
3 (100)
0 (0)

χ2 (2) = 0.74, p = 0.692

Not present
Present
Not attempted/completed
Not present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

8 (40)
9 (45)
3 (15)
17 (85)
3 (15)
8 (40)
5 (25)
4 (20)
5 (25)
4 (20)
9 (45)
2 (10)
3 (15)

1 (33.3)
2 (66.7)
0 (0)
3 (100)
0 (0)
1 (33.3)
0 (0)
2 (66.7)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
0 (0)

χ2 (2) = 4.49, p = 0.106

χ2 (1) = 0.00, p = 0.955

χ2 (1) = 0.00, p = 0.955

χ2 (1) = 0.00, p = 0.955
χ2 (1) = 0.00, p = 0.955

χ2 (1) = 0.00, p = 0.955

χ2 (1) = 0.73, p = 0.394
χ2 (1) = 0.27, p = 0.602
χ2 (1) = 0.52, p = 0.472

χ2 (1) = 0.52, p = 0.472
χ2 (3) = 3.41, p = 0.333

χ2 (3) = 3.31, p = 0.346

χ2 (2) = 0.73, p = 0.695
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Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front to
back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors
WAT completion
WAT balance

WAT starts early

WAT1 stops walking

Not present
Present
Not attempted/completed

1 (5)
16 (80)
3 (15)

0 (0)
3 (100)
0 (0)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

6 (30)
11 (55)
3 (15)
15 (75)
2 (10)
3 (15)

0 (0)
3 (100)
0 (0)
3 (100)
0 (0)
0 (0)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
0

6 (30)
4 (20)
7 (25)
3 (15)
5 (25)
12 (60)
0 (0)
8 (40)

0 (0)
1 (33.3)
2 (66.7)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
1 (33.3)

< 2 inches
2 inches or more
0
< 2 inches
2 inches or more
0-24
25-35
36 or higher
No

4 (20)
8 (40)
7 (35)
5 (25)
8 (40)
6 (30)
4 (20)
10 (50)
14 (70)

1 (33.3)
1 (33.3)
1 (33.3)
0 (0)
2 (66.7)
1 (33.3)
2 (66.7)
0 (0)
1 (33.3)

Yes
No

6 (30)
19 (95)

2 (66.7)
3 (100)

Yes
Not attempted
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
Not attempted/completed
0
1

1 (5)
1 (5)
19 (95)
1 (5)
6 (30)
9 (45)
4 (20)
1 (5)
17 (85)
2 (10)
1 (5)
13 (65)
3 (15)

0 (0)
0 (0)
3 (100)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
3 (100)
0 (0)
0 (0)
1 (33.3)
1 (33.3)

χ2 (2) = 2.22, p = 0.330

χ2 (2) = 0.96, p = 0.619

χ2 (3) = 2.23, p = 0.526

χ2 (2) = 2.27, p = 0.322

χ2 (2) = .273, p = 0.873

χ2 (2) = 1.18, p = 0.555

χ2 (2) = 3.68, p = 0.158

χ2 (1) = 1.55, p = 0.214

χ2 (1) = 0.16, p = 0.692

χ2 (1) = 0.16, p = 0.692
χ2 (3) = 1.02, p = 0.797

χ2 (2) = 0.52, p = 0.772

χ2 (3) = 1.59, p = 0.662
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WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or more
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
4
6
Not available
No

3 (15)
1 (5)
9 (45)
3 (15)
7 (35)
1 (5)
9 (45)
8 (40)
2 (10)
1 (5)
11 (55)
4 (20)
4 (20)
1 (5)
2 (10)
9 (45)
8 (40)
1 (5)
13 (65)
3 (15)
3 (15)
1 (5)
9 (45)
4 (20)
6 (30)
1 (5)
14 (70)
4 (20)
1 (5)
1 (5)
11 (55)
5 (25)
3 (15)
1 (5)
3 (15)
12 (60)
4 (20)
3 (15)
5 (25)
6 (30)
1 (5)
5 (25)
2 (10)
7 (35)

1 (33.3)
0 (0)
1 (33.3)
1 (33.3)
1 (33.3)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
3 (100)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

χ2 (3) = .738, p = 0.864

χ2 (3) = 0.96, p = 0.811

χ2 (3) = 4.19, p = 0.242

χ2 (3) = .77, p = 0.865

χ2 (3) = 4.23, p = 0.237

χ2 (3) = 3.69, p = 0.297

χ2 (3) = 3.02, p = 0.389

χ2 (3) = 5.07, p = 0.167

χ2 (3) = 0.83, p = 0.842

χ2 (4) = 6.47, p = 0.167

χ2 (2) = 2.22, p = 0.330
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FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD
Left pupil size DL1
Left pupil size DL2
Right pupil size RL

Right pupil size NTD
Right pupil size DL1
Right pupil size DL2
Rebound dilation
Reaction to light

Yes
Not available
No
Yes
Not available

11 (55)
2 (10)
15 (75)
3 (15)
2 (10)

3 (100)
0 (0)
2 (66.7)
1 (33.3)
0 (0)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

10 (50)
8 (40)
2 (10)
14 (70)
4 (20)
2 (10)
13 (65)
5 (25)
2 (10)
16 (80)
2 (10)
2 (10)

3 (100)
0 (0)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
2 (66.7)
1 (33.3)
0 (0)
3 (100)
0 (0)
0 (0)

No
Yes
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
No
Yes
Not available
Normal
Slow
Little to none

17 (85)
1 (5)
2 (10)
16 (80)
2 (10)
6 (30)
14 (70)
18 (90)
2 (10)
16 (80)
4 (20)
2 (10)
16 (80)
2 (10)
6 (30)
14 (70)
18 (90)
2 (10)
16 (80)
4 (20)
15 (75)
5 (25)
0 (0)
10 (50)
8 (40)
2 (10)

2 (66.7)
1 (33.3)
0 (0)
3 (100)
0 (0)
1 (33.3)
2 (66.7)
3 (100)
0 (0)
3 (100)
0 (0)
0 (0)
3 (100)
0 (0)
1 (33.3)
2 (66.7)
3 (100)
0 (0)
3 (100)
0 (0)
3 (100)
0 (0)
1 (33.3)
0 (0)
1 (33.3)
1 (33.3)

χ2 (2) = 0.83, p = 0.661

χ2 (2) = 2.65, p = 0.265

χ2 (2) = 3.02, p = 0.221

χ2 (2) = 0.37, p = 0.831

χ2 (2) = 0.73, p = 0.695

χ2 (2) = 2.81, p = 0.245

χ2 (2) = 0.73, p = 0.695

χ2 (1) = 0.01, p = 0.907
χ2 (1) = 0.33, p = 0.567
χ2 (1) = 0.73, p = 0.394
χ2 (2) = 0.73, p = 0.695

χ2 (1) = 0.01, p = 0.907
χ2 (1) = 0.33, p = 0.567
χ2 (1) = 0.73, p = 0.394
χ2 (1) = 0.96, p = 0.328
χ2 (3) = 9.29, p = 0.026
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Nasal area
Oral cavity
Left arm injection sites

Right arm injection sites

BP systolic

BP diastolic
Body temperature

Muscle tone

Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
None
Old
Fresh
Below range
Within range
Above range
Within range
Above range
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

16 (80)
4 (20)
10 (50)
10 (50)
17 (85)
1 (5)
2 (10)
18 (90)
1 (5)
1 (5)
4 (20)
10 (50)
6 (30)
14 (70)
6 (30)
12 (60)
6 (30)
2 (10)
1 (5)
9 (45)
9 (45)
1 (5)

2 (66.7)
1 (33.3)
0 (0)
3 (100)
2 (66.7)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
1 (33.3)
2 (66.7)
0 (0)
1 (33.3)
3 (100)
0 (0)
2 (66.7)
0 (0)
1 (33.3)
0 (0)
2 (66.7)
1 (33.3)
0 (0)

χ2 (1) = 0.27, p = 0.602
χ2 (1) = 2.65, p = 0.103
χ2 (2) = 1.35, p = 0.510

χ2 (2) = 2.72, p = 0.256

χ2 (2) = 3.69, p = 0.158

χ2 (1) = 1.22, p = 0.270
χ2 (2) = 2.01, p = 0.366

χ2 (3) = 0.64, p = 0.888

Table 18 displays crosstabulations of each factor with the misidentification of narcotic
analgesic as an active drug category. Factors significantly associated with missed calls of
narcotic analgesic were slow pulse rates and right arm injection sites.
Table 18
Crosstabulation of Face Sheet Measures with Missed Narcotic Analgesic Call
Variable

Value

Have you eaten today

Not available
No
Yes
No
Yes
10 minutes or less
difference
11 to 30 minutes
difference

Have you drank today
Est. time vs. actual time

Narcotic Analgesic
Not Missed
Missed
n (%)
n (%)
0 (0)
1 (14.3)
4 (25)
1 (14.3)
12 (75)
5 (71.4)
3 (18.8)
3 (42.9)
13 (81.3)
4 (57.1)
2 (12.5)
1 (14.3)
3 (18.8)

2 (28.6)

Bivariate Test Result
χ2 (2) = 2.55, p = 0.279

χ2 (1) = 1.47, p = 0.226
χ2 (3) = 2.16, p = 0.540
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Duration of last sleep

Sick or injured
Physical disabilities
Under care of doctor or
dentist
Taking medications or
drugs
Coordination
Breath
Face
Speech
Eyes appearance

Eyelids
Pulse

Left eye lack of smooth
pursuit
Left eye maximum
deviation
Eye angle of onset
Right eye lack of smooth
pursuit
Right eye maximum
deviation

31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
No
Yes
No

7 (43.8)

4 (57.1)

4 (25)

0 (0)

3 (18.8)
1 (6.3)
10 (62.5)
2 (12.5)
14 (87.5)
2 (12.5)
11 (68.8)
5 (31.3)
9 (56.3)

0 (0)
2 (28.6)
4 (57.1)
1 (14.3)
3 (42.9)
4 (57.1)
4 (57.1)
3 (42.9)
5 (71.4)

Yes
No

7 (43.8)
7 (43.8)

2 (28.6)
3 (42.9)

Yes
Fair/good
Other
Normal
Other
Normal
Other
Normal
Other
Normal
Bloodshot
Watery
Bloodshot and watery
Normal
Droopy
Below range
Within range
Above range
No

9 (56.3)
5 (31.3)
11 (68.8)
9 (56.3)
7 (43.8)
9 (56.3)
7 (43.8)
6 (37.5)
10 (62.5)
2 (12.5)
6 (37.5)
2 (12.5)
6 (37.5)
9 (56.3)
7 (43.8)
0 (0)
8 (50)
8 (50)
4 (25)

4 (57.1)
0 (0)
7 (100)
5 (71.4)
2 (28.6)
1 (14.3)
6 (85.7)
1 (14.3)
6 (85.7)
2 (28.6)
1 (14.3)
2 (28.6)
2 (28.6)
4 (57.1)
3 (42.9)
3 (42.9)
2 (28.6)
2 (28.6)
4 (57.1)

Yes or present
No

12 (75)
4 (25)

3 (42.9)
4 (57.1)

Yes or present
Not present
30 to 45 Degrees
No

12 (75)
4 (25)
12 (75)
4 (25)

3 (42.9)
4 (57.1)
3 (42.9)
4 (57.1)

Yes or present
No

12 (75)
4 (25)

3 (42.9)
4 (57.1)

χ2 (3) = 3.21, p = 0.361

χ2 (1) = 5.03, p = 0.025
χ2 (1) = 0.29, p = 0.591
χ2 (1) = 0.47, p = 0.493

χ2 (1) = 0.00, p = 0.968

χ2 (1) = 2.8, p = 0.095
χ2 (1) = 0.47, p = 0.493
χ2 (1) = 3.49, p = 0.062
χ2 (1) = 1.24, p = 0.266
χ2 (3) = 2.42, p = 0.490

χ2 (1) = 0.00, p = 0.968
χ2 (2) = 7.89, p = 0.019

χ2 (1) = 2.22, p = 0.136

χ2 (1) = 2.22, p = 0.136

χ2 (1) = 2.22, p = 0.136
χ2 (1) = 2.22, p = 0.136

χ2 (1) = 2.22, p = 0.136
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Vertical gaze nystagmus
Lack of convergence
Completion of one leg
stand (left)
Completion of one leg
stand (right)
Left OLS sways while
balancing

Left OLS uses arms to
balance

Left OLS hopping
Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

Yes or present
No
Yes
Absent
Present
Not attempted

12 (75)
12 (75)
4 (25)
3 (18.8)
13 (81.3)
1 (6.3)

3 (42.9)
7 (100)
0 (0)
2 (28.6)
5 (71.4)
2 (28.6)

Attempted and completed
Not attempted

15 (93.8)
1 (6.3)

5 (71.4)
2 (28.6)

χ2 (1) = 2.14, p = 0.144

Attempted and completed
Not attempted/completed

15 (93.8)
1 (6.3)

5 (71.4)
2 (28.6)

χ2 (2) = 2.8, p = 0.247

Not present
Present
Not attempted/completed

1 (6.3)
14 (87.5)
1 (6.3)

1 (14.3)
4 (57.1)
2 (28.6)

χ2 (2) = 2.68, p = 0.262

Not present
Present
Not attempted/completed
Not present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

6 (37.5)
9 (56.3)
1 (6.3)
15 (93.8)
1 (6.3)
6 (37.5)
3 (18.8)
6 (37.5)
3 (18.8)
5 (31.3)
7 (43.8)
1 (6.3)
1 (6.3)

3 (42.9)
2 (28.6)
2 (28.6)
5 (71.4)
2 (28.6)
3 (42.9)
2 (28.6)
0 (0)
2 (28.6)
1 (14.3)
3 (42.9)
1 (14.3)
2 (28.6)

Not present
Present
Not attempted/completed

1 (6.3)
14 (87.5)
1 (6.3)

0 (0)
5 (71.4)
2 (28.6)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

5 (31.3)
10 (62.5)
1 (6.3)
13 (81.3)
2 (12.5)
1 (6.3)

1 (14.3)
4 (57.1)
2 (28.6)
5 (71.4)
0 (0)
2 (28.6)

0
1
2 or more
Not attempted/completed
0-14

4 (25)
2 (12.5)
9 (56.3)
1 (6.3)
6 (37.5)

2 (28.6)
3 (42.9)
0 (0)
2 (28.6)
1 (14.3)

χ2 (1) = 2.12, p = 0.146
χ2 (1) = 0.28, p = 0.599
χ2 (1) = 2.14, p = 0.144

χ2 (1) = 2.14, p = 0.144
χ2 (3) = 4.74, p = 0.192

χ2 (3) = 1.12, p = 0.773

χ2 (2) = 2.45, p = 0.294

χ2 (2) = 2.42, p = 0.298

χ2 (2) = 2.80, p = 0.247

χ2 (4) = 7.89, p = 0.096

χ2 (2) = 2.73, p = 0.256
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MRB swaying front to
back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors
WAT completion
WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

15-29
30 or more
0

9 (56.3)
0 (0)
5 (31.3)

4 (57.1)
0 (0)
4 (57.1)

< 2 inches
2 inches or more
0
< 2 inches
2 inches or more
0-24
25-35
36 or higher
No

4 (25)
7 (43.8)
5 (31.3)
3 (18.8)
8 (50)
6 (37.5)
3 (18.8)
7 (43.8)
9 (56.3)

1 (14.3)
2 (28.6)
3 (42.9)
2 (28.6)
2 (28.6)
1 (14.3)
3 (42.9)
3 (42.9)
6 (85.7)

Yes
No

7 (43.8)
15 (93.8)

1 (14.3)
7 (100)

Yes
Not attempted
Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9

1 (6.3)
0 (0)
16 (100)
0 (0)
4 (25)
9 (56.3)
3 (18.8)
0 (0)
14 (87.5)
2 (12.5)
0 (0)
9 (56.3)
4 (25)
3 (18.8)
0 (0)
9 (56.3)
2 (12.5)
5 (31.3)
0 (0)
9 (56.3)
6 (37.5)
1 (6.3)
0 (0)
9 (56.3)
4 (25)
3 (18.8)
0 (0)
2 (12.5)
8 (50)

0 (0)
1 (14.3)
6 (85.7)
1 (14.3)
3 (42.9)
2 (28.6)
1 (14.3)
1 (14.3)
6 (85.7)
0 (0)
1 (14.3)
5 (71.4)
0 (0)
1 (14.3)
1 (14.3)
1 (14.3)
2 (28.6)
3 (42.9)
1 (14.3)
1 (14.3)
4 (57.1)
1 (14.3)
1 (14.3)
2 (28.6)
1 (14.3)
3 (42.9)
1 (14.3)
0 (0)
3 (42.9)

χ2 (2) = 1.38, p = 0.502

χ2 (2) = 0.92, p = 0.632

χ2 (2) = 1.95, p = 0.378

χ2 (1) = 1.86, p = 0.172

χ2 (1) = 0.46, p = 0.499

χ2 (1) = 2.39, p = 0.122
χ2 (3) = 3.63, p = 0.304

χ2 (2) = 3.16, p = 0.206

χ2 (3) = 4.28, p = 0.233

χ2 (3) = 5.17, p = 0.160

χ2 (3) = 5.05, p = 0.168

χ2 (3) = 4.41, p = 0.221

χ2 (3) = 3.25, p = 0.355
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WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

WAT2 raised arms

WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted
0
1
4
6
Not available
No
Yes
Not available
No
Yes
Not available

6 (37.5)
0 (0)
11 (68.8)
3 (18.8)
2 (12.5)
0 (0)
8 (50)
3 (18.8)
5 (31.3)
0 (0)
12 (75)
3 (18.8)
1 (6.3)
0 (0)
10 (62.5)
4 (25)
2 (12.5)
0 (0)
3 (18.8)
9 (56.3)
4 (25)
2 (12.5)
5 (31.3)
5 (31.3)
1 (6.3)
3 (18.8)
1 (6.3)
6 (37.5)
9 (56.3)
1 (6.3)
11 (68.8)
4 (25)
1 (6.3)

3 (42.9)
1 (14.3)
3 (42.9)
2 (28.6)
1 (14.3)
1 (14.3)
1 (14.3)
3 (42.9)
2 (28.6)
1 (14.3)
3 (42.9)
3 (42.9)
0 (0)
1 (14.3)
1 (14.3)
2 (28.6)
3 (42.9)
1 (14.3)
0 (0)
5 (71.4)
1 (14.3)
1 (14.3)
3 (42.9)
1 (14.3)
0 (0)
2 (28.6)
1 (14.3)
1 (14.3)
5 (71.4)
1 (14.3)
6 (85.7)
0 (0)
1 (14.3)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes

10 (62.5)
5 (31.3)
1 (6.3)
10 (62.5)
5 (31.3)
1 (6.3)
9 (56.3)
6 (37.5)
1 (6.3)
13 (81.3)
2 (12.5)

3 (42.9)
3 (42.9)
1 (14.3)
5 (71.4)
1 (14.3)
1 (14.3)
6 (85.7)
0 (0)
1 (14.3)
6 (85.7)
0 (0)

χ2 (3) = 3.05, p = 0.384

χ2 (3) = 4.97, p = 0.174

χ2 (3) = 4.58, p = 0.205

χ2 (3) = 6.74, p = 0.081

χ2 (3) = 4.04, p = 0.257

χ2 (4) = 1.39, p = 0.846

χ2 (2) = 1.41, p = 0.495

χ2 (2) = 2.30, p = 0.316

χ2 (2) = 0.88, p = 0.643

χ2 (2) = 0.96, p = 0.619

χ2 (2) = 3.64, p = 0.162

χ2 (2) = 1.25, p = 0.536
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FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD
Left pupil size DL1
Left pupil size DL2
Right pupil size RL

Right pupil size NTD
Right pupil size DL1
Right pupil size DL2
Rebound dilation
Reaction to light

Nasal area
Oral cavity
Left arm injection sites

Right arm injection sites

BP systolic

BP diastolic
Body temperature

Not available

1 (6.3)

1 (14.3)

No
Yes
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
No
Yes
Not available
Normal
Slow
Little to none
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
None
Old
Fresh
Below range
Within range
Above range
Within range
Above range
Below range
Within range

15 (93.8)
0 (0)
0 (0)
15 (93.8)
1 (6.3)
3 (18.8)
13 (81.3)
15 (93.8)
1 (6.3)
13 (81.3)
3 (18.8)
0 (0)
15 (93.8)
1 (6.3)
3 (18.8)
13 (81.3)
15 (93.8)
1 (6.3)
13 (81.3)
3 (18.8)
12 (75)
4 (25)
1 (6.3)
8 (50)
6 (37.5)
1 (6.3)
12 (75)
4 (25)
6 (37.5)
10 (62.5)
15 (93.8)
0 (0)
1 (6.3)
16 (100)
0 (0)
0 (0)
3 (18.8)
8 (50)
5 (31.3)
11 (68.8)
5 (31.3)
9 (56.3)
5 (31.3)

4 (57.1)
2 (28.6)
2 (28.6)
4 (57.1)
1 (14.3)
4 (57.1)
3 (42.9)
6 (85.7)
1 (14.3)
6 (85.7)
1 (14.3)
2 (28.6)
4 (57.1)
1 (14.3)
4 (57.1)
3 (42.9)
6 (85.7)
1 (14.3)
6 (85.7)
1 (14.3)
6 (85.7)
1 (14.3)
0 (0)
2 (28.6)
3 (42.9)
2 (28.6)
6 (85.7)
1 (14.3)
4 (57.1)
3 (42.9)
4 (57.1)
1 (14.3)
2 (28.6)
4 (57.1)
1 (14.3)
2 (28.6)
3 (42.9)
2 (28.6)
2 (28.6)
6 (85.7)
1 (14.3)
5 (71.4)
1 (14.3)

χ2 (2) = 5.72, p = 0.057

χ2 (2) = 5.72, p = 0.057

χ2 (1) = 3.39, p = 0.066
χ2 (1) = 0.40, p = 0.529
χ2 (1) = 0.07, p = 0.795
χ2 (2) = 5.72, p = 0.057

χ2 (1) = 3.39, p = 0.066
χ2 (1) = 0.40, p = 0.529
χ2 (1) = 0.07, p = 0.795
χ2 (1) = 0.33, p = 0.567
χ2 (3) = 2.85, p = 0.416

χ2 (1) = 0.33, p = 0.567
χ2 (1) = 0.77, p = 0.382
χ2 (2) = 4.94, p = 0.085

χ2 (2) = 7.89, p = 0.019

χ2 (2) = 1.61, p = 0.447

χ2 (1) = 0.73, p = 0.394
χ2 (2) = 0.73, p = 0.693
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Muscle tone

Above range
Not available
Normal
Flaccid
Rigid

2 (12.5)
1 (6.3)
8 (50)
7 (43.8)
0 (0)

1 (14.3)
0 (0)
3 (42.9)
3 (42.9)
1 (14.3)

χ2 (3) = 2.78, p = 0.427

Table 19 displays crosstabulations of each factor with the misidentification of cannabis as
an active drug category. Factors significantly associated with missed calls of cannabis were
MRB eyelid tremors and rebound dilation.
Table 19
Crosstabulation of Face Sheet Measures with Missed Cannabis Call
Variable

Value

Have you eaten today

Not available
No
Yes
No
Yes
10 minutes or less
difference
11 to 30 minutes
difference
31 to 90 minutes
difference
More than 90 minutes
difference
Not available
Less than 4 hours
4 to 8 hours
More than 8 hours
No
Yes
No
Yes
No

Have you drank today
Est. time vs. actual time

Duration of last sleep

Sick or injured
Physical disabilities
Under care of doctor or
dentist
Taking medications or
drugs
Coordination

Cannabis
Not Missed
Missed
n (%)
n (%)
1 (6.7)
0 (0)
5 (33.3)
0 (0)
9 (60)
8 (100)
5 (33.3)
1 (12.5)
10 (66.7)
7 (87.5)
1 (6.7)
2 (25)

Bivariate Test Result
χ2 (2) = 4.33, p = 0.115

χ2 (1) = 1.17, p = 0.278
χ2 (3) = 4.25, p = 0.236

2 (13.3)

3 (37.5)

9 (60)

2 (25)

3 (20)

1 (12.5)

2 (13.3)
3 (20)
7 (46.7)
3 (20)
12 (80)
3 (20)
9 (60)
6 (40)
9 (60)

1 (12.5)
0 (0)
7 (87.5)
0 (0)
5 (62.5)
3 (37.5)
6 (75)
2 (25)
5 (62.5)

Yes
No

6 (40)
5 (33.3)

3 (37.5)
5 (62.5)

χ2 (1) = 1.81, p = 0.179

Yes
Fair/good

10 (66.7)
3 (20)

3 (37.5)
2 (25)

χ2 (1) = 0.08, p = 0.782

χ2 (3) = 4.63, p = 0.201

χ2 (1) = 0.83, p = 0.363
χ2 (1) = 0.52, p = 0.472
χ2 (1) = 0.01, p = 0.907
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Breath
Face
Speech
Eyes appearance

Eyelids
Pulse

Left eye lack of smooth
pursuit
Left eye maximum
deviation
Eye angle of onset
Right eye lack of smooth
pursuit
Right eye maximum
deviation
Vertical gaze nystagmus
Lack of convergence
Completion of one leg
stand (left)
Completion of one leg
stand (right)
Left OLS sways while
balancing

Left OLS uses arms to
balance

Other
Normal
Other
Normal
Other
Normal
Other
Normal
Bloodshot
Watery
Bloodshot and watery
Normal
Droopy
Below range
Within range
Above range
No

12 (80)
9 (60)
6 (40)
5 (33.3)
10 (66.7)
3 (20)
12 (80)
3 (20)
3 (20)
3 (20)
6 (40)
7 (46.7)
8 (53.3)
2 (13.3)
6 (40)
7 (46.7)
4 (26.7)

6 (75)
5 (62.5)
3 (37.5)
5 (62.5)
3 (37.5)
4 (50)
4 (50)
1 (12.5)
4 (50)
1 (12.5)
2 (25)
6 (75)
2 (25)
1 (12.5)
4 (50)
3 (37.5)
4 (50)

Yes or present
No

11 (73.3)
4 (26.7)

4 (50)
4 (50)

Yes or present
Not present
30 to 45 Degrees
No

11 (73.3)
4 (26.7)
11 (73.3)
4 (26.7)

4 (50)
4 (50)
4 (50)
4 (50)

Yes or present
No

11 (73.3)
4 (26.7)

4 (50)
4 (50)

Yes or present
No
Yes
Absent
Present
Not attempted

11 (73.3)
11 (73.3)
4 (26.7)
2 (13.3)
13 (86.7)
3 (20)

4 (50)
8 (100)
0 (0)
3 (37.5)
5 (62.5)
0 (0)

Attempted and completed
Not attempted

12 (80)
3 (20)

8 (100)
0 (0)

χ2 (1) = 1.84, p = 0.175

Attempted and completed
Not attempted/completed

12 (80)
3 (20)

8 (100)
0 (0)

χ2 (2) = 5.37, p = 0.068

Not present
Present
Not attempted/completed

0 (0)
12 (80)
3 (20)

2 (25)
6 (75)
0 (0)

χ2 (2) = 2.16, p = 0.339

Not present
Present

6 (40)
6 (40)

3 (37.5)
5 (62.5)

χ2 (1) = 0.01, p = 0.907
χ2 (1) = 1.81, p = 0.179
χ2 (1) = 2.22, p = 0.136
χ2 (3) = 2.22, p = 0.528

χ2 (1) = 1.70, p = 0.192
χ2 (2) = 0.22, p = 0.894

χ2 (1) = 1.25, p = 0.263

χ2 (1) = 1.25, p = 0.263

χ2 (1) = 1.25, p = 0.263
χ2 (1) = 1.25, p = 0.263

χ2 (1) = 1.25, p = 0.263

χ2 (1) = 2.58, p = 0.108
χ2 (1) = 1.79, p = 0.181
χ2 (1) = 1.84, p = 0.175
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Left OLS hopping
Left OLS puts foot down

Left OLS time

Right OLS sways while
balancing

Right OLS uses arms to
balance

Right OLS hopping

Right OLS puts foot
down

Right OLS time

MRB swaying front to
back

MRB swaying left to right

MRB internal clock

MRB presence eyelid
tremors
MRB presence body or
leg tremors
WAT completion

χ2 (1) = 1.84, p = 0.175

Not attempted/completed
Not present
Not attempted/completed
0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
Not attempted/completed

3 (20)
12 (80)
3 (20)
5 (33.3)
3 (20)
4 (26.7)
4 (26.7)
5 (33.3)
5 (33.3)
1 (6.7)
3 (20)

0 (0)
8 (100)
0 (0)
4 (50)
2 (25)
2 (25)
1 (12.5)
1 (12.5)
5 (62.5)
1 (12.5)
0 (0)

Not present
Present
Not attempted/completed

0 (0)
12 (80)
3 (20)

1 (12.5)
7 (87.5)
0 (0)

Not present
Present
Not attempted/completed
Not present
Present
Not attempted/completed

5 (33.3)
7 (46.7)
3 (20)
11 (73.3)
1 (6.7)
3 (20)

1 (12.5)
7 (87.5)
0 (0)
7 (87.5)
1 (12.5)
0 (0)

0
1
2 or more
Not attempted/completed
0-14
15-29
30 or more
0

4 (26.7)
3 (20)
5 (33.3)
3 (20)
4 (26.7)
8 (53.3)
5 (33.3)
5 (33.3)

2 (25)
2 (25)
4 (50)
0 (0)
3 (37.5)
5 (62.5)
1 (12.5)
4 (50)

< 2 inches
2 inches or more
0
< 2 inches
2 inches or more
0-24
25-35
36 or higher
No

4 (26.7)
6 (40)
4 (26.7)
4 (26.7)
7 (46.7)
4 (26.7)
5 (33.3)
6 (40)
12 (80)

1 (12.5)
3 (37.5)
4 (50)
1 (12.5)
3 (37.5)
3 (37.5)
1 (12.5)
4 (50)
3 (37.5)

Yes
No

3 (20)
15 (100)

5 (62.5)
7 (87.5)

χ2 (1) = 1.96, p = 0.161

0 (0)
1 (6.7)

1 (12.5)
0 (0)

χ2 (1) = 0.56, p = 0.455

Yes
Not attempted

χ2 (3) = 2.04, p = 0.565

χ2 (3) = 2.58, p = 0.462

χ2 (2) = 3.51, p = 0.173

χ2 (2) = 3.90, p = 0.142

χ2 (2) = 1.94, p = 0.379

χ2 (3) = 2.04, p = 0.565

χ2 (2) = 1.88, p = 0.391

χ2 (2) = 0.86, p = 0.650

χ2 (2) = 1.40, p = 0.497

χ2 (2) = 1.19, p = 0.552

χ2 (1) = 4.15, p = 0.042
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WAT balance

WAT starts early

WAT1 stops walking

WAT1 missed heel to toe

WAT1 steps off line

WAT1 raised arms

WAT1 steps

WAT2 stops walking

WAT2 missed heel to toe

WAT2 steps off line

WAT2 raised arms

Attempted and completed
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
<9
9
>9
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher
Not attempted/completed
0
1
2 or higher

14 (93.3)
1 (6.7)
6 (40)
6 (40)
2 (13.3)
1 (6.7)
13 (86.7)
1 (6.7)
1 (6.7)
8 (53.3)
3 (20)
3 (20)
1 (6.7)
7 (46.7)
3 (20)
4 (26.7)
1 (6.7)
5 (33.3)
7 (46.7)
2 (13.3)
1 (6.7)
7 (46.7)
3 (20)
4 (26.7)
1 (6.7)
2 (13.3)
6 (40)
6 (40)
1 (6.7)
9 (60)
3 (20)
2 (13.3)
1 (6.7)
5 (33.3)
5 (33.3)
4 (26.7)
1 (6.7)
9 (60)
4 (26.7)
1 (6.7)
1 (6.7)
6 (40)
4 (26.7)
4 (26.7)

8 (100)
0 (0)
1 (12.5)
5 (62.5)
2 (25)
0 (0)
7 (87.5)
1 (12.5)
0 (0)
6 (75)
1 (12.5)
1 (12.5)
0 (0)
3 (37.5)
1 (12.5)
4 (50)
0 (0)
5 (62.5)
3 (37.5)
0 (0)
0 (0)
4 (50)
2 (25)
2 (25)
0 (0)
0 (0)
5 (62.5)
3 (37.5)
0 (0)
5 (62.5)
2 (25)
1 (12.5)
0 (0)
4 (50)
1 (12.5)
3 (37.5)
0 (0)
6 (75)
2 (25)
0 (0)
0 (0)
5 (62.5)
2 (25)
1 (12.5)

χ2 (3) = 2.79, p = 0.425

χ2 (2) = 0.74, p = 0.691

χ2 (3) = 1.27, p = 0.736

χ2 (3) = 1.62, p = 0.655

χ2 (3) = 2.72, p = 0.437

χ2 (3) = 0.61, p = 0.894

χ2 (3) = 2.16, p = 0.540

χ2 (3) = 0.60, p = 0.896

χ2 (3) = 1.97, p = 0.578

χ2 (3) = 1.25, p = 0.741

χ2 (3) = 1.57, p = 0.666
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WAT2 steps

FTN hit count

FTN used pad

FTN used wrong hand

FTN does not return arm
to side

FTN swaying

FTN eyelid tremors

FTN body tremors

FTN does not keep eyes
closed

Left pupil size RL

Left pupil size NTD
Left pupil size DL1
Left pupil size DL2
Right pupil size RL

Right pupil size NTD

Not attempted/completed
<9
9
>9
Not attempted
0
1
4
6
Not available
No
Yes
Not available
No
Yes
Not available

1 (6.7)
3 (20)
8 (53.3)
3 (20)
1 (6.7)
7 (46.7)
2 (13.3)
1 (6.7)
4 (26.7)
1 (6.7)
5 (33.3)
9 (60)
1 (6.7)
11 (73.3)
3 (20)
1 (6.7)

0 (0)
0 (0)
6 (75)
2 (25)
2 (25)
1 (12.5)
4 (50)
0 (0)
1 (12.5)
1 (12.5)
2 (25)
5 (62.5)
1 (12.5)
6 (75)
1 (12.5)
1 (12.5)

No
Yes
Not available
No
Yes
Not available
No
Yes
Not available
No
Yes
Not available

8 (53.3)
6 (40)
1 (6.7)
10 (66.7)
4 (26.7)
1 (6.7)
12 (80)
2 (13.3)
1 (6.7)
13 (86.7)
1 (6.7)
1 (6.7)

5 (62.5)
2 (25)
1 (12.5)
5 (62.5)
2 (25)
1 (12.5)
3 (37.5)
4 (50)
1 (12.5)
6 (75)
1 (12.5)
1 (12.5)

No
Yes
Below range
Within range
Above range
Below range
Within range
Within range
Above range
Not available
Within range
Below range
Within range
Above range
Below range

12 (80)
2 (13.3)
2 (13.3)
12 (80)
1 (6.7)
5 (33.3)
10 (66.7)
14 (93.3)
1 (6.7)
14 (93.3)
1 (6.7)
2 (13.3)
12 (80)
1 (6.7)
5 (33.3)

7 (87.5)
0 (0)
0 (0)
7 (87.5)
1 (12.5)
2 (25)
6 (75)
7 (87.5)
1 (12.5)
5 (62.5)
3 (37.5)
0 (0)
7 (87.5)
1 (12.5)
2 (25)

χ2 (3) = 2.60, p = 0.458

χ2 (4) = 6.80, p = 0.147

χ2 (2) = 0.33, p = 0.848

χ2 (2) = 0.38, p = 0.829

χ2 (2) = 0.62, p = 0.734

χ2 (2) = 0.22, p = 0.894

χ2 (2) = 4.34, p = 0.114

χ2 (2) = 0.49, p = 0.781

χ2 (2) = 1.31, p = 0.520

χ2 (2) = 1.31, p = 0.520

χ2 (1) = 0.17, p = 0.679
χ2 (1) = 0.22, p = 0.636
χ2 (1) = 3.45, p = 0.063
χ2 (2) = 1.31, p = 0.520

χ2 (1) = 0.17, p = 0.679
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Right pupil size DL1
Right pupil size DL2
Rebound dilation
Reaction to light

Nasal area
Oral cavity
Left arm injection sites

Right arm injection sites

BP systolic

BP diastolic
Body temperature

Muscle tone

Within range
Within range
Above range
Not available
Within range
No
Yes
Not available
Normal
Slow
Little to none
Clear/normal
Other
Clear/normal
Other
None
Old
Fresh
None
Old
Fresh
Below range
Within range
Above range
Within range
Above range
Below range
Within range
Above range
Not available
Normal
Flaccid
Rigid

10 (66.7)
14 (93.3)
1 (6.7)
14 (93.3)
1 (6.7)
14 (93.3)
1 (6.7)
1 (6.7)
4 (26.7)
7 (46.7)
3 (20)
11 (73.3)
4 (26.7)
6 (40)
9 (60)
11 (73.3)
1 (6.7)
3 (20)
12 (80)
1 (6.7)
2 (13.3)
4 (26.7)
6 (40)
5 (33.3)
13 (86.7)
2 (13.3)
10 (66.7)
3 (20)
2 (13.3)
0 (0)
5 (33.3)
9 (60)
1 (6.7)

6 (75)
7 (87.5)
1 (12.5)
5 (62.5)
3 (37.5)
4 (50)
4 (50)
0 (0)
6 (75)
2 (25)
0 (0)
7 (87.5)
1 (12.5)
4 (50)
4 (50)
8 (100)
0 (0)
0 (0)
8 (100)
0 (0)
0 (0)
2 (25)
4 (50)
2 (25)
4 (50)
4 (50)
4 (50)
3 (37.5)
1 (12.5)
1 (12.5)
6 (75)
1 (12.5)
0 (0)

χ2 (1) = 0.22, p = 0.636
χ2 (1) = 3.45, p = 0.063
χ2 (1) = 5.76, p = 0.016
χ2 (3) = 5.56, p = 0.135

χ2 (1) = 0.62, p = 0.433
χ2 (1) = 0.21, p = 0.645
χ2 (2) = 2.58, p = 0.275

χ2 (2) = 1.84, p = 0.399

χ2 (2) = 0.25, p = 0.885

χ2 (1) = 3.64, p = 0.056
χ2 (2) = 0.85, p = 0.653

χ2 (3) = 7.01, p = 0.072

Hypothesis 3 Conclusion
The analyses revealed significant associations between the face sheet measures and
missed calls of CNS depressant, CNS stimulant, narcotic analgesic, and cannabis. The results
indicate that there are face sheet measures associated with drug categories inaccurately called by
DREs. Therefore, the null hypothesis was rejected.
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Conclusion
DRE opinions compared to the toxicology results for drug influence evaluations
completed by DREs in Florida during 2019 resulted in an accuracy rate of approximately 88%.
The accuracy rate was higher than previous studies that reported 80% (Beirness et al., 2007) but
were less than the 95% reported in a study of the DECP in Canada (Beirness et al., 2009). Due to
the difference in the accuracy rates of previous studies, the null hypothesis for research question
1 (RQ1) was rejected. However, the analysis did report that the Florida DREs measures of
accuracy had a sensitivity rate of 97% and a corroboration rate of 91%. Chapter five will discuss
the additional measures of accuracy (sensitivity, specificity, false alarm rate, miss rate, and
corroboration rate).
The study revealed signs and symptoms from the DIE face sheet significantly associated
with the four drug categories of CNS depressant, CNS stimulant, narcotic analgesic, and
cannabis. CNS depressant had seventeen signs and symptoms, CNS stimulant had eleven signs
and symptoms, narcotic analgesic had thirty-five signs and symptoms, and cannabis had twentyseven signs and symptoms that were significantly associated. A binary logistic regression
revealed a prediction model accuracy of approximately 74% for CNS depressant, 79% for CNS
stimulant, 81% for narcotic analgesics, and 76% for cannabis. The forward stepwise regression
selected three predictors for CNS depressants, one predictor for CNS stimulants, five predictors
for narcotic analgesics, and four predictors for cannabis. The regression models for these drug
categories were significant, indicating that there are sets of measures from the face sheet that can
significantly predict active drug categories. Therefore, the null hypothesis for research question 2
(RQ2) was rejected. Chapter five will also discuss each set of measures from the DIE face sheets
associated with their respective drug categories.
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The null hypothesis for research question 3 (RQ3) was also rejected due to analysis
revealing a significant association between the DIE face sheet measures and missed opinion calls
of CNS depressant, CNS stimulant, narcotic analgesic, and cannabis. In addition, the analysis
revealed twenty-one signs and symptoms significantly associated with the four drug categories.
Chapter five discusses each of the signs and symptoms identified by the analysis.
The signs and symptoms identified in the study have a significant association with their
respective drug categories and correspond with the Drug Evaluation and Classification Program
(DECP) curriculum and symptomology drug matrix (appendix B). The findings of this study
reinforce and corroborate the various signs and symptoms the DECP has identified as being
associated with the seven drug categories. Chapter five will discuss the study's findings and how
the results compare and impact the DECP.
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CHAPTER FIVE: CONCLUSIONS
Overview
This study was a quantitative cross-sectional descriptive and predictive examination of
Florida's DECP. Chapter five discusses the study's findings on the measures of accuracy, the
identified set of measurements (signs and symptoms) significantly associated with the four drug
categories (CNS depressant, CNS stimulant, narcotic analgesic, cannabis), and the identified set
of measurements from the missed DRE opinions significantly associated with the four drug
categories. The study's limitations when interpreting the study's findings are discussed in this
chapter to include data collection, documentation inconsistency, sample size, and toxicology
procedures. Implications of this study for the DECP were addressed by identifying trends,
associations, and relationships from the results to assist the DECP curriculum. Finally, future
research, suggestions, and recommendations are identified after chapter five.
Discussion
The purpose of this study was to evaluate the drug evaluation and classification program
(DECP) in Florida to determine the accuracy rates of drug recognition experts (DREs) and
determine which core set of measurements (signs and symptoms) from the Drug Influence
Evaluation (DIE) face sheets correspond to each of the seven drug categories, and to determine if
any common themes or indicators from the DIEs are identified with the inaccuracies of DRE
opinions.
Research Question 1
Research question 1 (RQ1) asks: what is the accuracy rate of DRE opinions compared to
the toxicology results for drug influence evaluations completed by DREs in Florida during 2019?
DRE opinions compared to the toxicology results for drug influence evaluations completed by
DREs in Florida during 2019 resulted in an accuracy rate of approximately 88%. The accuracy
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rate was higher than previous studies that reported 80% (Beirness et al., 2007), 85% (Adler &
Burns, 1994), and 87% (Compton, 1986) but was less than the 95% reported in a study of the
DECP in Canada (Beirness et al., 2009). Due to the difference in the accuracy rates of previous
studies, the null hypothesis for research question 1 (RQ1) was rejected. The DECP's third
training phase consists of field evaluation certifications requiring a passing rate (overall accuracy
rate) of 75% for the DRE drug category opinions compared to toxicological specimens
(International Association of Chiefs of Police [IACP], 2018c). This study was consistent with
previous studies of the DECP field evaluation accuracy rates exceeding the minimum
requirement of 75% of the DECP certification phase by DRE candidates (Adler & Burns, 1994;
Beirness et al., 2007; Beirness et al., 2009).
The goals of the DECP training program are to determine if a subject is impaired and, if
impaired by drugs, then which category (or categories) of drugs are likely causing the subject's
impairment (International Association of Chiefs of Police [IACP], 2018c). As stated in chapter
two, program evaluation theory's function is to ascertain the theoretical sensibility of the
program evaluated (Sharpe, 2011). A program evaluation theory consists of a set of statements
that describe a particular program, explain why, how, and under what conditions the program
effects occur, predict the outcomes of the program, and specify the requirements necessary to
bring about the desired program effects (Sedani & Sechrest, 1999; Sharpe, 2011). In this study,
the measures of accuracy (sensitivity, specificity, false alarm rate, miss rate, and corroboration
rate) for the DECP assists in determining if the 12-step DRE protocol successfully achieves the
program's goals. The Florida DREs in this study had 172 correct opinions and 23 missed
opinions resulting in a sensitivity rate of 97%, specificity rate of 23%, false alarm rate of 77%, a
miss rate of 3%, and a corroboration rate of 91%.
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Sensitivity addresses if the 12-step DRE protocol can correctly identify a suspected driver
being under the influence of a drug and correctly identify the drug causing the impairment
(Beirness et al., 2009). The sensitivity results are approximately 97%, with the DRE's opinion
correctly identifying 167 (true-positive) drug-positive cases divided by the total number of drugpositive cases identified by toxicology (184 cases). It is desirable to have a procedure that
maximizes sensitivity (Beirness et al., 2009). Regarding the DECP goals, the sensitivity measure
of 97% indicates the 12-step DRE protocol is having the desired effect on DREs formulating
correct opinions.
Specificity is the correct rejection rate and identifies if the 12-step DRE protocol can
correctly identify drivers, not under the influence of a drug (Beirness et al., 2009). The
specificity results are approximately 23%, with the DREs opinion correctly identifying 5 (truenegative) drug-negative cases divided by the total number of drug-negative cases identified by
toxicology (22 cases). It is desirable to have a procedure with high specificity (Beirness et al.,
2009). Regarding the DECP goals, the specificity measure of 23% indicates the 12-step DRE
protocol is not having the desired effect on DREs formulating correct opinions. The lack of
specificity was addressed in this chapter's research question 3 (RQ3) section.
The false alarm rate is the likelihood of a DRE falsely identifying a driver as being under
the influence of a drug when the toxicology results indicate no drugs are found. The false alarm
rate is approximately 77%, with the DRE's opinion identifying 17 (false-positive) cases divided
by the total number of drug-negative cases identified by toxicology (22 cases). It is desirable to
have a procedure with a low false alarm rate (Beirness et al., 2009). Regarding the DECP goals,
the false alarm rate of 77% indicates the 12-step DRE protocol is not having the desired effect on
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DREs formulating correct opinions. The high false alarm rate was addressed in the research
question 3 (RQ3) section of this chapter.
Miss rate is the cases DREs did not identify the correct drug category identified by
toxicology results as being the drug category causing the impairment (a psychoactive drug). The
miss rate was approximately 3%, with the DRE's opinion identifying 6 (false-negative) cases
divided by the total drug-positive cases (173 cases). It is desirable to have a procedure with a low
miss rate (Beirness et al., 2009). Regarding the DECP goals, the miss rate of 3% indicates the
12-step DRE protocol is having the desired effect on DREs formulating correct opinions.
The corroboration rate is what most legal representatives in the criminal justice court
system reference when examining validation studies (Beirness et al., 2007). DREs in this study
determined that the individuals under the influence of a drug (DRE opinion) were correct 91% of
the time when confirmed by toxicology. Previous studies of validation for the DECP resulted in
73% (Compton, 1986), 87% (Hardin et al., 1993), 82.7% (Alder, 1990), 90% (Adler & Burns,
1994), 92% (Bigelow et al., 1985). The range of corroboration rates from previous studies was
73% to 92% (Beirness et al., 2007; Talpins et al., 2018). This study resulted in a 91%
corroboration rate on the higher end of the previous studies range. Regarding the DECP goals,
the corroboration rate of 91% indicates the 12-step DRE protocol is having the desired effect on
DREs formulating correct opinions.
Research Question 2
Research question 2 (RQ2) asks: What set of measures (signs and symptoms) from the
drug influence evaluations that completed by DREs in Florida during 2019 significantly predict
the drug categories? To answer the research question and test the hypothesis, logistic regression
models were performed. Due to the low frequencies of specific combinations of active drug
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categories, binary logistic regressions were performed to predict each active drug category
observed in the data (CNS depressant, CNS stimulant, narcotic analgesic, and cannabis). Before
conducting each regression, bivariate tests (i.e., chi-square tests) were performed to determine
which factors from the face sheets were significantly associated with the drug category and to
test the assumption of adequate expected frequencies. Factors significantly associated with the
drug category were entered into the regression using a forward (conditional) stepwise procedure
to select the factors that contribute most significantly to the prediction of the drug category.
The analyses revealed significant associations between the face sheet measures and the
active drug categories of CNS depressant, CNS stimulant, narcotic analgesic, and cannabis. The
regression models for these drug categories were significant, indicating that there are sets of
measures from the face sheet that can significantly predict active drug categories. Therefore, the
null hypothesis for research question 2 (RQ2) was rejected.
Before each binary logistic regression, bivariate tests (i.e., chi-square tests) were
performed to determine which factors from the face sheets were significantly associated with the
drug category and to test the assumption of adequate expected frequencies. The factors obtained
from each DIE face sheet were entered into an SPSS data set using the coding instrument
obtained from Dr. Porath-Waller. The coding instrument (appendix C) was adjusted for this
study to take a detailed approach to the variables obtained from the DIE face sheets. PorathWaller et al., (2021) identified 22 signs and symptoms with a significant association with the
seven drug categories. This study broke down each of the signs and symptoms into a more
restrictive detail analysis.
An example is in Porath-Waller et al., (2021) study, one of the factors identified was
Horizontal Gaze Nystagmus and is classified as not impaired and impaired. The bivariate tests
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performed in this study classified Horizontal Gaze Nystagmus according to the indicators of
impairment identified in the DRE course curriculum as lack of smooth pursuit, distinct and
sustained nystagmus at maximum deviation, and angle of nystagmus for both eyes for a total of
six factors (International Association of Chiefs of Police [IACP], 2018c) instead of the two
factors identified in the Porath-Waller et al., (2021) study. In addition, detailing each variable
from the DIE face sheet allowed the study to conduct a bivariate test for each sign and symptom
at varying levels instead of an overall summary of the sign and symptoms.
Bivariate Results
Multiple research studies focused on the signs and symptoms (factors) produced by
individual types of drugs on how the drugs affected the human body and compared these results
with the DECP curriculum for validation (Bramness et al., 2003; Downey et al., 2016; Hartman
et al., 2016; Heishman et al., 1998; Perry et al., 2015; Silber et al., 2005; Vaillancourt et al.,
2021). The DECP places these various effects of drugs on the human body into seven drug
categories each having singular drug factors identified associated with each drug category
(International Association of Chiefs of Police [IACP], 2018c). These individual drug effect
factors are identified in the symptomology drug matrix as sign and symptoms of the seven drug
categories. This study examined each of these signs and symptoms as they are related to four of
the drug categories (CNS depressant, CNS stimulant, narcotic analgesic, and cannabis).
CNS Depressants. Factors significantly associated with CNS depressants were abnormal
speech, bloodshot eye appearance, lack of smooth pursuit and maximum deviation (both eyes),
30 to 45-degree angle of onset (both eyes), vertical gaze nystagmus, putting the foot down on the
right OLS, starting WAT before instructions are finished, stepping off the line in WAT1, both
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pupil size in near total darkness (NTD) was within normal ranges, abnormal reaction to light,
below range blood pressure, and flaccid muscle tone.
The symptomology drug matrix (appendix B) lists in the general indicator for a CNS
depressant that a subject could have thick, slurred speech (abnormal speech). Bloodshot eye
appearance is also an indicator outlined in the DECP curriculum (International Association of
Chiefs of Police [IACP], 2018c). In addition, Porath-Waller et al. (2021) identified horizontal
gaze nystagmus (HGN) as being a factor of impairment associated with CNS depressants. HGN
contains six indicators in the DRE evaluation: a lack of smooth pursuit in both eyes, distinct and
sustained nystagmus at maximum deviation in both eyes, and an angle of nystagmus for both
eyes (International Association of Chiefs of Police [IACP], 2018c).
Several medical validation studies have shown drug impairment can cause HGN in
subjects under the influence of a CNS depressant above the normal therapeutic dose for the
subject (Dhingra et al., 2019; Kosnoski et al., 1998). The results of the bivariate test in this study
confirm that all six factors of HGN independently had a significant association with a subject
being under the influence of a CNS depressant. The results of all six HGN indicators are also
identified in the DECP curriculum as being indicators of impairment for a subject under the
influence of a CNS depressant (International Association of Chiefs of Police [IACP], 2018c).
The purpose of field sobriety testing (MRB, OLS, WAT, FTN) in a DRE evaluation is to
assist the DRE in determining the secondary goal of the DECP of whether or not the subject is
impaired (International Association of Chiefs of Police [IACP], 2018c). Validation studies were
conducted and suggested the usefulness of identifying drug impairment in individuals through
the administration of the field sobriety testing (Alder & Burns, 1994; Downey et al., 2012;
Downey et al., 2016; Fiorentino et al., 2020; Ip et al., 2013; Perry et al., 2015; Porath-Waller &
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Beirness, 2013). CNS depressant active cases identified a significant association of a subject
placing their right foot down on OLS (73.4%), starting WAT before instructions are finished
(34.4%), and stepping off the line in first nine step of WAT (59.4%).
The symptomology drug matrix also indicated the pupil sizes will be normal for a subject
under the influence of a CNS depressant except for the drugs of Soma, Quaaludes, and some
Anti-depressant medications, which usually dilate pupils (International Association of Chiefs of
Police [IACP], 2018c). Bivariate tests in this study identified that 76.6% of subjects in the CNS
depressant cases had normal pupil size in near total darkness conditions, and 9.4% of subjects
had dilated pupils.
A subject’s reaction to light will usually be slowed when estimated in the darkroom
evaluation for subjects under the influence of a CNS depressant (Dargan et al., 2013; Stephenson
et al., 2013). In addition, the symptomology drug matrix also indicated a slow reaction to light
during the 12-step DRE protocol, which was also corroborated in the bivariate tests of this study,
revealing that 60.9% of subjects under the influence of CNS depressant cases had a slow reaction
to light.
The final two factors in bivariate tests are below the normal DRE range for blood
pressure (34.4%) and flaccid muscle tone (59.4%). These factors are identified in the
symptomology drug matrix as blood pressure being down for CNS depressant and the subject
having a flaccid muscle tone (International Association of Chiefs of Police [IACP], 2018c;
Snozek, 2020; Stephenson et al., 2013).
Seventeen signs and symptoms from the DIE face sheet were significantly associated
with the CNS depressant drug category. The results of the bivariate tests help solidify the DECP
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curriculum in identifying the signs and symptoms associated with subjects under the influence of
a CNS depressant.
CNS Stimulant. Factors significantly associated with CNS stimulants were inability to
follow stimulus, above range pulse rates, faster MRB internal clock, MRB eyelid tremors,
stopped walking on the second nine steps of the walk-and-turn test, pupil size in near total
darkness for both eyes, no rebound dilation, slow reaction to light in the dark room, abnormal
nasal area, and rigid muscle tone.
The symptomology drug matrix and previous studies indicate that subjects under a CNS
stimulant will exhibit a faster pulse rate above the average range (Caplan et al., 2007; Porath &
Beirness, 2019). CNS stimulant active cases identified a significant association of a subject
having a faster pulse rate (53.7%). In addition, active cases also identified a significant
association of subjects having a faster internal clock (46.3%) on the Modified Romberg Balance
test, which the DECP curriculum identifies as an indicator of CNS stimulant use (International
Association of Chiefs of Police [IACP], 2018c).
The lack of a sign or symptoms is just as crucial as a sign or symptom being present to
assist DREs in making an opinion of drug categories being psychoactive at the time of the
evaluation. For example, no rebound dilation (85.4%) had a significant association for CNS
stimulant in this study and is also identified in the DECP curriculum as not being present for a
CNS stimulant (International Association of Chiefs of Police [IACP], 2018c). Significant
association of subjects having eyelid tremors (85.4%), slow reaction to light (78%), and a rigid
muscle tone (29.3%) are considered a sign and symptoms by previous studies for subjects under
the influence of a CNS stimulant (Caplan et al., 2007; Chang et al., 2019; Dhingra et al., 2019;
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International Association of Chiefs of Police [IACP], 2018a; International Association of Chiefs
of Police [IACP], 2018c; Porath & Beirness, 2019).
Eleven signs and symptoms from the DIE face sheet were significantly associated with
the CNS stimulant drug category. The results of the bivariate tests help validate the DECP
curriculum identifying the signs and symptoms associated with subjects under the influence of a
CNS stimulant.
Narcotic Analgesic. Factors significantly associated with narcotic analgesics were being
sick or injured, being diabetic or epileptic, being under the care of a doctor or dentist, abnormal
coordination, abnormal speech, droopy eyelids, no lack of smooth pursuit, and no maximum
deviation (both eyes), angle of onset not present (both eyes), lack of convergence absent,
difficulty on OLS, MRB swaying front to back, no MRB eyelid tremors, stopping walking on
WAT2, miss heel to toe on WAT2, stepping off the line on WAT2, steps taken on WAT2, no
FTN eyelid tremors, left and right pupil size (all lights), no rebound dilation, abnormal reaction
to light, arm injection sites, and flaccid muscle tone.
As stated previously, the lack of a sign or symptoms is just as crucial as a sign or
symptom being present to assist DREs in making an opinion of drug categories being
psychoactive at the time of the evaluation. DREs formulate their opinions on active drug
categories not only on what factors are present in the evaluations but also on factors not present
in the evaluation. Previous studies have identified that subjects on a narcotic analgesic will not
exhibit horizontal gaze nystagmus, lack of convergence, eyelid tremors, or rebound dilation
(International Association of Chiefs of Police [IACP], 2018c). Factors of not having lack of
smooth pursuit in both eyes (61.4%), no distinct and sustained nystagmus at maximum deviation
in both eyes (70.5%), no angle of onset in both eyes (75%), the absence of lack of convergence
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(34.1%), no MRB eyelid tremors (86.4%), no FTN eyelid tremors (86.4%), and no rebound
dilation (90.9%) are all significantly associated with narcotic analgesics.
Narcotic analgesic drug category is unique because it is the only DRE drug category that
causes miosis and little to no reaction to light (Armenian et al., 2018; Dhingra et al., 2019;
Edwards, 2019; Finegan, 2021). Miosis in near total darkness (70.5%) and little to no reaction to
light (45.5%) had significant associations with narcotic analgesics.
A common side effect of narcotic analgesics is sedation, which may impact psychomotor
performance (Ferreira et al., 2018). The impact on psychomotor performance is prevalent with
the significant associations identified in this study with difficulty on the field sobriety tests. On
OLS, subjects used their arms for balance on the left foot (72.7%), placed their left foot down
(75%), and used their arms for balance on the right foot (70.5%). MRB subjects had more than a
2-inch sway from front to back (70.5%). On WAT, subjects had difficulties on the second nine
steps of the test by stepping off the line (43.2%) and missing heel to toe (66%).
The third step (Preliminary Examination) in the 12-step DRE protocol assists DREs in
formulating drug category opinions by documenting several signs and symptoms associated with
drug categories. The subject's medical history is also obtained during the preliminary
examination (International Association of Chiefs of Police [IACP], 2018c). DREs document and
observe the subjects' physical behavior, speech, and visual observations and ascertain medical
history. Significant associations of narcotic analgesics were being sick or injured (43.2%),
diabetic or epileptic (88.6%), under the care of a doctor or dentist (59.1%), poor coordination
(90.9%), abnormal speech (93.2%), and droopy eyelids (93.2%).
Thirty-five signs and symptoms from the DIE face sheet were significantly associated
with the narcotic analgesic drug category. The results of the bivariate tests help reinforce the
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DECP curriculum is identifying the signs and symptoms associated with subjects under the
influence of a narcotic analgesic.
Cannabis. Factors significantly associated with cannabis were not being sick or injured,
not having a physical disability, not being under the care of a doctor or dentist, abnormal breath,
lack of convergence, less difficulty on OLS, MRB eyelid tremors, MRB body or leg tremors, not
stepping off the line in WAT, FTN eyelid and body tremors, left and right pupil size (all lights),
rebound dilation, reaction to light, abnormal oral cavity, within range body temperature, and
normal muscle tone.
Similar to narcotic analgesic bivariate results, step three (Preliminary Examination) in the
12-step DRE protocol indicated several signs and symptoms associated with cannabis.
Significant associations with cannabis were not being sick or injured (81.2%), being under the
care of a doctor or dentist (69.4%), and having abnormal breath (55.3%).
The DECP curriculum identifies a strong association of subjects having eyelid and body
tremors, rebound dilation, normal body temperature, normal muscle tone, and a slow reaction to
light as being under the influence of cannabis (International Association of Chiefs of Police
[IACP], 2018c). In addition, the bivariate results identified the same factors as having a
significant association with cannabis.
Twenty-seven signs and symptom from the DIE face sheet were significantly associated
with the narcotic analgesic drug category. The results of the bivariate tests help corroborate the
DECP curriculum is identifying the signs and symptoms associated with subjects under the
influence of a cannabis.

151
Binary Logistics Regression
A binary logistic regression revealed a prediction model accuracy of approximately 74%
for CNS depressants, 79% for CNS stimulants, 81% for narcotic analgesics, and 76% for
cannabis. The forward stepwise regression selected three predictors for CNS depressants
(bloodshot eye appearance, vertical gaze nystagmus, and stepping off the line for WAT first nine
steps), one predictor for CNS stimulants (MRB eyelid tremors), five predictors for narcotic
analgesics (sick or injured, abnormal speech, hooping during left OLS, stopping one time during
WAT second nine steps, and no rebound dilation), and four predictors for cannabis (physical
disability, abnormal breath, MRB eyelid tremors, and rebound dilation).
Porath-Waller et al. (2019) identified twenty-two drug-related signs and symptoms that
significantly predicted the correct drug category associated with four drug categories (CNS
depressant, CNS stimulant, narcotic analgesics, and cannabis) with an overall classification rate
of 86%. Porath-Waller et al. (2019) grouped the twenty-two signs and symptoms into four
conceptual blocks of clinical indicators, performance on psychophysical tests, appearance and
physiological response of the eyes, and observations and self-reported statements. The four
conceptual blocks were then entered into a “sequential multinomial logistic regression procedure
to determine the relative importance of the four groups of indicators in predicting drug category”
(p. 258).
Building upon previous research studies of the DECP analyzing the predictability of signs
and symptoms for the drug categories (Porath-Waller et al., 2009; Porath & Beirness, 2010;
Porath-Waller, 2019), this study intended to take a more detailed approach to the classification of
the independent variables of the signs and symptoms. Therefore, this study examined eighty-four
independent variables versus the twenty-two independent variables used by previous researchers.
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Previous studies completed logistic regression models to identify which signs and
symptoms predict drug categories (Porath-Waller et al., 2009; Porath & Beirness, 2010; PorathWaller, 2019). The previous studies grouped signs and symptoms into a binary outcome of not
impaired versus impaired or present versus not present for the various factors. This study built
upon the previous literature by analyzing these factors into a detailed set of criteria versus a
binary outcome. Instead of impaired versus not impaired for the field sobriety tests, this study
extended the findings of previous studies by re-coding the individual indicators of impairment
outcomes into independent variables with various categorical outcomes. For example, Porath &
Beirness (2010) identified performance on the OLS test as not impaired and impaired. This study
identified performance on the OLS by the indicators of impairment outlined in the DECP
curriculum as left OLS swaying while balancing, left OLS using arms to balance, left OLS
hopping, and left OLS putting a foot down (0, 1, and 2 or more times), left OLS time (0-14, 1529, and 30 or more). This re-coding was repeated for the right foot section of the OLS test for a
total of 10 variables versus the one variable used in previous studies.
The lower predictability rates and identification of a low number of signs and symptoms
as a predictor between this study and previous studies reveal that creating a detailed approach
versus a grouping classification does not increase the predictability model. DECP curriculum is
designed to teach DREs to utilize the entire 12-step DRE protocol and not be selective on which
steps to consider in formulating an opinion. This study reinforces the concept set by the DECP
that a holistic approach to identifying the signs and symptoms associated with the DIE creates a
higher probability of classifying the correct drug categories causing impairment.
The bivariate test showed significant associations between independent variables of signs
and symptoms. The binary logistic regression revealed that being too detailed in the process on
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categorizing the signs and symptoms can lead to lower drug classification rates for DREs.
Previous research has answered this dilemma with a stronger level of the association by
identifying the independent variables and then grouping these significant association variables
into conceptual blocks for analysis (Porath & Beirness, 2009; Porath-Waller et al., 2010: PorathWaller et al., 2019). The results of grouping the significant association variables into blocks
created a higher predictability of correct drug classification, which in turn assists the DECP in
identifying a core set of measures for signs and symptoms that DREs can focus on for
formulating an opinion of drug classification.
Research Question 3
Research question 3 (RQ3) asks: Among the inaccurate drug influence evaluations
(missed opinions) completed by DREs in Florida during 2019, what set of measures (signs and
symptoms) significantly predict the drug categories inaccurately determined by the DREs? To
answer the research question and test the hypothesis, crosstabulations and bivariate tests (i.e.,
chi-square tests) were performed on the cases with missed opinions (23 cases) to determine
which factors from the face sheets were significantly associated with the drug categories (CNS
depressant, CNS stimulant, narcotic analgesic, cannabis) that were called incorrectly. Bivariate
test results indicate that DREs inaccurately call the face sheet measures associated with drug
categories. Therefore, the null hypothesis was rejected.
DRE’s opinioned seventeen cases as being drug positive when the toxicology report
indicated no drugs were found in the subject’s biological samples. This resulted in a 77% false
alarm rate and a 23% specificity rate in research question 1 (RQ1). Thirteen cases were
incorrectly called CNS depressants; bivariate results identified all six indicators of HGN, no FTN
eyelid tremors, pupil size in DL, and abnormal nasal are significantly associated with the missed

154
calls. In three cases incorrectly called CNS stimulants, bivariate results identified droopy eyelids,
MRB swaying, MRB internal clock, and slow reaction to light are significantly associated with
the missed calls. In seven cases incorrectly called a narcotic analgesic, bivariate results identified
slow pulse rate and right arm injection sites. DREs incorrectly called cannabis for eight cases
with bivariate results identifying MRB eyelid tremors and rebound dilation as significantly
associated.
A review of the individual DIE face sheets confirmed that all thirteen CNS depressant
missed opinion face sheets indicated the subjects had a lack of smooth pursuit, distinct and
sustained nystagmus at maximum deviation, and an angle of onset between 30 to 45 degrees.
CNS depressants, inhalants, and dissociative anesthetics may cause HGN. CNS stimulants,
hallucinogens, narcotic analgesics, and cannabis do not cause HGN (International Association of
Chiefs of Police [IACP], 2018c). The toxicology results for the thirteen cases indicate that no
drugs were found in 10 of the subject’s biological samples.
In researching the missed opinions of the DREs and examining the individual DIE face
sheets, it was apparent that the general and clinical indicators outlined in the DECP curriculum
were present. The question is then: if the signs and symptoms of a drug category match the
curriculum reinforced by validation studies as being reliable, then why are toxicology results
showing no drugs present?
Toxicologists will only analyze the biological samples for drugs controlled under Florida
Statute 893. The commonly abused drugs Florida Department of Law Enforcement (FDLE)
laboratories analyze for are amphetamines, methamphetamine, ecstasy, barbiturates,
benzodiazepines, carisoprodol, cocaine, methadone, heroin, oxycodone, codeine, morphine,
hydrocodone, and Tetrahydrocannabinols. Over-the-counter and many prescription medications
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are not routinely included in drug analysis (Florida Department of Law Enforcement [FDLE],
2021).
FDLE Testing Limitations
Most prescription medications in Florida are routinely not analyzed in biological samples
submitted to FDLE laboratories in DUI-related cases unless the criminal case involves a fatality
(Florida Department of Law Enforcement [FDLE], 2021). “Analysts do not routinely test for
non-controlled substances, such as over-the-counter medications of antihistamines or prescribed
antidepressants in DUI casework” (Florida Department of Law Enforcement [FDLE], 2022, pg.
3). The first step in the FDLE toxicology testing procedure is to conduct a sample screening
which consists of cutoff concentration levels. If a drug is below the assigned cutoff concentration
level, the sample screening produces no detected drug (Florida Department of Law Enforcement
[FDLE], 2022). FDLE will not continue to analyze the sample if the test results in no drugs being
detected even though the drug may be present. FDLE (2022) toxicology reported they do not
routinely test for: “Klonopin (Clonazepam), Ativan (Lorazepam), GHB, Demerol, Phencyclidine
(PCP), Ketamine, Fentanyl, Propoxyphene (Darvon), Ambien, Tramadol, and other novel
psychoactive substances (designer drugs)” (p. 4).
In addition to the lack of drugs tested by FDLE toxicology laboratories is the detection
time associated with the drugs they test. Amphetamines (Adderall), Methamphetamine, and
MDMA (Molly or Ecstasy) are CNS stimulants with a detection time in the urine of three to 5
days. Barbiturates like Secobarbital and Amytal are CNS depressants with a detection time in the
urine of four to six days. Other CNS depressants of Alprazolam (Xanax) or Diazepam (Valium)
have a detection time in the urine of two to seven days (Florida Department of Law Enforcement
[FDLE], 2022). Every drug category has a list of detection times, according to FDLE
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toxicologists. This means that if a subject decides to ingest a handful of Alprazolam, they would
most likely be unable to operate a motor vehicle due to their level of impairment from the CNS
depressant. However, if the subject did not previously take the drug, a urine sample would yield
a negative drug presence and produce a no-drug found result because of the detention time.
A review of missed opinions by DREs in this study consisted of examining the individual
DIE face sheets. Twenty-two of the twenty-three contained signs and symptoms identified in the
bivariate testing as having a significant association with the drug category opinioned by the
DRE. The toxicology results indicated no drugs were found, resulting in the case being classified
as a missed opinion. After reviewing the literature provided by FDLE, it is apparent that these
individual cases could have been drug positive. However, low cutoff concentration levels,
detection time restraints, or the lack of not testing the particular drug the subject ingested
resulted in a missed opinion.
Designer Drugs
Designer drugs are another influencer of possible missed opinions for DRE evaluations.
Currently, in Florida, kratom (mitragynine) is sold over the counter at local convenience stores
and is a popular drug used by subjects. Kratom is a natural opioid that exerts opioid and alpha-2
agonistic effects with stimulant properties that do not require a prescription in the United States
(White, 2019). Kratom has been documented to have stimulating effects at low doses and opioidlike effects at higher doses (Bowe & Kerr, 2020; Schmitt, 2021; White, 2019). Wright (2018)
conducted a study on a subject who participated in a DIE administered by a DRE after she was
arrested for DUI in Virginia. The DIE face sheet indicated the subject was under the influence of
a CNS stimulant and cannabis due to the signs and symptoms she exhibited being consistent with
the two drug categories. The DRE in White’s (2018) study reported the subject had dilated
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pupils, slowed reaction to light, elevated pulse, elevated blood pressure, normal body
temperature, eyelid and body tremors, restlessness, talkativeness, faster internal clock on MRB
(White, 2019). During the 12-step DRE protocol interview, the subject reported having used
kratom for opioid withdrawal relief. A biological blood sample was collected from the subject,
and the results indicated kratom (mitragynine) was present in the sample.
Some designer drugs are extracted from a natural source, and others are created in
laboratories. These drugs produce the same signs and symptoms as all seven drug categories in
the DECP curriculum. Researchers use the terminology of novel psychoactive substances (NPS),
designer drugs, and synthetic drugs to describe these various drugs (Logan et al., 2017).
Examples of designer drugs are synthetic cannabinoids (AMB-FUBINACA), salvia divinorum
(natural perennial herb), synthetic stimulants (Alpha-PVP, 4-Fluoroamphetamine, Ethylone,
Methylone), novel hallucinogens (25I-NBOMe, MXE, MXP), designer benzodiazepines
(Phenazepam, Clonazolam, Flubromazolam), designer opioids (Acetyl fentanyl, Butyryl
fentanyl), novel synthetic opioid agonists (Mitraynine- kratom), liberty caps (mushrooms with
psilocybin) (Logan et al., 2017). Multiple research studies have been conducted on the various
designer drugs, which resulted in the drugs producing similar effects on the human body being
consistent with all seven drug categories of the DECP (Logan et al., 2017; Logan et al., 2018;
Mohr et al., 2018; Tabarra, 2019; White, 2018; White, 2019).
Implications
The results of this study have important implications for the DECP, Florida legislators,
and DREs performing drug influence evaluations. This study reduced the signs and symptoms
into a detailed categorial list of independent variables. By narrowing down the summary of
independent variables into detailed indicators of impairment, this study assists the DECP
curriculum in identifying which singular indicators have significant associations with the various
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drug categories. The study revealed individual characteristics of the signs and symptoms in
relation to the drug categories. The study also showed that taking a holistic approach to
conducting a drug evaluation and formulating an opinion has a higher predictability of
identifying the appropriate drug category causing impairment. The DECP curriculum focuses on
a holistic approach to teaching DREs to conduct the entire systematic and standardized 12-step
DRE protocol before rendering an opinion on drug classification.
This study assists the Florida legislature in their confidence in the DECP accuracy and
corroboration rates. Florida is currently trying to amend the driving under the influence law to
include language identifying "any substance that causes impairment" versus only "controlled
substances." If the law is changed, then the role of the DRE will be to conduct a DIE to show the
impairment of subjects. The findings of this study assist legislators in showing that DREs have a
91% corroboration rate in opening impaired subjects on drugs. The study also showed that the
miss identification by toxicology results is possibly due to the low cutoff rates, subjects being
under the influence of prescription medications or designer drugs not tested by FDLE
laboratories, or drug detection time restraints.
Previous studies focusing on accuracy rates of the DECP in the United States contain data
over thirty years old. With the updated data obtained in this study, in combination with
performing a program evaluation, this study reinforces that the DECP curriculum is meeting the
program's goals. Each research question helped identify whether the DECP curriculum was
meeting the standards and goals of the program by providing statistical analysis and confirmation
of the DECP 12-step DRE protocol. This study built upon previous studies focusing on
individual signs and symptoms and their associations with drug categories. The results of this
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study confirm the previous studies finding with current data versus data obtained over twenty
years ago.
This study also assists the DECP with understanding which signs and symptoms are
significantly associated with missed DRE opinions. This type of analysis of miss opinions was
previously lacking from prior research studies. In addition, identifying the significant
associations of signs and symptoms of missed opinions with drug categories revealed a gap in
the literature on the possible misidentification of positive drug cases due to toxicology testing
procedures.
Limitations
Potential limitations should be considered when interpreting the study's findings,
including data collection, documentation inconsistency, sample size, and toxicology procedures.
First, data collection was complex in this study due to the DRE database only containing the
opinion of the DRE and the toxicology results for completed DIEs in 2019. An email requesting
the DIE face sheets was sent to 405 certified DREs. Several DREs responded to the email
advising that they were not certified in 2019, and this study could not obtain a list of 2019certified DREs. DREs also responded to the email advising they do not keep copies of their
evaluations or they do not produce a DIE face sheet and narrative report unless the State’s
Attorney Office request it for court. In addition, many DREs who participated in the program in
2019 had retired, transitioned to another agency, or left the criminal justice profession. The lack
of a centralized database containing the DIE face sheets, narrative reports, and toxicology limited
this study's data collection. A total of 236 DIE face sheets and corresponding toxicology results
were collected out of 986 enforcement drug influence evaluations completed in 2019.
Second, the study lacked consistency in documenting signs and symptoms on the DIE
face sheets. DREs independently have their version of shorthand to document the various signs
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and symptoms. The DECP is a systematic and standardized program but lacks the
standardization of the documentation portion of the DIE face sheets. On several occasions,
additional contact was made with the DREs to interrupt the shorthand they had documented on
the DIE face sheets. Unfortunately, not all DREs responded to the request, which led the study to
enter a non-available or missing data set for the particular sign and symptom.
Third, the target sample size calculation indicated that a total of 177 cases were needed
for the analysis, which was achieved. However, a limitation of the study was the lack of no-drug
cases. Therefore, the study could not complete a multinomial logistic regression due to not
having a decent number of no-drug cases to be used as a reference for the seven drug categories.
In order to overcome this limitation, future studies will need to collect 177 cases from each drug
category to include another 177 cases from the no-drugs opinioned by DREs. The findings also
showed several drug combinations in the selected DIE cases. When poly-drug or poly-category is
present, the analysis cannot separate the signs and symptoms from drug combinations into
distinct drug categories due to null, overlapping, additive, or antagonistic drug effects described
in the DECP curriculum.
The last limitation identified in this study is the lack of standardized toxicology testing in
Florida which created another limitation in this study. The low cut-off rates for drugs, selective
drug testing, drug detection times, and lack of testing for all impairing substances limited the
findings of this study. The missed opinions by DREs were identified due to "no-drugs" being
located in the biological sample. This classification could be false due to the Florida toxicology
testing procedures.
Recommendations for Future Research
The data collection limitations were also recognized in Porath-Waller's et al. (2021)
study. The DECP changed procedures for the IACP-NHTSA DRE database in 2020 based on the

161
recommendations from Porath-Waller et al. (2021) study. DREs are now required to enter the
entire DIE face sheet and narrative into the database to assist with future data collection. The
DIEs are also being reviewed by the DECP regional or state coordinators for the accuracy of the
data. Although the DECP has corrected many of the limitations identified in this study, there is
still room for improvement.
This study recommends that the DECP provide more consistent training on standardizing
documentation of the DIE face sheets. As stated previously, the DIE face sheets collected for this
study contained individual DREs shorthand which was difficult to interpret on several occasions
leading the study to identify the variable as being unavailable or missing. The loss of data could
have influenced the statistical analysis outcomes. This study recommends that the DECP
implement a standardized and systematic documentation procedure for all DREs when
completing the DIE face sheets. Providing a standardized procedure of DRE shorthand on the
DIEs will assist future researchers in interpreting the face sheets. It will also assist other DREs
when reviewing their peer's face sheets.
Research question 3 identified several issues relating to the missed opinions of the DREs.
First, further research is needed to identify the various designer drugs that cause impairment and
their association with the signs and symptoms of the seven drug categories. Suppose the
associated research determines that designer drugs contain poly-category similarities. In that
case, the DECP should research adding a drug category to the DECP for designer drugs. Another
limitation identified in the study was the FDLE testing procedures. The low cut-off rates of
tested drugs, the lack of testing prescription medications, and the lack of testing non-controlled
substances hinder the DECP. A recommendation for further studies is to ascertain the number of
no-drug cases identified by FDLE testing procedures that contain an impairing substance in their
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biological sample. This study could assist Florida legislators in changing the language of the
DUI law to "any impairing substances."
The last recommendation of this study is the sample size used for analysis. Further
studies need to be conducted using the 177 cases identified as the appropriate number of cases
for a sample size. However, 177 cases will need to be collected for each of the seven drug
categories, 177 for each drug combination case, and 177 cases of no impairment (rule out)
opinioned by DREs. Collecting the sample size for each drug category to include the rule-out
cases will assist the DECP in obtaining accurate results regarding the significant associations
between the drug category and the set of measurements (signs and symptoms) from the DIEs.
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Appendix A
Drug Influence Evaluation (DIE) Face Sheet
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Appendix B
Drug Evaluation and Classification Program Signs and Symptomology Matrix
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Appendix C
Drug Influence Evaluation Coding Instrument
**If there are any of the following codes that are missing from the face sheets then enter a value
of -999.
1. File number (1) *assign each face sheet with a number (i.e., the first file you enter into the
database will be assigned number 1, etc.) and write this number on the actual face sheet and
corresponding toxicology report or rolling log.
2. Age
-enter two-digit age
3. Age (recoded)
0 – 24 or younger
1 – 25 to 34
2 – 35 to 44
3 – 45 or older
-if missing from the face sheet, enter -999
4. Gender
0 – male
1 – female
5. Race
0—white
1—black
2—Hispanic
3—Indian
4—other
6. Type of Crash (1)
0 – none
1 – fatal
2 – injury
3 – property
-if missing from the face sheet, enter -999
7. Type of Crash (2)
0 – none
1 – fatal
2 – injury
3 – property
-if missing from the face sheet, enter -999
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8. Date Examined
-enter the date as is on the face sheet without any spaces or hyphens
9. Time Examined
-enter time without any spaces or colons according to the 24-hour clock
10. Breath Results
-enter number without any decimals (usually it will be expressed as a percent)
-if the test was refused, then enter -999
-if the words "fail" are included in this section, then enter 100 (as per Evan's instructions)
-the Instrument # is not required
11. Chemical Test
0 – refused
1 – urine
2 – blood
-if none, then enter -999
12. Eaten Today (what the suspect has eaten is not important; just whether or not he/she has
eaten)
0 – no
1 – yes
13. Time of Eating Today
-enter time without any spaces or colons according to the 24-hour clock
-enter -999 if not applicable
14. Have you drank today
0—no
1—yes
-enter 999 if not applicable
15. Time of Last Drink
-enter time without any spaces or colons according to the 24-hour clock
-enter -999 if not applicable
16. Time Now
-enter time without any spaces or colons according to the 24-hour clock
17. Actual time
-enter time without any spaced or colons according to the 24-hour clock
18. Minutes Difference
-enter total difference of minutes between “time now and actual time”
19. Minutes Difference (recoded)
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0 – 10 minutes or less difference
1 – 11 to 30 minutes difference
2 – 31 to 90 minutes difference
3 – more than 90 minutes difference
-enter -999 if not applicable
20. Time of Last Sleep
-enter what is written in this section of the face sheet
-enter -999 if not applicable
21. Duration of Last Sleep (in hours)
-enter the number
22. Duration of Sleep (recoded)
0 – less than 4 hours
1 – 4 to 8 hours
2 – more than 8 hours
23. Sick or Injured
0 – no
1 – yes
24. Sick or Injured Commentary
-enter any text that is written in this section of the face sheet
25. Diabetic or Epileptic
0 – no
1 – yes
26. Taking of Insulin
0 – no
1 – yes
27. Physical Defects or Disabilities
0 – no
1 – yes
28. Type of Physical Defects or Disabilities or other Commentary
-enter any text that is written in this section of the face sheet
29. Under Care of Doctor or Dentist
0 – no
1 – yes
30. Taking of Medication or Drugs
0 – no
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1 – yes
31. Taking of Medication or Drugs Commentary
-enter any text that is written in this section of the face sheet
32. Attitude
-enter any text that is written in this section of the face sheet
33. Coordination
-enter any text that is written in this section of the face sheet
34. Coordination (recoded) *recode #33 into binary below
0 – fair/good
1 – Other
35. Breath
-enter any text that is written in this section of the face sheet
36. Breath (recoded) *recode #35 into binary below
0 – normal
1 – Other
37. Face
-enter any text that is written in this section of the face sheet
38. Face (recoded) *recode # 37 into binary below
0 – normal
1 – other
-enter -999 if not applicable
39. Speech
-enter any text that is written in this section of the face sheet
40. Speech (recoded) *recode # 37 into binary below
0 – normal
1 – Other
41. Eyes Appearance
0 – normal
1 – bloodshot
2 – watery
3 – bloodshot and watery
-enter -999 if not applicable
42. Blindness
0 – none
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1 – left eye
2 – right eye
3 – partial
4 – total
-enter -999 if not applicable
43. Tracking
0 – equal
1 – unequal
-enter -999 if not applicable
44. Corrective Lenses
0 – none
1 – glasses
2 – contacts
-enter -999 if not applicable
45. Pupil Size
0 – equal
1 – unequal
-enter -999 if not applicable
46. Ability to Follow Stimulus
0 – no
1 – yes
-enter -999 if not applicable
47. Eyelids
0 – normal
1 – droopy
-enter -999 if not applicable
48. Pulse 1
-enter the number that is written in this section of the face sheet
49. Pulse 1 Time
-enter time without any spaces or colons according to the 24-hour clock
50. Pulse 2
-enter the number that is written in this section of the face sheet
51. Pulse 2 Time
-enter time without any spaces or colons according to the 24-hour clock
52. Pulse 3
-enter the number that is written in this section of the face sheet
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53. Pulse 3 Time
-enter time without any spaces or colons according to the 24-hour clock
54. Pulse (recoded) * Pulse range 60 – 90 beats per minute, if any pulse rate from pulse 1, 2, or
3 falls into the below category
0 – below range
1 – within range
2 – above range
-enter -999 if not applicable
55. Left Eye Lack of Smooth Pursuit
0 – no
1 – yes or "present"
-999 – unable to perform test
56. Left Eye Maximum Deviation
0 – no
1 – yes or "present"
-999 unable to perform test
57. Left Eye Angle of Onset
-enter the angle number
-if "none", then enter zero
-if the word "present" is written, then leave blank
-999 – unable to perform test
58. Left Eye Angle of Onset (recoded)
0 – not present
1 – 30 to 45 degrees
2 – immediate on-set
-999 – unable to perform test
59. Right Eye Lack of Smooth Pursuit
0 – no
1 – yes or "present"
-999 – unable to perform test
60. Right Eye Maximum Deviation
0 – no
1 – yes or "present"
-999 – unable to perform test
61. Right Eye Angle of Onset
-enter the angle number
-if "none", enter zero
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-if the word "present" is written, then leave blank
-999 – unable to perform test
62. Right Eye Angle of Onset (recoded)
0 – not present
1 – 30 to 45 degrees
2 – immediate on-set
-999 – unable to perform test
63. Vertical Nystagmus
0 – no
1 – yes
64. Convergence *If the arrows for both eyes are pointing together (right eye at 3 o'clock
position and left eye at 9 o'clock position) then this indicates that convergence is present;
otherwise, there is an absence of convergence.
0 – absent
1 – present
-enter -999 if unable to perform the test
65. Completion of One Leg Stand Test for the Left Leg *there is not a specific box on the face
sheet for this. There will often be a comment in the One Leg Stand diagram portion of the face
sheet indicating "Test Stopped." You can also determine which portion of the test (i.e., left leg
or the right leg) was stopped by looking at the diagram and the checklist that is located below the
diagram. (Note that the test for the left leg appears on the left side of the diagram and the test for
the right leg appears on the right side of the diagram). If there is/are no (often circled) number(s)
above a set of "footprints" and no check marks in the corresponding column below, then this
suggests that the test was not completed for that particular leg.
0 – not attempted
1 – attempted but stopped
2 – attempted and completed
66. Completion of One Leg Stand Test for the Right Leg *there is also not a specific box on the
face sheet for this.
0 – not attempted
1 – attempted but stopped
2 – attempted and completed
67. Left One Leg Stand – Sways While Balancing
0—not present
1—present
68. Left One Leg Stand – Uses Arms to Balance
0—not present
1—present
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69. Left One Leg Stand - Hopping
0—not present
1—present
70. Left One Leg Stand – Puts Foot Down
-enter the number of check marks/tallies. If none, then enter zero. If there are no check
marks/tallies because the test was not attempted or completed, then assign a value of -999
71. Left One Leg Stand – Puts Foot Down (recoded)
0 – none
1 – 1 time down
2 – 2 or more down
-enter -999 if not applicable
72. Left One Leg Stand- Time
-enter the number subject count was on at end of 30 seconds, indicated in box on top left
73. Left One Leg Stand- Time (recoded)
0 – 0 to 14
1 – 15 to 29
2 – 30 or more
-enter -999 if not applicable
74. Right One Leg Stand – Sways While Balancing
0—not present
1—present
75. Right One Leg Stand – Uses Arms to Balance
0—not present
1—present
76. Right One Leg Stand - Hopping
0—not present
1—present
77. Right One Leg Stand – Puts Foot Down
-enter the number of check marks/tallies. If none, then enter zero. If there are no check
marks/tallies because the test was not attempted or completed, then assign a value of -999
78. Right One Leg Stand – Puts Foot Down (recoded)
0–0
1 – 1 time down
2 – 2 or more down
-enter -999 if not applicable
79. Right One Leg Stand- Time
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-enter the number subject count was on at end of 30 seconds, indicated in box on top right
80. Right One Leg Stand- Time (recoded)
0 – 0 to 14
1 – 15 to 29
2 – 30 or more
-enter -999 if not applicable
81. Type of Footwear
-enter any text that is written in this section of the face sheet
82. Completion of Modified Romberg Balance Test (i.e., "stickman" on the left side of the
diagram) *there is not a specific box on the face sheet for this. There will often be a comment in
the Modified Romberg Balance diagram portion of the face sheet indicating "Test Stopped."
There will also be information in the narrative section of the face sheet.
0 – not attempted
1 – attempted but stopped
2 – attempted and completed
83. Modified Romberg Balance Front to Back Sway – Front Measurement in inches
-enter the first number above the "stickman"
-if no number is provided, then enter zero if the test was done
-enter -999 if the test was not completed
84. Modified Romberg Balance Front to Back Sway – Back Measurement
-enter the second number above the "stickman"
-if no number is provided, then enter zero if the test was done
-enter -999 if the test was not completed
85. Modified Romberg Balance Front to Back Sway (recoded)
0 – none
1 – less than 2 inches
2 – 2 inches or more
86. Modified Romberg Balance Side to Side Sway – Left Side Measurement
-enter the first number (is in inches) above the "stickman"
-if no number is provided, then enter zero if the test was done
-enter -999 if the test was not completed
87. Modified Romberg Balance Side to Side Sway – Right Side Measurement
-enter the second number (is in inches) above the "stickman"
-if no number is provided, then enter zero if the test was done
-enter -999 if the test was not completed
88. Modified Romberg Balance Side to Side Sway (recoded)
0 – none
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1 – less than 2 inches
2 – 2 inches or more
89. Modified Romberg Balance Internal Clock
-enter the number (in secs)
-if test was not attempted or completed, enter -999
90. Modified Romberg Balance Internal Clock (recoded)
0 – 0 to 24 seconds (fast)
1 – 25 – 35 seconds (normal range)
2 – 36 or higher (slow)
-enter -999 if not applicable
91. Presence of Eyelid Tremors (there isn’t a separate box for this – it would be written in the
Modified Romberg test box)
0 = no
1 = yes
92. Presence of Body or Leg Tremors (there isn’t a separate box for this – it would be written in
the Modified Romberg test box)
0 = no
1 = yes
93. Completion of Walk and Turn Test *there is not a specific box on the face sheet for this.
There will often be a comment in the Walk and Turn Test diagram portion of the face sheet
indicating "Test Stopped."
0 – not attempted
1 – attempted but stopped
2 – attempted and completed
94. Walk and Turn Test - Cannot Keep Balance *In cases where the words "continuous" or "all"
are provided in the various boxes for this test (instead of check marks or tallies), enter the
number 5
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
95. Walk and Turn Test - Starts too Soon
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
96. Walk and Turn Test 1st Nine – Stops Walking
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
97. Walk and Turn Test 1st Nine – Misses Heel to Toe
-enter the number of check marks/tallies (if none, then enter zero)
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-if none because the test was stopped or not attempted, then enter -999
98. Walk and Turn Test 1st Nine – Steps Off Line
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
99. Walk and Turn Test 1st Nine – Raises Arms
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
100. Walk and Turn Test 1st Nine – Actual # of Steps
-enter the number from the box (if none, then enter zero)
-if the test was stopped or not attempted, then enter -999
101. Walk and Turn Test 2nd Nine – Stops Walking
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
102. Walk and Turn Test 2nd Nine – Misses Heel to Toe
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
103. Walk and Turn Test 2nd Nine – Steps Off Line
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
104. Walk and Turn Test 2nd Nine – Raises Arms
-enter the number of check marks/tallies (if none, then enter zero)
-if none because the test was stopped or not attempted, then enter -999
105. Walk and Turn Test 2nd Nine – Actual # of Steps
-enter the number from the box (if none, then enter zero)
-if the test was stopped or not attempted, then enter -999
106. Walk and Turn Test - Cannot Keep Balance (recoded)
-if test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or higher
107. Walk and Turn Test - Starts too Soon (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or higher
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108. Walk and Turn Test 1st Nine – Stops Walking (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or higher
109. Walk and Turn Test 1st Nine – Misses Heel to Toe (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or more
110. Walk and Turn Test 1st Nine – Steps Off Line (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or higher
111. Walk and Turn Test 1st Nine – Raises Arms (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or more
112. Walk and Turn Test 1st Nine – Actual # of Steps (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 steps
1 - < 9 steps
2 – 9 steps
3 - > 9 steps
113. Walk and Turn Test 2nd Nine – Stops Walking (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or higher
114. Walk and Turn Test 2nd Nine – Misses Heel to Toe (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or more
115. Walk and Turn Test 2nd Nine – Steps Off Line (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
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1 – 1 mark or numbers
2 – 2 or higher
116. Walk and Turn Test 2nd Nine – Raises Arms (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 marks or numbers
1 – 1 mark or numbers
2 – 2 or more
117. Walk and Turn Test 2nd Nine – Actual # of Steps (recoded)
-if the test was stopped or not attempted, then enter -999
0 – 0 steps
1 - < 9 steps
2 – 9 steps
3 - > 9 steps
118. Describe Turn from Walk and Turn Test
-enter any text from this section of the face sheet
119. Describe Turn from Walk and Turn Test (recoded)
- if the test was stopped or not attempted, then enter -999
0 – proper turn
1 – improper turn
120. Hit on Finger to Nose Test 1 (Draw Lines to Spots Touched) *each test corresponds to the
triangle with the corresponding number inside it. A hit is when the tip of the finger touches the
tip of the nose. If pad is used it does not count as a hit.
0 – no
1 – yes
-999 did not attempt/complete
121. Hit on Finger to Nose Test 2
0 – no
1 – yes
-999 did not attempt/complete
122. Hit on Finger to Nose Test 3
0 – no
1 – yes
-999 did not attempt/complete
123. Hit on Finger to Nose Test 4
0 – no
1 – yes
-999 did not attempt/complete
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124. Hit on Finger to Nose Test 5
0 – no
1 – yes
-999 did not attempt/complete
125. Hit on Finger to Nose Test 6
0 – no
1 – yes
-999 did not attempt/complete
126. Total Hit count on Finger to Nose Test (recoded)
0–0
1–1
2–2
3–3
4–4
5–5
6–6
-999 did not attempt/complete
127. Use of Pad of the Finger during Finger to Nose Test *This will be noted on the face sheet.
If this happens at least once, then code as "yes"
0 – no
1 – yes
-999 not available
128. Use wrong hand for test when instructed *This will be noted on the face sheet.
0 – no
1 – yes
-999 not available
129. Does not return arm to front or side *This will be noted on face sheet.
0 – no
1 – yes
-999 not available
130. Swaying during test *This will be noted on face sheet.
0 – no
1 – yes
-999 not available
131. Eyelid tremors *This will be noted on face sheet.
0 – no
1 – yes
-999 not available
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132. Body or leg tremors *This will be noted on face sheet.
0 – no
1 – yes
-999 not available
133. Does not keep eyes closed during test *This will be noted on face sheet.
0 – no
1 – yes
-999 not available
134. Left Pupil Size – Room Light
-enter the number (with the decimal)
135. Left Pupil Size – Near Total Darkness
-enter the number (with the decimal)
136. Left Pupil Size – Direct Light
-enter the number (with the decimal)
137. Left Pupil Size – Direct Light 2 (recoded)**if rebound dilation is present a 2nd estimated is
on the face sheet
-enter the number (with the decimal)
138. Right Pupil Size – Room Light
-enter the number (with the decimal)
139. Right Pupil Size – Near Total Darkness
-enter the number (with the decimal)
140. Right Pupil Size – Direct Light
-enter the number (with the decimal)
141. Right Pupil Size – Direct Light 2 (recoded)**if rebound dilation is present a 2nd estimated
is on the face sheet
-enter the number (with the decimal)
142. Left Pupil Room Light within Average DRE Range (recoded). Face sheet contains ranges
for all three lighting conditions.
0—below range (<2.5mm)
1—within range (2.5 – 5.0mm)
2—above range (>5.0mm)
-999 not available
143. Left Pupil Near Total Darkness within Average DRE Range (recoded). Face sheet contains
ranges for all three lighting conditions.
0—below range (<5.0mm)
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1—within range (5.0 – 8.5mm)
2—above range (>8.5mm)
-999 not available
144. Left Pupil Direct Light within Average DRE Range (recoded). Face sheet contains ranges
for all three lighting conditions.
0—below range (<2.0mm)
1—within range (2.0 – 4.5mm)
2—above range (>4.5mm)
-999 not available
145. Left Pupil Direct Light 2 within Average DRE Range (recoded). Face sheet contains ranges
for all three lighting conditions.
0—below range (<2.0mm)
1—within range (2.0 – 4.5mm)
2—above range (>4.5mm)
-999 not available
146. Right Pupil Room Light within Average DRE Range (recoded). Face sheet contains ranges
for all three lighting conditions.
0—below range (<2.5mm)
1—within range (2.5 – 5.0mm)
2—above range (>5.0mm)
-999 not available
147. Right Pupil Near Total Darkness within Average DRE Range (recoded). Face sheet
contains ranges for all three lighting conditions.
0—below range (<5.0mm)
1—within range (5.0 – 8.5mm)
2—above range (>8.5mm)
-999 not available
148. Right Pupil Direct Light within Average DRE Range (recoded). Face sheet contains ranges
for all three lighting conditions.
0—below range (<2.0mm)
1—within range (2.0 – 4.5mm)
2—above range (>4.5mm)
-999 not available
149. Right Pupil Direct Light 2 within Average DRE Range (recoded). Face sheet contains
ranges for all three lighting conditions.
0—below range (<2.0mm)
1—within range (2.0 – 4.5mm)
2—above range (>4.5mm)
-999 not available
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150. Rebound Dilation
0 – no
1 – yes
151. Reaction to Light
0—normal
1—slow
2—little to none
-999 not available
152. Nasal Area
-enter any text that is written in this section of the face sheet
153. Nasal Area (recoded)
0 – clear / normal
1 – other
-999 not available
154. Oral Cavity
-enter any text that is written in this section of the face sheet
155. Oral Cavity (recoded)
0 – clear / normal
1 – other
-999 not available
156. Left Arm Injection Sites
0 – none
1 – old
2 – fresh
3 - both
157. Right Arm Injection Sites
0 – none
1 – old
2 – fresh
3 - both
158. Blood Pressure – Systolic
-enter the first number
159. Blood Pressure – Diastolic
-enter the second number
160. Body Temperature
-enter the number (with the decimal)
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161. Blood Pressure – Systolic (recoded)
0 – below range (< 120)
1 – within range (120 – 140)
2 – above range (> 140)
-999 not available
162. Blood Pressure – Diastolic (recoded)
0 – below range (< 70)
1 – within range (70 – 90)
2 – above range (> 90)
-999 not available
163. Body Temperature (recoded)
0 – below range (< 97.6 degree)
1 – within range (97.6 – 99.6 degrees)
2 – above range (> 99.6 degree)
-999 not available
164. Muscle Tone
0 – normal
1 – flaccid
2 – rigid
-999 not available
165. Type of Medication/Drug Taken
-enter any text that is written in this section of the face sheet
166. Amount of Medication/Drug Taken
-enter any text that is written in this section of the face sheet
167. Time of Medication/Drug use time
-enter time without any spaces or colons according to the 24-hour clock
168. Date of Arrest
-enter the date as is on the face sheet without any spaces or hyphens
169. Time of Arrest
-enter time without any spaces or colons according to the 24-hour clock
170. Evaluation Start Time
-enter time without any spaces or colons according to the 24-hour clock
171. Evaluation Completion Time
-enter time without any spaces or colons according to the 24-hour clock
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172. Opinion of Evaluator – Drug 1 *If more than one drug is selected, then code each one using
a separate drug variable.
0 – rule out (no impairment)
1 – medical rule out
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic (PCP)
7 – narcotic analgesic
8 – inhalant
9 – cannabis
-999 unknown
-if left blank on the face sheet, then leave blank in the database
173. Opinion of Evaluator – Drug 2
0 – rule out (no impairment)
1 – medical rule out
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic (PCP)
7 – narcotic analgesic
8 – inhalant
9 – cannabis
174. Opinion of Evaluator – Drug 3
0 – rule out (no impairment)
1 – medical rule out
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic (PCP)
7 – narcotic analgesic
8 – inhalant
9 – cannabis
175. Opinion of Evaluator – Drug 4
0 – rule out (no impairment)
1 – medical rule out
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
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6 – dissociative anesthetic (PCP)
7 – narcotic analgesic
8 – inhalant
9 – cannabis
176. Toxicology Results – Drug 1
0 – no drugs found
1 – medical
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic
7 – narcotic analgesic
8 – inhalant
9 – cannabis
177. Toxicology Results – Drug 2
0 – no drugs found
1 – medical
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic
7 – narcotic analgesic
8 – inhalant
9 – cannabis
178. Toxicology Results – Drug 3
0 – no drugs found
1 – medical
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic
7 – narcotic analgesic
8 – inhalant
9 – cannabis
179. Toxicology Results – Drug 4
0 – no drugs found
1 – medical
2 – alcohol
3 – CNS depressant
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4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic
7 – narcotic analgesic
8 – inhalant
9 – cannabis
180. Toxicology Results – Drug 5
0 – no drugs found
1 – medical
2 – alcohol
3 – CNS depressant
4 – CNS stimulant
5 – hallucinogen
6 – dissociative anesthetic
7 – narcotic analgesic
8 – inhalant
9 – cannabis
181. CNS depressant active drug (recoded). If DRE opinion is drug and toxicology confirms
drug mark as active
0 – not active
1 – active
182. CNS stimulant active drug (recoded). If DRE opinion is drug and toxicology confirms drug
mark as active
0 – not active
1 – active
183. Hallucinogens active drug (recoded). If DRE opinion is drug and toxicology confirms drug
mark as active
0 – not active
1 – active
184. Dissociative Anesthetics active drug (recoded). If DRE opinion is drug and toxicology
confirms drug mark as active
0 – not active
1 – active
185. Narcotic Analgesic active drug (recoded). If DRE opinion is drug and toxicology confirms
drug mark as active
0 – not active
1 – active
186. Inhalants active drug (recoded). If DRE opinion is drug and toxicology confirms drug mark
as active
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0 – not active
1 – active
187. Cannabis active drug (recoded). If DRE opinion is drug and toxicology confirms drug mark
as active
0 – not active
1 – active
188. Total Active Drug Categories- drug combinations (recoded)
0 – no drug found
1 – CNS depressant
2 – CNS stimulant
3 – Hallucinogen
4 – Dissociate Anesthetic
5 – Narcotic Analgesic
6 – Inhalant
7 – Cannabis
8 – CNS stimulant/Narcotic analgesic
9 – CNS depressant/Narcotic analgesic
10 – CNS depressant/CNS stimulant
11 – Narcotic analgesic/Cannabis
12 – CNS stimulant/Cannabis
13 – CNS depressant/Cannabis
14 – CNS depressant/CNS stimulant/Cannabis
15 – CNS depressant/CNS stimulant/Narcotic analgesic/Cannabis
189. Missed DRE opinion (recoded)**follow DECP guidelines for classification for DRE
opinion.
0 – not missed
1 – missed

